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1. Summary 
A hallmark of protective immunity during fungal infections is the regulated secretion of pro-
and anti-inflammatory cytokines. Suppressor of cytokine signalling (SOCS) proteins 
constitute a class of key regulators of cytokine function. SOCS proteins are known as 
inducible negative feedback inhibitors of JAK/STAT (janus kinase/signal transducer and 
activator of transcription) pathways, but they can also be induced by Toll-like receptors. 
Dectin-1, another member of the PRR (pattern recognition receptor) family, is described to 
detect surface structures of fungal pathogens. However, induction and inhibition properties of 
SOCS proteins upon Dectin-1 stimulation have not been described yet. 
In this study it is shown that SOCS1 mRNA and protein is induced in murine bone marrow-
derived macrophages (BMMs) and dendritic cells (BMDCs) upon engagement of Dectin-1. 
SOCS1 was expressed independently of any TLR engagement as a direct target gene of the 
Dectin-1 ligand depleted Zymosan, which lacks TLR-binding capabilities. Additionally, the 
induction of SOCS1 by depleted Zymosan was completely independent of secreted type I 
interferon.  
Induction of SOCS1 was mediated by a novel pathway that had not been described in 
conjunction with SOCS1 induction previously. In contrast to BMDCs, the transcription factor 
NF-κB was not responsible for SOCS1 expression in BMMs. This novel pathway 
encompassed the receptor proximal tyrosine kinases Src and Syk that activated the 
downstream tyrosine Proline-rich tyrosine kinase 2 (Pyk2). In BMMs, Pyk2 in turn caused 
activation of the MAPK (mitogen-activated kinase) ERK (extracellular signal-regulated 
kinase) thereby triggering SOCS1 induction. Inhibition of Pyk2 abolished Pyk2 and ERK 
phosphorylation as well as SOCS1 expression, whereas the activity of the MAPKs p38 and 
JNKII (c-jun N-terminal kinase) was completely unaffected.  
Subsequently, a possible influence of Dectin-1 induced SOCS1 on Dectin-1 and TLR 
signalling was tested. SOCS1 did not modulate Dectin-1 signalling pathway but affected TLR 
signalling. Stimulation with depleted Zymosan led to an increased and prolonged NF-κB 
activation in SOCS1 knockout BMMs triggered by TLR9. Furthermore, IL12 and IL10 
secretion induced upon stimulation via TLR9 was inhibited by Dectin-1 induced SOCS1.  
In addition, it could be shown that IL17 producing T-helper (Th)-cells were increased by 
SOCS1 in BMMs. Therefore, BMMs from SOCS1 knockout as well as the respective controls 
were co-stimulated via TLR9 and Dectin-1 and co-cultured with wildtype CD4+ Th-cells. 
Afterwards, a significant increase in IL17 production could be observed only in co-cultures 
with co-stimulated BMMs that still expressed endogenous SOCS1. Thus, SOCS1 is 
responsible for shaping the immune response towards an anti-fungal, IL17 producing Th-cell 
phenotype. 
The results show that SOCS1 is expressed via a new pathway in Dectin-1 triggered myeloid 
cells. In BMMs, the SOCS1 expression is independent of NF-κB. SOCS1 induced via Dectin-
1 influences TLR crosstalk and T-cell priming thus contributing to the appropriate immune 
regulation in fungal infections. 
Zusammenfassung 
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1. Zusammenfassung 
Die präzise Regulation der Sekretion pro- und anti-inflammatorischer Zytokine stellt einen 
der wichtigsten Mechanismen bei der Immunantwort gegen pathogene Pilzinfektionen dar. 
Suppressor of Cytokine Signalling (SOCS) Proteine stellen eine Klasse von induzierbaren 
feedback Inhibitoren für den JAK/STAT (janus kinase/signal transducer and activator of 
transcription) Signalweg dar. Diese intrazellulären Proteine werden durch Zytokine, aber 
auch durch Toll-like Rezeptor (TLR) Liganden induziert. Neben TLRs ist Dectin-1 als 
weiteres Mitglied der PRRs (pattern recognition receptors) beschrieben. Dectin-1 erkennt 
Zellwandbestandteile pathogener Pilze. In dieser Arbeit sollte untersucht werden, ob Dectin-
1 Aktivierung mit der Induktion von SOCS Proteinen und damit der Modulation von 
Zytokinantworten einhergeht. 
Es kann gezeigt werden, dass SOCS1 (mRNA und Protein) nach Dectin-1 Stimulation 
muriner Makrophagen (BMMs) oder Dendritischer Zellen (BMDCs) induziert wird. Dabei 
erfolgte die SOCS1 Expression durch einen  Dectin-1 Liganden, der keine TLR-
Bindekapazität aufweist (modifiziertes Zymosan), direkt und TLR unabhängig.  
Die SOCS1 Induktion wurde über einen Signalweg vermittelt, der in Zusammenhang mit der 
SOCS1 Expression noch nicht beschrieben war. Dabei war der Transkriptionsfaktor NF-κB in 
BMMs, im Gegensatz zu BMDCs, nicht für die SOCS1 Induktion verantwortlich. Nach Dectin-
1 Stimulation wurden Tyrosin Kinasen der Src und Syk Familie aktiviert; diese stimulierten 
wiederum die nachgeschaltete Tyrosin Kinase Pyk2 (Proline rich tyrosine kinase 2). In BMMs 
induzierte phosphoryliertes Pyk2 die Aktivierung der MAPK (Mitogen-activated kinase) ERK 
(extracellular signal-regulated kinase). Phosphoryliertes ERK induzierte die NF-κB 
unabhängige Expression von SOCS1. Eine Inhibition der Pyk2 Aktivierung führte zu einer 
spezifischen Hemmung der ERK Phosphorylierung sowie der Induktion des SOCS1 Proteins. 
Die Aktivität der MAP Kinasen JNKII und p38 blieb unbeeinflusst. 
SOCS1 wurde weiterhin auf seine Wirkung im Dectin-1 und TLR Signalweg untersucht. Es 
konnte eine inhibitorische Wirkung des SOCS1 Proteins auf den TLR Signalweg beobachtet 
werden, jedoch nicht auf den Dectin-1 Signalweg. Die Stimulation mit modifiziertem Zymosan 
führte zu einer verlängerten NF-κB Aktivierung in SOCS1 defizienten BMMs, die zusätzlich 
über TLR9 stimuliert wurden. Zudem war die TLR9 induzierte Sekretion der Zytokine IL12 
und IL10 durch Dectin-1 induziertes SOCS1 Protein inhibiert. Zusätzlich konnte ein 
signifikanter Anstieg der IL17 Produktion in T-Helfer (Th) Zellen beobachtet werden, der 
abhängig von der Dectin-1 induzierten SOCS1 Expression in BMMs war. Dazu wurden 
BMMs aus SOCS1 knockout Mäusen und den entsprechenden Kontrollen via TLR9 und 
Dectin-1 kostimuliert und mit isolierten Wildtyp CD4+ Th-Zellen kokultiviert. Eine erhöhte IL17 
Produktion konnte nur in Kokulturen mit BMMs gezeigt werden, die noch endogenes SOCS1 
Protein exprimierten. SOCS1 ist somit assoziiert mit einem Th-Zell Phänotyp mit erhöhter 
IL17 Produktion. 
Die Ergebnisse zeigen, dass SOCS1 in Dectin-1 stimulierten myeloiden Zellen über einen 
neuartigen Signalweg induziert wird. In BMMs wird SOCS1 NF-κB unabhängig exprimiert. 
Darüber hinaus beeinflusst SOCS1 TLR-Signalwege und Th-Zell Antworten und wirkt somit 
an der Regulation von Immunantworten bei Pilzinfektionen mit. 
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2. Introduction 
The immune system defends the host organism against invading microbes. Hence, the 
detection of a wide variety of different infectious microbes, such as bacteria, fungi and 
viruses is mandatory. This task implies that cells of the immune system have to discriminate 
between self and non-self structures.  
In general, the immune system can be divided into innate and adaptive immunity. The innate 
immune system constitutes the first line of defense. It comprises cellular components, 
namely dendritic cells, macrophages, granulocytes and cellular factors, i.e. the complement 
system, that patrol constantly throughout the body to be in place when an infectious 
organism invades the body. Upon activation, innate immune cells in turn are capable of 
activating adaptive immunity. The mechanisms by which cells of the adaptive immune 
system respond to infections are decisively different from those of innate immunity. 
Lymphocytes share the common feature of somatical recombination of receptor molecules 
and clonal selection and thereby produce a large repertoire of individually different, high-
affine receptors as postulated by Burnet. This allows the immune system to increase defense 
capabilities with further exposures of the host to the same pathogen (memory effects). 
2.1. Innate immunity 
The innate immune system represents a phylogenetically very old way to defeat pathogens 
at utmost efficiency. The innate immune response is the first line of host defense. It is 
responsible for immediate recognition and defense of microbial invasion. Thus, the 
components of the innate immune system often eliminate microbes even before adaptive 
immunity gets activated. Serving the need of rapid immune reactivity, the innate immune 
response is rather non-specific and does not provide long-lasting or protective immunity to 
the host organism. Epithelial cells build up a first physiological barrier to invading microbes 
and secret soluble cytokines and antimicrobial peptides, i.e. defensins. The cellular fraction 
of the innate immune system is composed of circulating or resting cells, i.e. dendritic cells 
(DCs), macrophages, neutrophils or natural killer cells that act as sentinels of innate 
immunity. Upon invasion of microbes that have penetrated the epithelial barrier, these cells 
get activated and start secreting cytokines and chemokines to recruit further immune cells to 
the site of infection. Innate immune cells combat pathogens by phagocytosis, secretion of 
antimicrobial factors and induction of an inflammatory reaction. Further, macrophages and 
dendritic cells are able to present microbial components on their cell surface, therefore acting 
as antigen presenting cells (APCs). APCs that were activated by contact with microbes in 
turn stimulate the adaptive immune system; these cells represent a pivotal interface between 
innate and adaptive immunity. 
2.2. Recognition within the innate immune system 
Ancient germline encoded receptors, the pattern-recognition receptors (PRRs), constitute the 
sensors by which innate immune cells recognize infectious microbes (1, 2). The respective 
ligands that bind to PRRs are highly conserved microbial molecules which were initially being 
termed pathogen associated molecular patterns (PAMPs). These patterns represent 
Introduction 
4 
molecules that are essential for microbial survival. Therefore, PAMPs are unlikely to mutate 
during evolution (3, 4). PRRs enable the host to detect a broad range of pathogens using 
only a limited number of receptors. Recognition is quick without the need of somatic 
recombination that is intrinsic to the lymphatic cells of the adaptive immune system (3, 5, 6). 
PRRs are present in the cytoplasm or on the cell surface of innate immune cells. In 
opposition to the concept that PRRs only recognize non-self structure, recent discoveries 
have led to the perception that PRRs are also able to detect host structures under certain 
conditions (4, 7).  
2.3. Pattern recognition receptors 
PRRs can broadly be divided into three groups based on their cellular location: (I) serum or 
tissue fluid, (II) surface or (III) cytoplasm and intracellular compartments like endosomes. 
They can be further subdivided into related families based on their molecular structure and/or 
function. Toll like receptors (TLRs), Retinoic acid inducible gene-I (RIG-I)-like receptors, 
Aim2-like receptors (absent in melanoma 2), Ifi (interferon inducible protein) and NOD 
(nucleotide-binding and oligomerization domain)-like receptors (NLRs) belong to these 
families (8-12). Further proteins with C-type lectin-binding domains (C-type lectin receptors, 
CLRs) have various functions but also serve as pattern recognition receptors in innate 
immunity (13). All of these receptors are composed of ligand binding domains and signalling 
domains. They are regulated either through dimerization and oligomerization or through 
conformational changes by enzymatic activities. Subsequently, signalling domains are 
activated and recruit adaptor proteins that initiate intracellular signalling. 
2.3.1. Cytoplasmic receptors 
Particular subgroups of PRRs reside in the cytosol and are expressed in a broad range of 
somatic cells, thus they are not restricted to professional innate immune cells like dendritic 
cells or macrophages. RIG-I-like receptors (RLRs) were originally described as RNA 
helicases (14). Beside this function, the family members RIG-I and MDA5 are able to 
recognize viral components, i.e. viral RNA, and consequently initiate an immune response 
(15, 16). NLRs represent the largest family of PRRs in humans (17). All NLRs possess a 
carboxy-terminal LRR domain that is responsible for ligand binding (11). NLRs are grouped 
in NODs and NALPs (11, 18). NODs mediate signaling upon ligand binding that leads to 
NFκB activation. NALPs activate caspase-1. Upon activation, NALPs undergo conformational 
changes and build up multimeric protein complexes which are termed inflammasomes (19, 
20) (Fig. 2-1). The formation and activation of inflammasomes results in secretion of 
inflammatory cytokines, IL1β and IL18 after cleavage of their pro-forms by caspase-1 (21). In 
addition, Aim2-like receptors recognize foreign, cytoplasmatic dsDNA (12). Activation of 
Aim2-like receptors induces the recruitment of the adaptor protein ASC. Thereupon, 
Procaspase 1 is recruited to ASC via its CARD domain leading to the formation of an 
inflammasome. Within the NALP- as well as the Aim2-inflammasome, Procaspase 1 is 
cleaved to the active form, caspase 1, that results in the release of IL1-β (21-23). Ifi belongs 
to the same family as Aim2 and recognizes pathogenic dsDNA, leading to the induction of 
Type I IFNs (24, 25). In addition, several other DNA sensing receptors have been implicated, 
Introduction 
5 
including Lrrfip 1 (Leucin-reach repeat (in Flightless 1) interacting protein 1) and DExD/H box 
helicases DHX 9 and DHX 36 (12). 
2.3.2. Surface receptors 
Toll like receptors (TLRs) 
The Toll protein was first described to play a pivotal role in the development of the fruit fly 
Drosophila melanogaster (26). However, loss-of-function mutations within the Toll protein 
also resulted in higher susceptibility of Drosophila melanogaster to fungal infection. This 
obsevation hinted towards another important function of Toll as a pathogen sensing receptor 
of the immune system (27, 28). The TLRs represent the mammalian homologes to the Toll-
protein. TLRs are either expressed in the membranes of intracellular compartments, namely 
endosomes (TLR3, 7, 8 and 9) or on the cell surface (TLR1, 2, 4, 5, 6 and 10) (29-31). So 
far, 10 TLRs are described in humans (TLR 1-10) and 12 TLRs are described in mice (TLR 
1-9 and 11-13) (32). Proximal events of activated TLRs are initiated by TIR-domain-
containing adaptor molecules (TIRAP) or MyD88 adptor like proteins (MAL) (33). Most of the 
TLRs, like TLR2, TLR4, TLR6 or TLR9 employ the central adaptor protein myeloid 
differentiation factor 88 (MyD88), TLR 4 is capable of utilizing also TIR-domain- containing 
adaptor inducing IFN-β (TRIF; also known as TICAM1) and TLR3 only signals via TRIF (33-
35). MyD88-dependent signalling cascades additionally use another adaptor molecule for the 
signal transduction, namely TIRAP. TLR-mediated MyD88 recruitment activates a conserved 
inflammatory pathway leading to activation of mitogen-activated protein kinases (MAPK) and 
translocation of active NF-κB into the nucleus (36-38). TRIF dependent signalling (i.e. TLR3) 
activates interferon regulatory factors (IRF) in a MyD88-independent manner. IRF activation 
links TLR-signalling to IFN secretion (39, 40). In mice, it is shown that TLRs not only activate 
NF-κB upon ligand binding, but are also able to activate other transcription factors like 
nuclear factor of activated T-cells (NFAT) (41).  
Non-TLR PRRs 
Although the secretion of cytokines and attraction of adaptive immune cells is mainly 
mediated by the TLRs, non-TLR PRRs can contribute to this response. They either present 
distinct PAMPs to the TLRs, such as described for CD36, which presents diacylglycerids to 
TLR2-TLR6 heterodimers, or CD14 that presents lipopolysaccharide (LPS) to the TLR4-MD2 
complex (42, 43). On the other hand, non-TLR PRRs might also directly contribute to the 
inflammatory responses to invading microbes. Among the non-TLR PRRs, Dectin-1 is the 
only example that can act independently of TLRs, thereby inducing pro-and anti-inflammatory 
cytokines (44, 45). Dectin-1 is a membrane bound C-type lectin receptor that recognizes 
carbohydrate structures in the cell wall of different microbes, i.e. fungi. Figure 2-1 provides 
an overview of pathogen recognition by pattern-recognition receptors. 
C-type lectins 
The term C-type lectin was established to distinguish between Ca2+ dependent and Ca2+ 
independent carbohydrate binding lectins. C-type lectin receptors (CLRs) share at least one 
carbohydrate recognition domain that contains conserved residues and determine the 
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specificity of the respective CLR. The family of C-type lectin receptors consists of soluble and 
transmembrane forms (table 2-1) (46). 
CLRs are central for fungal recognition but also contribute to recognition of other microbes. 
They interact with pathogens primarily through the recognition of fucose, mannose and 
glucan carbohydrate structures. Importantly, CLRs are highly specific for the glucan β-(1-3) 
linked backbone structures within these carbohydrates (45-47). In DCs, it is shown that 
recognition by CLRs leads to pathogen internalization and subsequent antigen presentation 
(48, 49). Several CLRs, such as DC-specific ICAM3-grabbing non-integrin (DC-SIGN) induce 
signalling cascades that modulate TLR-induced gene expression on the transcriptional or 
post-transcriptional level (46, 50). By contrast, other CLRs like Dectin-1 are also able to 
induce gene expression following carbohydrate recognition independently of other PRRs (51-
54).  
 
Fig. 2-1  Overview of some different pattern recognition receptors in myeloid cells 
Stimulation of different PRRs entails the production of pro-.and anti-inflammatory cytokines, chemokines or interferons. TLR1, 
2, 4, 5 and 6 are expressed on the cell surface and lead to activation of NF-κB upon stimulation, whereas other TLRs like 
TLR3, TLR7, TLR8 and TLR9 are situated within endosomes or are recruited after internalization of stimuli, i.e. CpG DNA 
(endocytotic pathway). These endosomal TLRs mainly activate IRF (interferon regulatory factor) transcription factors, for 
example after viral infection. Receptors located within the cytoplasm are able to recognize different PAMPs. dsRNA or 5´-
triphosphate  RNA, derived from viruses, are recognized by RIG-I like receptors (RLRs). These receptors are expressed in the 
cytoplasm of most cell-types, whereas other PRRs, like TLRs are only found in innate immune cells, i.e. DCs and 
macrophages. RLR binding leads to activation of IRF transcription factor. Further, NLRs (Nod like receptors) are also present 
in the cytoplasm of immune cells. Upon activation, NLRs form inflammasome complexes and activate NF-κB. Active caspase 1 
within inflammasome complexes cleaves pro-IL1β to active IL1β. C-type lectin receptors (CLRs) are situated on the plasma 
membrane and are activated via fungal cell wall particles, viruses (HIV) or certain bacteria. Upon ligation, signalling cascades 
induce activation of transcription factors like NFAT (nuclear factor of activated T-cells) or NF-κB. Additionally, CLRs mediate 
phagocytosis of bound pathogens. 
The CLR Dectin-1 is the onliest known PRR that is able to signal in a TLR-independent 
manner. On the other hand, it could be demonstrated that Dectin-1 signalling pathways can 
influence TLR signalling as depicted in more detail in later sections (2.2.1.2.1, 2.3.1) (46, 53, 
55, 56). One important aim of this study was to clarify the question if Dectin-1, once 
stimulated, is able to negatively influence TLR signalling by inhibition, i.e. through inhibitory 
molecules like SOCS (suppressors of cytokine signalling). Therefore, Dectin-1 and its 
downstream signalling molecules are discussed in the following chapters in more detail. 
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Additionally, SOCS proteins and possible links between SOCS and Dectin-1 are described 
below. 
Table 2-1  C-type lectin receptors and pathogen recognition (46) 
 
CLR 
 
Glycan PAMPs and in vivo ligands 
 
 
Expression of CLR 
 
Immunological outcome 
 
Group I CLRs (mannose receptor family) 
   
 
Mannose receptor 
(CD206) 
 
High mannose, fucose and sulphated 
sugars, M. tuberculosis, M. kansasii, 
Francisella tularensis, Klebsiella 
pneumonia and Streptococcus 
pneumonia. HIV-1 and dengue virus, C. 
albicans, Cryptococcus neoformans and 
P. carinii. Leishmania spp. 
 
Myeloid DCs and 
macrophages 
 
Phagocytosis and antigen 
presentation 
 
Group II CLRs (asialoglycoprotein receptor family) 
 
   
 
Dectin2 (CLEC 6A) 
 
High mannose, M. tuberculosis, A. 
fumigatus, C.albicans, 
 
Myeloid DCs, pDCs, 
macrophages, B cells and 
neutrophils 
 
TNF and IL6 production 
 
Mincle (CLEC 4E) 
 
 
α-mannose, Malassezia spp. 
 
Myeloid DCs, monocytes 
and macrophages 
 
 
Induction of TNF, IL10 
and production of CXCL2 
 
 
DCIR (CLEC4A) 
 
HIV 
 
Myeloid DCs, monocytes, 
macrophages, Bcells, 
neutrophils 
 
Inhibition of IL8-induced 
TNF and IL12 production, 
inhibition of IL9 induced 
TNF and IFNα production 
 
 
DC-SIGN (CD209) 
 
High mannose and fucose, M. 
tuberculosis, M. leprae, BCG, 
Helicobacter pylori, Lactobacilli spp. 
 
Myeloid DCs 
 
 
Upregulation of TLR 
induced IL10 production, 
induction of Th1, Th2, 
Th17 and Treg 
differentiation, inhibition of 
Th1 cell differentiation, 
antigen presentation 
 
 
Group II CLRs (asialoglycoprotein receptor family, Dectin-1 subfamily) 
 
 
   
 
Dectin-1 (CELC7A) 
 
 
β-1,3-glucan, M. tuberculosis, M. 
abscessus, C. albicans, Aspergillus 
fumigatus, Pneumocystis carinii, 
Penicillium marneffei, Coccidioides 
posadasii and Histoplasma capsulatum 
 
 
Myeloid DCs, monocytes, 
macrophages and B cells 
 
 
Induction of Th1 and 
Th17 cell differentiation 
through induction of IL1β, 
IL6, IL23 and IL12, 
induction of TNF and 
CXCL2 production, 
phagocytosis (DCs), LTB4 
synthesis 
 
 
MICL (CLEC12A) 
 
 
ND 
 
 
Myeloid DCs, monocytes, 
macrophagesand 
neutrophils 
 
 
Inhibition of TLR4 induced 
IL12 production 
 
 
Dectin-1 
Dectin-1 is a type II transmembrane receptor that comprises a single extracellular 
carbohydrate recognition domain (CRD) connected to the intracellular domain via a stalk 
region of variable length. The cytoplasmatic tail of Dectin-1 is built up of an immunoreceptor 
tyrosine-based activation motif (ITAM)-like motif which is involved in signalling initiation (Fig. 
2-2 A)(44, 52, 57). In contrast, other known CLRs like NK-cell-receptor-like C-type lectins 
(i.e. NKGD2 expressed on NK cells) associate with intracellular adaptor signalling molecules, 
i.e. DAP12, to carry out cellular activation (46). Dectin-1 was originally discovered to be 
restricted to dendritic cells; therefore, it was named “dendritic-cell-associated C-type lectin-
1”. The receptor is now known to be expressed by many other cell types like macrophages or 
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monocytes as depicted in Table 2-1 (44, 46, 58, 59). Additionally, it was found that Dectin-1 
is expressed in epithelial cells of the lung and the intestine which emphasizes its role in 
immune surveillance (58, 60). The molecular ligands for Dectin-1 are specified as β-(1-3)- 
and/or β-(1-6)-linked glucans, named carbohydrate polymers that have immunomodulatory 
activities. β-glucans are found, amongst others, in the cell wall of the yeast Saccharomyces 
cerevisiae where they are called Zymosan (44, 45, 54, 61). 
Zymosan is composed of repeating glucose units connected by β-1,3-glycosidic linkages. 
Besides Dectin-1, Zymosan is described to bind to TLR2 or TLR6, thus acting in a 
collaborative way with TLRs (53, 55, 62, 63). Compared to other C-type lectins, Dectin-1 is 
an atypical C-type lectin receptor as the carbohydrate recognition takes place independent of 
metal-ions (45). Mutagenic analysis has indicated that at least two residues, Trp221 and 
His223, in the carbohydrate recognition domain are essential for carbohydrate binding (64). 
In addition to its β-glucan ligands, Dectin-1 is proposed to detect an endogenous T-cell ligand 
as it is described that Dectin-1 can bind to CD4+ and CD8+  Th-cells in vitro thereby 
increasing their proliferation (57). Therefore Dectin-1 has been suggested to act as a co-
stimulatory molecule (57, 65).  
Concerning downstream signalling in CLRs, Dectin-1 is the first example of non-TLR PRRs 
that can mediate intracellular signalling without the contribution of any other PRRs (46, 54). 
Upon ligand binding, Dectin-1 induces the production of various pro- and anti-inflammatory 
cytokines and chemokines, including tumor-necrosis factor, CXC-chemokine ligand 2 
(CXCL2, also known as MIP2), IL2, IL10 and IL12 (63, 66-68). In addition, it can induce 
respiratory burst and antigen uptake via phagocytosis as described for DCs (69, 70). 
Importantly, Zymosan or other β-glucans are able to activate NF-κB in DCs but not in 
macrophages (71). The group of Goodridge et al. could show that Dectin-1 signals alone are 
insufficient for NF-κB activation and cytokine production. Whereas the adaptor molecules of 
Dectin-1 CARD9 (caspase recruitment domain-containing protein 9), Bcl10 (B-cell lymphoma 
10) and MALT1 (mucosa associated lymphoid tissue lymphoma translocation gene 1) led to 
NF-κB activation in DCs, these proteins did not activate NF-κB in macrophages. CARD9 was 
rather recruited to phagosomes where it coordinated signalling to p38 MAPKs (71) (Fig. 2-
2B).  
On the one hand, Dectin-1 is sufficient to induce most of the described responses in DCs, 
but also collaborates with signals from TLR2 and TLR6 (i.e, TNF, IL12) (62, 63). The TLR 
ligand in Zymosan is unknown as TLRs do not bind to β-glucans. Signalling abilities of 
Dectin-1 depend on the intracellular ITAM like motif (Fig. 2-2 A). Sequences within this motif 
are also found in other activation molecules like DAP12 or Fc receptors (72-74). Upon ligand 
binding, YXXI/L (X is any amino acid) repeats within the ITAM like motif get phosphorylated 
by Src tyrosine kinases. ITAM phosphorylation leads to docking and phosphorylation of the 
SH2 domains of Spleen-tyrosine kinase (Syk), possibly by Dectin-1 dimerization (52, 70). 
The requirement for Syk in Dectin-1 signalling is cell type specific, as it is shown that in 
macrophages Syk is only needed for induction of the respiratory burst (69, 70); whereas in 
DCs, Syk is involved in cytokine production (i.e., IL10, IL2) (52). Activation of Syk leads to 
the recruitment of CARD9 (71, 75). Gross et. al. reported that CARD9 knockout mice are 
more susceptible to Candida albicans infections. Further, CARD9-deficient DCs are defective 
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in NF-κB activation upon ligand binding (75). In addition to CARD9, Zymosan stimulated DCs 
recruit Bcl10 and MALT1 to build up a complex with CARD9 (Fig. 2-2 B). The 
CARD9/Bcl10/MALT1 complex ultimately leads to release of NF-κB subunits from the NF-κB 
inhibitor IκBα, inducing nuclear transport of the subunits and subsequent activation of 
transcription of pro-and anti-inflammatory genes (Fig. 2-2 B) (44, 46, 75, 76).  
Adjacent to Syk, Dectin-1 activation can lead to phosphorylation and activation of the 
serine/threonine kinase Raf1 by Ras, which drives phosphorylation of the NF-κB subunit p65 
at Ser276 as shown for DCs (Fig. 2-2 B). Phosphorylated p65 serves as a docking site for 
the Histone acetyl transferase CREB binding protein (CBP) to acetylate p65 at different sites. 
This results in a prolonged and increased NF-κB activity (76, 77).  
In addition to this canonical NF-κB pathway, a recent study has shown that activation of the 
Syk pathway by Dectin-1 also leads to the induction of the non-canonical NF-κB pathway, 
which mediates the processing of p100 subunits to p52. Thereupon, p52 couples with RelB 
and p52-RelB subunits enter the nucleus (75, 76). In addition, Dectin-1 was described to 
activate the transcription factor NFAT (nuclear factor of activated T-cells) very rapidly after 
stimulation as well (61) (Fig. 2-2). It is shown that NFAT contributes to IL10 induction in DCs 
in a Ca2+ dependent manner. Whether NFAT takes part in IL10 induction in macrophages is 
still controversially discussed (61, 66). On the one hand, it could be shown by Goodridge et 
al. that the transcription factors early growth response factor (egr) 2 and 3 are clearly 
induced upon Zymosan stimulation of Raw 264.7 cells (61). The family of egr transcription 
factors (egr1-egr3) is described to be induced by NFAT. Triggering of Dectin-1 led to the 
secretion of IL10 in a NFAT and egr dependent manner (61). In contrast, it had been shown 
by the group of Kelly et al. that other transcription factors may participate in IL10 production 
as well (66). They treated human macrophages with a NFAT inhibitor and observed only a 
modest decrease in IL10 production. It was rather found out that ERK as well as the 
transcription factor CREB mediate IL10 secretion upon Zymosan stimulation in these cells 
(66).  
Upon engagement of Dectin-1 by pathogens like fungi or mycobacteria, downstream 
signalling pathways described above are activated and well described (44, 46). Importantly, 
the activation of signalling pathways within innate immune cells via receptor-bound cytokines 
or PRR ligands is only transient to prevent overwhelming immune reactions. Thus, a 
hallmark of protective immunity during infection is the regulated secretion of pro-and anti-
inflammatory cytokines produced via these pathways (i.e. IL10, IL2, TNFα, IL12) (78). 
Several intracellular inhibitors are described. Among these, constitutive active tyrosine 
phosphatases (SHP1: SH2-containing phosphatase 1, PTP1B: protein tyrosine phosphatase 
1 B, TCPTP: T-cell protein tyrosine phosphatase) and lipid-phosphatases (PTEN:  
phosphatase and tensin homolog deleted on chromosome ten, SHIP: SH2-containing 5’-
inositol phosphatase) inactivate the respective activated receptors (79-82). The abrogation of 
the signalling is mediated by dephosphorylation of the tyrosine-phosphorylated intracellular 
ITAM motifs of the respective receptor. Further, proteins of the PIAS family (protein inhibitor 
of activated STAT) are described that interact with activated STAT molecules and thus inhibit 
binding of STAT transcription factors to the DNA (78, 83). 
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Fig. 2-2  Intracellular signalling by Dectin-1 (44)  
(A), simplified schematic structure of Dectin-1 monomeric receptor. (B), Schematic overview of Dectin-1 signalling through Syk. 
Left site, dendritic cells (DCs): The binding of fungi to Dectin-1 induces phosphorylation of the YXXI/L motif in its cytoplasmic 
domain. Syk kinase is recruited to the dimerized phosphorylated receptor. Activated Syk (pSyk) leads to the formation of a 
complex composed of CARD9, Bcl10 and MALT1. This induces the activation of IκB kinase complex. IKKβ phosphorylates IκB, 
whereupon NF-κB subunits are released and translocate into the nucleus. In a Syk independent manner, Dectin-1 ligation also 
activates the serin/threonin kinase Raf1 via the Ras protein which leads to phosphorylation of p65 at S276 residue. 
Phosphorylated p65 acts as a docking site for CBP. The histone acetyltransferase CBP thereupon acetylates p65 resulting in a 
prolonged NF-κB activity. Depicted are only signalling events that lead to the activation of the non-canonical NF-κB pathway. 
Right site, macrophages (Mos): In contrast to DCs, macrophages do not activate NF-κB upon Dectin-1 ligand binding. 
Phosphorylation of Syk on the one hand is described to activate MAPKs. MAPKs thereupon recruit transcription factors, i.e. 
CREB, AP-1 or ATF1.On the other hand, pSYK induces respiratory burst. 
Ac, acetylation; BCL-10, B cell lymphoma 10; CARD9, caspase recruitment domain family member 9; CBP, CREB binding 
protein; DCs, dendritic cells; Mos, macrophages; Syk, spleen tyrosine kinase; Raf1, rapidly growing fibrosarcoma 1. 
In addition, SOCS (suppressor of cytokine signalling) proteins constitute a class of 
intracellular feedback inhibitors that are not induced until activating signals are transferred 
into the cell. It could be demonstrated that the CLR DC-SIGNR1 is able to induce SOCS1 
upon infection of murine DCs with Mycobacterium tuberculosis (84). Additionally, the 
stimulation with manLAM, a specific ligand for DC-SIGNR1 led to induction of SOCS1 as well 
(84). However, if Dectin-1 is able to mediate SOCS1 expression is not known yet. One 
important aim of this study was to analyze if SOCS1 can be induced upon stimulation of 
Dectin-1 as well as the underlying pathway that leads to SOCS1 expression. 
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2.4. Suppressors of cytokine signaling (SOCS) 
One group of proteins that negatively regulates intracellular signaling is termed suppressors 
of cytokine signaling (SOCS) (85). SOCS proteins are expressed in many cell types, i.e. 
dendritic cells, macrophages and also in T-cell subsets (86-88) 
SOCS proteins were found to be induced via type I and type II cytokine receptors in a 
Jak/STAT dependent manner. Upon activation, they exert their inhibitory function on the 
activated receptor complex. Thus, they inhibit further signalling and therefore can be 
classified as negative feedback inhibitors. The SOCS family is composed of eight structurally 
related proteins, namely SOCS1-SOCS7 and CIS (cytokine inducible SH2 domain containing 
protein). SOCS1, SOCS2, SOCS3 and CIS are the best characterized members of the 
SOCS family (89). Each of the SOCS proteins exhibits a central SH2 (SRC homology 2) 
domain that is responsible for the binding to phosphorylated tyrosine residues (90, 91), an 
amino-terminal domain of variable length and divergent sequence (92) and a carboxy-
terminal 40-amino-acid domain (known as the SOCS-box). This SOCS-box is conserved 
throughout the SOCS family members. The SOCS-box interacts with elongin B and elongin 
C, cullin-5 and RING-box-2 (RBX2), which recruits E2 ubiquitin transferase. Thus, CIS-
SOCS-family proteins act as E3 ubiquitin ligase and mediate protein degradation (93, 94). In 
addition, SOCS1 and SOCS3 can directly inhibit JAK tyrosine kinase activity through their 
kinase inhibitory region (KIR) by acting as a pseudosubstrate (90, 95). The central SH2 
domain determines the target of each SOCS or CIS protein. The SH2 domain of SOCS2, 
SOCS3 and CIS binds to phosphorylated tyrosines on activated cytokine receptors (89-91). 
SOCS3 binds to gp130-related cytokine receptors (96). The SH2 domain of SOCS1 directly 
attaches to Y1007 within the activation loop of JAK 2 (90, 97). Additionally, SOCS1 has been 
shown to bind directly to the type I IFN receptor (IFNAR) and the IFNγ receptor (IFNGR) (98, 
99). As an inhibitor, SOCS1 regulates IFNAR1 specific signalling and abrogates 
phosphorylation of STAT1 (signal transducer and activator of transcription) transcription 
factor. Importantly, SOCS1 first binds to the activated IFN receptors and thereupon it 
interacts with JAK2 (89, 99). It was demonstrated that beside type I and type II interferons, 
SOCS proteins are induced by many different ligands in a JAK/STAT independent manner. 
For example, insulin or different TLR ligands have been proposed to induce SOCS1, 
SOCS2, SOCS3 and CIS (100, 101).  
2.4.1. The role of SOCS1 in the immune system 
Recently, it has been proposed that SOCS 1 and other SOCS proteins, e.g. SOCS3 are not 
only induced by cytokines like IFNs but also by TLR ligands such as LPS or CpG-DNA in a 
JAK/STAT independent manner (100, 102-104). Dalpke et.al. could show that this induction 
was fast and independent of any paracrine factor (103). Dendritic cells isolated from type 1 
receptor deficient (IFNAR1-/-) mice were still able to induce SOCS1 to the same level as 
compared to WT cells upon stimulation by different TLR ligands (103). Additionally, 
stimulation of the TNF-receptor led to an induction of SOCS1 in a JAK/STAT independent 
way (100). Further, Ramana et al. could show that upon stimulation with IFNγ, SOCS2 and 
SOCS3 were induced via a JAK1-dependent, but STAT1-independent pathway (105). 
Introduction 
12 
SOCS1 deficient mice are hyperresponsive to LPS, leading to an increase in TNF and IL12 
production. Mice that are deleted for SOCS1 die within the first weeks after birth because of 
a multi-inflammatory syndrome caused by an infiltration of multiple organs with inflammatory 
cells (86, 106, 107). The increased production of IFNγ is indicted to be a crucial mediator of 
this multiorgan inflammation (108). However, as IFNγ-/-/SOCS1-/- are still very sensitive to 
LPS induced shock, IFNγ independent mechanisms may exist (109, 110). Macrophages and 
DCs from SOCS1-/- mice produce increased levels of pro-inflammatory cytokines, such as 
TNF, IL12 and IFNγ upon ligation of TLRs (111). Several mechanisms have been proposed 
for the suppression of TLR induced cytokines by SOCS1. A direct effect of SOCS1 on the 
TLR-NFκB pathway could be shown. SOCS1 directly bound to p65 subunits of NF-κB, 
thereby facilitating ubiquitination and degradation of p65 (112-114). SOCS1 also bound 
tyrosine phosphorylated MAL (MyD88-adaptor like protein) through its interaction with 
Bruton´s tyrosine kinase (BTK) and induced ubiquitination and subsequent proteasomal 
degradation of MAL (115). Another inhibitory function of SOCS1 on IFNγ/JAK/STAT 
independent pathways could be shown by different groups. JAK/STAT independently 
induced SOCS1 was able to bind to IRAK, thereby inhibiting IL4 signalling (109, 110). Thus, 
SOCS1 could be responsible for LPS tolerance, probably in an INFγ dependent as well as 
independent way as described above. In addition to the NF-κB pathway, SOCS1 might 
regulate the stress-activated mitogen-activated protein kinases (MAPKs) JNK (c-JUN N-
terminal kinase) and p38 by binding to ASK1 (apoptosis signal-regulating kinase 1), which is 
an upstream activator of both JNK and p38 (116). These data suggest that SOCS1 could 
interfere also with TLR signalling.  
Also, Dectin-1 was shown to influence TLR signalling as presented for TLR2, TLR4 and to 
some extent for TLR 9 (63). Dennehy et al. demonstrated that co-ligation of Dectin-1 with 
TLR2 or TLR4 synergistically triggered IL10, IL23, TNF and IL6 production. On the other 
hand, IL12 secretion was suppressed upon co-ligation of Dectin-1 and TLR2 or TLR4. These 
results are similar to recent findings demonstrating that human DCs down-regulate IL12 
expression when stimulated via TLR2 and TLR7/8 simultaneously (117). Additionally, it has 
been described that Dectin-1 inhibits IL12 expression induced by a number of different TLRs 
beside TLR2, such as TLR9 or TLR7 (55, 63). On the other hand, it has been shown that 
Dectin-1 is only able to down-regulate TLR2 induced IL12 secretion (118). Thus, it had to be 
clarified within this study if the observed reciprocal regulation of IL12 and IL10, IL6, IL23 and 
TNFα is relevant for co-ligation of Dectin-1 and different TLRs as well. 
However, the signaling mechanism by which IL12 is downregulated following co-ligation of 
Dectin-1 and TLR2 has not been defined yet. As already described, SOCS1 seems to 
additionally modulate the intracellular network in TLR triggered cells; independently of 
JAK/STAT dependent pathways. Therefore, the question was raised whether SOCS1 could 
be induced in innate immune cells like dendritic cells and macrophages via engagement of 
Dectin-1, independently of TLRs. Furthermore, a possible influence of Dectin-1 induced 
SOCS1 on TLR stimulated cells had to be investigated in this study. 
Other studies focused on the properties of SOCS1 expressed in macrophages and dendritic 
cells on T-cell lineages since Th17 cells are proposed to be crucial in protection against 
fungal pathogens.  
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2.5. T cell responses to fungi 
Dendritic cells and macrophages provide an important link between innate and adaptive 
immunity. They are characterized by a high capacity of antigen processing, migration to 
lymphoid organs and expression of co-stimulatory molecules for lymphocyte activation. DCs 
have been proposed to direct the type of T helper (Th)-cell differentiation through their 
cytokine profile. For example, high amounts of IL12 produced by innate immune cells 
promote Th1-cell differentiation. Otherwise, TGFβ, IL6 and IL23 promote Th17 differentiation 
(119-121). 
Recognition of β-glucan structures presented by fungi like Candida albicans to Dectin-1 on 
innate immune cells results in protective anti-fungal immunity (120, 122). Whole pathogens, 
i.e. Candida albicans, activate a panel of different PRRs on APCs (46). Thus, interactions 
between intracellular pathways influence the later T-cell response, e.g. via induction of Th17- 
cells and concomitant repression of other Th-cell types like Th2-cells (123, 124).  
Th17-cell activation mainly occurs through the Dectin-1-Syk-CARD9 and mannose receptor 
signalling pathway in dendritic cells and macrophages, leading to IL17 production of CD4+ 
Th-cells (125). Activation of this pathway in DCs leads to the secretion of pro-inflammatory 
cytokines, including IL6, IL23 and TNFα but less IL12 (55, 63, 125). Fungi or fungal particles 
not only consist of Dectin-1 ligands, but also bind to TLRs, as shown for TLR2 and TLR6 
(44). This co-ligation of TLRs and Dectin-1 by fungal particles may be responsible for the low 
IL12 expression, as described above (2.3.1).  
In conjunction with these findings, it has been described in vitro that the induction of Th17-
cells by Dectin-1 triggered DCs is mediated through high amounts of IL6 and IL23 (125). In 
vivo, infection with Candida albicans promotes the differentiation of Th1 and Th17 responses 
(126, 127). Importantly, mice deficient in components of the Dectin-1 signalling pathway, i.e. 
CARD9, were not able to induce Th17 responses and were more susceptible to infections 
with C. albicans (128, 129). The different regulation of Th17 inducing cytokines (high 
amounts of IL6, IL23, TGFβ) and Th1 inducing cytokines (low levels of IL12) upon fungal 
infections suggests a collaboration between Dectin-1 and TLRs or other PRRs. 
Again, the question arose whether SOCS proteins induced in innate immune cells could play 
a role as modulators in this cross-talk between Dectin-1 and TLRs. This would link SOCS 
proteins that are expressed in innate immune cells to the different Th-cell responses. Indeed, 
SOCS proteins produced by DCs were linked to DC activation followed by T-cell 
differentiation (89, 130). It could be shown that the CD11c+CD8α+ DC subset produced larger 
amounts of IL12 and IFNγ and expressed lower levels of SOCS1 (130, 131). Additionally, 
SOCS1-siRNA treated DCs produced enormous amounts of IL12, the key cytokine to induce 
Th1 cells (84). SOCS3 also seems to manipulate Th-cell responses. SOCS3-transduced 
DCs have been shown to be highly effective inducers of Th2-cell differentiation in vitro and in 
vivo (132). Injection of WT mice with SOCS3 transduced DCs suppressed the development 
of experimental autoimmune encephalomyelitis (EAE), a Th17-cell mediated autoimmune 
disease. Suppression of EAE by SOCS3-transduced DCs might be due to the reduced Th17-
cell differentiation as a result of reduced IL23 production (132). Thus, the expression of 
SOCS proteins in DCs or macrophages might have a crucial role in the balance between 
cytokines inducing different Th-cell subsets, i.e. Th17 and Th1 or Th2 (133). Furthermore, 
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SOCS proteins have been shown to be expressed in Th-cells as well. It has been described 
that SOCS1 has an important role in Th17-cell development as it is highly expressed in 
differentiated (memory) Th17-cells (89, 134) . The antagonistic effect of IFNγ on Th17-cell 
differentiation is tightly regulated by SOCS1 (130, 134). Thus, it was suspected that SOCS1 
expressed by memory Th17-cells could be a mechanism for IFNγ resistance of memory 
Th17-cells.  
However, a direct link between SOCS1 produced in APCs and the Th-17 cell response upon 
infection with pathogens like Candida albicans or other fungi was not described at the 
beginning of this study. 
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2.6. Objectives of this work 
As illustrated in the chapters above, immune reactions upon infection, i.e. with fungi, have to 
be controlled very precisely in order to prevent overwhelming immune reactions. Thus, the 
interplay between different types of pattern recognition receptors seems to be crucial. 
Intracellular signalling following ligand binding and subsequent cytokine release is regulated 
very accurately by negative regulation, for example through suppressors of cytokine 
signalling (SOCS) proteins. The aim of this work was to analyze the induction of SOCS1 in 
Dectin-1 triggered myeloid cells and to study the impact of SOCS1 on different signalling 
pathways. 
First of all, it should be analyzed whether murine bone marrow derived dendritic cells 
(BMDCs) and macrophages (BMMs) are capable of inducing SOCS1 upon stimulation of 
Dectin-1. SOCS1 expression was measured on mRNA and protein level after stimulating 
Dectin-1 with different concentrations of a specific ligand (depleted Zymosan). 
In this context, the downstream signalling pathway leading to SOCS1 production should be 
examined in detail and the possible differences in BMDCs compared to BMMs should be 
identified, i.e. the contribution of NF-κB transcription factor. As MAPKs are described in 
conjunction with SOCS induction as well as Dectin-1 downstream signalling, one issue was 
to identify possible candidates involved in SOCS1 expression.  
Finally, the outcome of SOCS1 expressed in BMMs or BMDCs should be examined. 
Therefore, on the one hand, myeloid cells from SOCS1-/- mice should be analyzed to 
ascertain if SOCS1 could function as negative feedback inhibitor in Dectin-1 signalling 
pathway. On the other hand, the impact of SOCS1 induced via Dectin-1 as a cross-regulator 
for TLR signalling should be analyzed. Further, a possible link between innate and adaptive 
immune cells should be analyzed. Therefore, it should be assessed whether SOCS1 
knockout myeloid cells could influence T-cell priming in a co-culture setting. 
Clarifying of these issues should help to disclose a role for Dectin-1 induced SOCS1 as an 
inhibitor within PRR signalling pathways. 
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3. Materials and Methods 
3.1. Materials 
3.1.1. Instrumentation 
Instruments used throughout this study are listed in table 3-1. 
Table 3-1  List of instruments and suppliers  
 
AutoMACS 
 
Balance 
 
Blotting chamber 
 
Centrifuges 
 
 
 
Counting chamber 
 
Electrophoresis chamber 
 
Flow Cytometry 
 
Fluorescence-Inverse Microscope 
 
Gel Documentation-Sytstem 
(Chemiluminsecence detection 
 
Inverse Microscope 
 
Heating Block 
 
Incubator 
 
Magnetic shaking device 
 
Microtiterplate Photometer 
 
Orbital Shaker 
 
 
 
pH-Meter 
 
Power Supply 
 
Reflected Light Microscope 
 
Safety cabinet 
 
SDS-PAGE System 
 
Thermocycler 
 
 
 
 
Spectrophotometer 
 
UV platform 
 
Vortexer 
 
 
Miltenyi Biotec, Bergisch-Gladbach 
 
EW600-2M, Kern & Sohn GmbH, Balingen 
 
PerfectBlue™ Tank-Elektroblotter Web S, Peqlab, Erlangen 
 
1. Biofuge stratos, Multifuge 3S-R, Hereaus Instruments, Hanau 
3. Biofuge fresco, Heraeus Instruments, Hanau 
4. Biofuge pico, Heraeus Instruments, Hanau 
 
Neubauer 0.00025 mm2/0.1 mm, Brand GmbH, Schwerin 
 
PerfectBlue Mini ExM, Gelsize 14.4 x 10.2 cm, Peqlab, Erlangen 
 
BD FACS Canto (2-laser, 6colour) BD Biosciences, Heidelberg 
 
Leica DMI 6000B, Leica Microsystems GmbH, Wetzlar 
 
CN-3000.WL, Peqlab, Erlangen  
 
 
Axiovert 25 CFL, Carl Zeiss Jena GmbH, Jena 
 
Thermomixer comfort, Eppendorf AG, Hamburg 
 
BBD6226, Heraus Instruments, Hanau 
 
IKA
®
 RCT basic, IKA
®
-Labortechnik, Staufen i.Br. 
 
SUNRISE Absorbance Reader, Tecan, Salzburg, Austria 
 
1. Mini Rocker MR-1, Peqlab, Erlangen 
2. Rocky
®
3D, Labortechnik Fröbel GmbH, Lindau 
3. RS-24, Lab4You GmbH, Berlin 
 
Seven Easy, Mettler Toledo, Gießen 
 
PowerSupply 1000/500, Bio-Rad, München 
 
Leica DMLS, Leica Microsystems GmbH, Wetzlar 
 
Herasafe, Class II, Heraus Instruments, Hanau 
 
PerfectBlue™ Twin S, Peqlab, Erlangen 
 
1.Quantitative RT-PCR: 7900HT Fast Real-Time PCR System, Applied 
Biosystems, Darmstadt 
2. Primus 25 advanced®, Peqlab, Erlangen 
3. Primus 96 advanced
®
 Gradient, Peqlab, Erlangen 
 
NanoDrop®ND-1000 Spectrophotometer, Peqlab, Erlangen 
 
ECX-26M, Peqlab, Erlangen 
 
MS 1, IKA
®
 Inc., Wilmington, USA 
 
 
Materials and Methods 
17 
3.1.2. Consumables 
Single-use material is listed in table 3-2. 
Table 3-2  List of consumables and suppliers  
 
Blot membrane, Nitrocellulose 
 
Blotting paper 
 
Caps 
 
Cell culture bottles 
 
Cell culture plates (flat bottom) 
 
Cell culture dishes 
 
Cell scraper 
 
Cell strainer 
 
Cryo tubes 
 
ELISA plates 
 
FACS tubes 
 
Gauge needle 
 
High performance chemiluminescence film 
 
PCR plates 
 
PCR tubes 
 
Petri dishes 
 
Pipet tips 
 
 
 
 
Protective Sheets 
 
Sterile filter 
 
Syringe 
 
Transwell inserts/plates 
 
Tubes 
 
 
Immobilon-P Transfer, 0.45 μm pore size, MilliporeBillerica, USA 
 
Whatman
®
 GB003, Whatman GmbH, Dassel 
 
Eppendorf-caps 0.5 ml; 1.5 ml; 2 ml; Eppendorf AG, Hamburg 
 
Cellstar
®
 25 cm
2
 / 75 cm
2
 / 175 cm
2
, Greiner Bio-One GmbH, Frickenhausen 
 
Cellstar
®
 6-/24-/96-well plates, Greiner Bio-One GmbH, Frickenhausen 
 
58 cm
2
;145 cm², Nunc GmbH & Co. KG, Wiesbaden 
 
Disposable Cell Scraper, Greiner Bio-One GmbH, Frickenhausen 
 
100 μm, 70 μm cell strainer, BD Biosciences, Heidelberg 
 
Nunc GmbH & Co. KG, Wiesbaden 
 
96 well, Greiner Bio-One GmbH, Frickenhausen 
 
BD Falcon
TM
 5 ml, BD Biosciences, Heidelberg 
 
MicrolanceTM 3, 27G, 0.4 mm x 19 mm, BD Biosciences, Heidelberg 
 
Amersham, GE Healthcare, Buckinghamshire, UK 
 
96 well plates, semi-skimed, Steinbrenner, Wiesenbach 
 
PP-PCR-tubes, Nat. 0.2 ml, Greiner Bio-One GmbH, Frickenhausen 
 
145 mm x 20 mm Greiner Bio-One GmbH, Frickenhausen 
 
1. TipOne® (0,1-100 µl; 1-200 µl; 100-1000 µl), Pipet tips, Starlab GmbH 
Ahrensburg 
2. TipOne® (0,1-100 µl; 1-200 µl; 100-1000 µl), Filter tips, Starlab GmbH 
Ahrensburg 
 
Absolute QPCR Seal, ABgene House, Epsom, UK 
 
Millex
®
-GS 0,22 µm, Millipore, Billerica, USA 
 
BD Discardit II 27G, 5 ml and 10ml, BD Biosciences, Heidelberg 
 
Costar
®
 6,5 mm Transwell
®
, pore size 0,4 μm, clear, 24 well, Corning 
 
Cellstar Tubes, (50 ml, 15 ml), Greiner Bio-One, Frickenhausen 
 
 
3.1.3. Chemicals and reagents 
If not stated otherwise, all solvents and chemicals were purchased from the following 
companies: Merck, Calbiochem (Darmstadt) and Sigma-Aldrich (Taufkirchen) with a purity of 
“pro analysi”. General reagents are listed in table 3-3. 
Table 3-3  List of essential materials with suppliers used in this study 
 
Aceton 
Acrylamid Rotiphenol 
Agarose ultra pure 
Ammoniumpersulfat (APS) 
Aprotinin 
Aqua ad iniectabilia (10 ml, 1000 ml) 
Bovine Serumalbumin (BSA) 
Bromphenol blue 
 
 
Riedel-de Haën AG, Seelze 
Roth, Karlsruhe 
Gibco BRL, Life TechnologiesTM, Eggenstein 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Braun, Melsungen 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
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Dimethylsulfoxid (DMSO) 
Dithiothreitol 
dNTPs 
Dulbecco´s Modified Eagle Medium (DMEM, 1x) 
Acetic acid (100%) 
Ethanol 
Ethidiumbromide 
FACSClean
TM 
FACSFlow
TM 
Fetale Calf Serum (FCS)
 
Gel-loading buffer (6x) for agarose gels 
Glycerol 
Glycin 
Hydrochloric acid (HCl) (37%) 
IGEPAL
® 
CA-630 
Isopropanol 
Kanamycin 
Leupeptin (-hydrochloride) 
L-Glutamin, 200mM (100x) 
Lipofectamin
TM 
2000 
Lipofectamin
TM 
2000 RNAiMax 
Magnesiumchloride-Hexahydrate (MgCl2x6H2O) 
Methylthiazoltetrazolium (MTT) 
ß-Mercaptoethanol 
Methanol 
Opti-MEM® I Reduced Serum Medium with GlutaMAX™ I  
Paraformaldehyde 
PBS (1x) for cell culture 
Penicillin/Streptomycin solution (100x) 
Pepstatin A 
Percoll (p = 1.09 g/ml) 
Phenylmethylsulfonylfluoride (PMSF) 
Phosphoric acid (H3PO4) 
Poly-D-Lysin 
Restore™ Western Blot stripping buffer 
RPMI 1640 Medium (1x) 
Sodiumchloride (NaCl) 
Sodiumdodecylsulfate (SDS) 
Sodiumfluoride (NaF) 
Sodiumorthovanadate (Na3VO4) 
Sodiumhydroxide (1 M) 
N,N,N´,N´-Tetramethylethylethylendiamine (TEMED) 
Tris-Base 
Triton X-100 
Trypan blue 
Trypsin/EDTA (10x) 
Tween 20 
 
 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
MBI Fermentas, St. Leon-Rot 
Biochrom AG, Berlin 
Merck, Darmstadt 
Riedel-de Haën AG, Seelze 
Merck, Darmstadt 
BD Biosciences, Heidelberg 
BD Biosciences, Heidelberg 
Biowest, Nuaillé, Frankreich 
MBI Fermentas, St. Leon-Rot 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Merck, Darmstadt 
Sigma-Aldrich, Taufkirchen 
Riedel-de Haën AG, Seelze 
InvitrogenTM, Karlsruhe 
Sigma-Aldrich, Taufkirchen 
Biochrom AG, Berlin 
InvitrogenTM, Karlsruhe 
InvitrogenTM, Karlsruhe 
Merck, Darmstadt 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Riedel-de Haën AG, Seelze 
Invitrogen
TM
, Karlsruhe 
Merck, Darmstadt 
PAA Laboratories, Pasching, Austria 
PAA Laboratories, Pasching, Austria 
Sigma-Aldrich, Taufkirchen 
Biochrome AG, Berlin 
Sigma-Aldrich, Taufkirchen 
Merck, Darmstadt 
Sigma-Aldrich, Taufkirchen 
ThermoScientific, Karlsruhe 
Biochrom AG, Berlin 
AppliChem GmbH, Darmstadt 
AppliChem GmbH, Darmstadt 
Roth, Karlsruhe 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
PAA Laboratories, Pasching, Austria 
Sigma-Aldrich, Taufkirchen 
 
 
3.1.4. Water 
To avoid microbial contaminations, all buffers, solutions and media for cell culture and 
stimulation experiments were prepared with pyrogen-free water (Braun, Melsungen, 
Germany), if not indicated otherwise. 
3.1.5. Buffers and solutions 
Selected buffers and solutions for Western blot, cell culture, ELISA, nucleic acid work and 
EMSA are listed in Table 3-4, Table 3-5, Table 3-6, Table 3-7 and Table 3-8, respectively. 
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Table 3-4  List of commonly used buffers and solutions used for western blot 
 
RIPA lysis buffer 
 
 
 
 
Acrylamid stock solution 
 
SDS running buffer 
 
SDS sample buffer (4x) 
 
 
SDS blot buffer 
 
Stripping buffer 
 
SDS stacking gel buffer (2x) 
 
SDS separating gel buffer (3x) 
 
Blocking buffer 
 
 
Antibody dilution buffer 
 
 
Wash buffer 
 
10x TBS 
 
 
50 mM Tris-HCl, pH 7.4; 1 % (v/v) Igepal; 0.25 % (v/v) Natriumdeoxycholat; 
150 mM NaCl; 1mM EDTA 
Ad before use: 1 µg/ml of Aprotinin; Leupeptin; Pepstatin and 1 mM Na3VO4, NaF 
and PMSF. 
 
30 % (v/v) acrylamid and bisacrylamid solved 29:1 
 
25 mM Tris-base, pH 8.3; 192 mM Glycin; 0.1 % SDS (w/v) 
 
200 mM Tris-HCl, pH 6.8; 20 % (v/v) β-Mercaptoethanol; 8 % (w/v) SDS; 40 % (v/v) 
Glycerol; 0.04 % (w/v) Bromphenoleblue 1 % (w/v) 
 
25 mM Tris-base, pH 8.3; 192 mM Glycin, 10 % (v/v) Methanol 
 
62.5 mM Tris-HCl, pH 6.7; 100 mM β-Mercaptoethanol; 2 % (w/v) SDS 
 
250 mM Tris-HCl, 0.2 % (w/v) SDS; degassed before use 
 
1.125 M Tris-HCl, pH 8.8; 0.3 % (w/v) SDS; degassed before use 
 
1x TBS; 0.1 % (v/v) Tween20; 5 % (w/v) milk powder 
For SOCS1 antibody: 1x PBS; 0.05% (v/v) Tween20; 3% (w/v) milk powder 
 
1x TBS; 0.1 % (v/v) Tween20; 5 % (w/v) BSA 
For SOCS1 antibody: 1x PBS; 0.05% (v/v) Tween20; 3% (w/v) milk powder 
 
1x TBS; 0.1 % (v/v) Tween20 
 
100 mM Tris-HCl, pH 8.0; 1.5 M NaCl 
 
Table 3-5  List of commonly used buffers and solutions used for cell culture 
 
Trypsin solution 
 
Trypan blue solution 
 
Penicillin/Streptomycin (100x) 
 
10x PBS 
 
0.05 % (v/v) trypsin; 0.02 % (v/v) EDTA in 1x PBS 
 
2 mg/ml trypan blue in 1x PBS 
 
10000 U/ml penicillin G; 10 mg/ml streptomycin; 0.09 % (w/v) NaCl 
 
80 mM di-sodiumhydrogenphosphate; 20 mM sodium-di-hydrogenphosphate; 1.4 M 
NaCl; pH 7.4 
 
Table 3-6  List of commonly used buffers and solutions for ELISA 
 
Coating buffer (pH 9.5) 
 
 
Coating buffer (pH 6.5) 
 
 
Blocking buffer 
 
Wash buffer 
 
0.1 M Sodiumcarbonate: 8.4 g NaHCO3 ; 3.6 g Na2CO3; adjust to pH 9.5; ad 1000 
ml H2O 
 
0.2 M Sodiumphosphate: 11.8 g Na2HPO4; 16.1 g NaH2PO4; adjust to pH 6.5; ad 
1000 ml H2O 
 
1x PBS; 10 % (v/v) FCS 
 
1x PBS; 0.05 % (v/v) Tween20 
 
Table 3-7  List of commonly used buffers and solutions used for nucleic acid work 
 
TAE (50x) 
 
TE 
 
Ethidium-bromide solution 
 
 
2 M Tris-Acetat, pH 8.0; 100 mM EDTA 
 
10 mM Tris-HCl, pH 8.0; 1 mM EDTA 
 
1µg/ml ethidium bromide in H2Odest 
Table 3-8  List of used buffers and solutions for EMSA 
 
Lysis buffer A 
 
Lysis buffer C 
 
 
TBE (10x) 
 
Native gel 
 
 
10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl 
 
20 mM HEPES-KOH, pH 7.9; 420 mM NaCl; 1.5 mM MgCl2; 
0.2 mM EDTA, pH 8.0; 25 % (v/v) Glycerol 
 
0.089 M Tris; 0.089 M Boric acid; 20 mM EDTA; pH 8.0 
 
9 % (v/v) Acrylamid 19:1, 1x TBE buffer; 13 % (v/v) Glycerol; 
0.06 % (v/v) TEMED; 0.06 % (v/v) APS 
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Binding buffer (5x) 
 
 
Loading buffer (20x) 
 
 
Reaction mixture (premix) 
 
 
100 mM HEPES, pH 8.0; 250 mM KCl; 2.5 mM DTT; 0.25 mM 
EDTA; 5 mM MgCl2; 25 % (v/v) Glycerol 
 
0.25 % (w/v) Bromphenol blue; 50 % (w/v) Xylem cyano; 40% 
(w/v) Sucrose 
 
1x binding buffer; 1x Poly (IC); 0.1 % (v/v) IGEPAL; 40 fmol 
biotinylated probe (egr1), 9 µg nuclear protein extract 
 
 
3.1.6. Kits 
Purchased kits used for this study are listed in table 3-9. 
Table 3-9  List of purchased kits and suppliers 
 
Absolute QPCR ROX
®
Mix 
 
BCA™ Protein Assay Reagent Kit 
 
BD OptEIA™ ELISA Set (IL12p40, IL10, IL6, TNFα) 
 
CD4+ T cell isolation kit II 
 
eBioscience ELISA (IFNγ, IL23, IL4, TGFß)  
 
ELISA R&D Systems (IL17, KC)  
 
High Pure RNA Isolation Kit 
 
High Speed Maxi Kit 
 
High-capacity cDNA transcription kit 
 
Immobilon™ Western Chemilumineszenz HRP Substrate 
 
Nuclear extract kit 
 
PowerSYBR
®
Green PCR Master Mix 
 
peqGOLD total RNA kit 
 
QIAamp
®
DNA Blood Mini kit 
 
TransAM
®
 NF-κB Transcription Factor Assay Kit 
 
 
Thermo Scientific, Warrington, UK 
 
Pierce Biotechnology, Rockford, USA 
 
BD Biosciences Pharminogen, Heidelberg 
 
Miltenyi Biotec, Bergisch Gladbach 
 
eBioscience, Frankfurt 
 
R&D Systems, Abindon, UK 
 
Roche, Mannheim 
 
Qiagen, Hilden 
 
Applied Biosystems, Life Technologies, Darmstadt 
 
Millipore, Schwalbach 
 
Active Motif, La Hulpe, Belgium 
 
Applied Biosystems, Life Technologies, Darmstad 
 
peqlab, Erlangen 
 
Qiagen, Hilden 
 
Active Motif, La Hulpe, Belgium 
 
3.1.7. Primer 
Probe for Electrophoretic Mobility Shift Assay (EMSA) 
Table 3-10  Sequence of probes used for EMSA 
 
Target gene 
 
 
Sequence 5’-3’ 
 
Transcription factor 
 
 
SOCS1.2 fw (promoter region) 
 
SOCS1.2 rv (promoter region) 
 
 
Cy3-AAGACTGGCGCAGGGGCGGGCGCC 
 
Cy3-GGCGCCCGCCCCTGCGCCAGTCTT 
 
egr1 
 
egr1 
 
 
Primer for quantitative real-time (RT )-PCR 
Primers were designed with the software Primer3 (http://frodo.wi.mit.edu). Where possible, 
primers were placed on exon/intron boundaries to avoid amplification of genomic DNA. For 
this reason, only monoexonic genes were sensitive to amplification from genomic DNA 
(Table 3-11). Lyophilized Primers (fw: forward primer; rv: reverse Primer; 0.01 µmol, salt 
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free) and probes (pr) were purchaised from Eurofins MWG Operon, adjusted to 50 pmol/µl 
with aquadest. Primer aliquots were stored at -20°C. 
Table 3-11  Primer sequences for the amplification of murine transcripts 
 
Gene 
 
 
Sequence 5’-3’ 
 
 
Product 
(cDNA) 
 
 
Product 
(gen. DNA)
a 
 
 
Amplicon 
position 
 
 
Data base
b
 
 
 
β-actin 
 
 
 
 
SOCS1 
 
 
 
 
SOCS3 
 
 
 
 
CIS 
 
 
 
 
egr1 
 
 
 
 
 
egr2 
 
 
 
 
 
IRF7 
 
 
 
 
 
IL17 
 
 
 
 
 
IFNγ 
 
 
 
 
 
IL23p19 
 
 
 
 
 
Pyk2 
 
 
 
 
 
IL10 
 
 
 
 
 
IFN-ß 
 
 
 
 
 
RORγT 
 
 
 
 
 
 
Tbet 
 
 
fw 
 
rv 
 
pr 
 
fw 
 
rv 
 
pr 
 
fw 
 
rv 
 
pr 
 
fw 
 
rv 
 
pr 
 
fw 
 
rv 
 
fw 
 
rv 
 
fw 
 
rv 
 
fw 
 
rv 
 
fw 
 
rv 
 
fw 
 
rv 
 
fw 
 
rv 
 
fw 
 
rv 
 
fw 
 
rv  
 
fw 
 
rv 
 
 
fw 
 
rv 
 
CCCTGTGCTGCTCACCGA 
 
ACAGTGTGGGTGACCCCGTC 
 
CCCCTGAACCCTAAGGCCAACCG 
 
CACCTTCTTGGTGCGCG 
 
CGCCACGTAGTGCTCCAG 
 
TCGCCAACGGAACTGCTTCTTCG 
 
ACCCACAGCAAGTTTCCCG 
 
AGTAGAATCCGCTCTCCTGCAG 
 
TTGCGCACGGCGTTCACCAC 
 
GAACCGAAGGTGCTAGACCCT 
 
TGTACCCTCCGGCATCTTCT 
 
ATCTGCTGTGCATAGCCAAGACGTTCTCC 
 
GCCTCGTGAGCATGACCAAT 
 
GCAGAGGAAGACGATGAAGCA 
 
GTGTCGGATCTGCATGCGAAACTT 
 
GCAAACTTGCGGCCACAATAGTCA 
 
CGAGTGCTGTTTGGAGACTG 
 
AGCCCAGGCCTTGAAGAT 
 
CAAAACCAGGGCATTTCTGT 
 
ATGGTGCTGTCTTCCTGACC 
 
TCAAGTGGCATAGATGTGGAAGAA 
 
TGGCTCTGCAGGATTTTCATG 
 
CCAGCGGGACATATGAATCT 
 
GATGTCAGAGTCAAGCAGGTG 
 
ACCAGTGGATGTGGAGAAGG 
 
ACTCAGGAGGATGGAGGTGA 
 
GGTTGCCAAGCCTTATCGGA 
 
ACCTGCTCCACTGCCTTGCT 
 
CCCTATGGAGATGACGGAG 
 
CTGTCTGCTGGTGGAGTTCA 
 
AATGTGGCCTACTCCTGCAC 
 
TCCCTCTGCTTCTTGGACAT 
 
 
GGTGTCTGGGAAGCTGAGAG 
 
CCACATCCACAAACATCCTG 
 
 
 
 186 bp 
 
 
 
 
 189 bp 
 
 
 
 
 136 bp 
 
 
 
 
 159 bp 
 
 
 
 77 bp 
 
 
 
 94 bp 
 
 
 
 163 bp 
 
 
 
 164 bp 
 
 
 
 92 bp 
 
 
 
 180 bp 
 
 
 
 145 bp 
 
 
 
 193 bp 
 
 
 
 161 bp 
 
 
 
 152 bp 
 
 
 
 
 173 bp 
 
 
 
 
- 
 
 
 
 
189 bp 
 
 
 
 
136 bp 
 
 
 
 
159 bp 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
 
- 
 
 
383-400 
 
568-549 
 
405-427 
 
418-434 
 
606-589 
 
439-461 
 
24-41 
 
159-138 
 
127-146 
 
313-351 
 
471-452 
 
359-387 
 
751-770 
 
827-807 
 
1517-1540 
 
1610-1587 
 
468-487 
 
630-613 
 
115-134 
 
278-259 
 
222-245 
 
313-293 
 
260-279 
 
459-439 
 
154-173 
 
298-279 
 
300-319 
 
492-473 
 
197-216 
 
357-338 
 
259-278 
 
429-410 
 
 
545-564 
 
736-717 
 
 
 
 
NM_007393 
 
 
 
 
U88325 
 
 
 
 
U88328 
 
 
 
 
D31943 
 
 
 
NM_007913.5 
 
 
 
NM_010118.3 
 
 
 
NM_001252601.1 
 
 
 
NM1_45856.2 
 
 
 
NM_008337.3 
 
 
 
NM_031252 
 
 
 
NM_011203.2 
 
 
 
NM_010548.2 
 
 
 
NM_010510 
 
 
 
NM_011281 
 
 
 
 
NM_019507 
 
 
 
                                                          
a no amplification of genomic DNA due to extended size by exon/intron structure 
b National Center for Biotechnology Information (NCBI: www.ncbi.nlm.nih.gov) 
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Primer for the genotyping of conditional SOCS1 ko mice 
Table 3-12  Primer sequences for genotyping of SOCS1 ko mice 
 
Gene locus 
 
 
Sequence 5’-3’ 
 
 
Product size 
 
 
Cre recombinase (LysMCre) 
 
 
SOCS1 ko 
 
 
SOCS1 wt 
 
 
LoxP (“hCD4 floxed”) 
 
 
fw 
 
rv 
 
fw 
 
rv 
 
fw 
 
rv 
 
fw 
 
rv 
 
CACCAAAATTTGCCTGCATT 
 
CCCAGGCTAAGTGCCTTCTC 
 
CCTCCAGCTGGCCCCTCGAGTAGGATG 
 
CATTCGCCATTCAGGCTGCGCAACTGTT 
 
GCATCCCTCTTAACCCGGTAC 
 
AAATGAAGCCAGAGACCCTCC 
 
TTAGGCACTTGCTTCTGGTGC 
 
TTCTGGAAAGCTAGCACCACG 
 
 
 
641 bp 
 
 
160 bp 
 
 
 
340 bp 
 
 
 
600 bp 
 
 
3.1.8. Markers 
Molecular markers used for electrophoresis are listed in table 3-13 
Table 3-13  Markers used in nucleic acid – and protein – work 
 
GeneRuler™DNA Ladder Mix (100-10000 bp) 
 
PageRuler™Prestained Protein Ladder Plus 
 
Fermentas, St. Leon-Rot 
 
Fermentas, St. Leon-Rot 
 
 
3.1.9. siRNAs 
All siRNAs were purchased in HPLC purity from Qiagen (Hilden). Sequences shown in table 
3-14 confer to the respective passenger-strand of the siRNA. 
Table 3-14  List of relevant siRNAs used in this study 
 
Name 
 
Sequence 5’-3’ 
 
 
Target gene 
 
Mm_Ptk2b_4  
 
siCon 
 
 
UAAAUUCCAAUGUACACUGTA 
 
GCAAGCUGACCCUGAAGUUCAU 
 
 
murine Pyk2 (Ptk2b) 
 
no target 
 
3.1.10. Enzymes 
Enzymes (provided with reaction buffers) used throughout the study are listed in table 3-15. 
Table 3-15  List of essential enzymes and suppliers 
 
AccuTaq™ LA DNA Polymerase (5 U/µl) 
 
DNase I 
 
Pfu Polymerase  
 
Proteinase K 
 
Taq DNA Polymerase 
 
 
Sigma-Aldrich, Taufkirchen 
 
MBI Fermentas, St. Leon-Rot 
 
MBI Fermentas, St. Leon-Rot 
 
MBI Fermentas, St. Leon-Rot 
 
MBI Fermentas, St. Leon-Rot 
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3.1.11. Antibodies 
Antibodies used for the indicated applications are listed in table 3-16 to 3-18. 
Table 3-16  List of antibodies for flow-cytometry 
 
Species 
reactivity 
 
 
Supplier 
 
Fluorescence 
label 
 
 
Antigen 
 
Clone 
 
mouse 
 
mouse 
 
mouse 
 
mouse 
 
mouse 
 
mouse 
 
mouse 
 
mouse 
 
mouse 
 
mouse 
 
mouse 
 
human 
 
 
AbD Serotec (Düsseldorf) 
 
BD (Heidelberg) 
 
BD (Heidelberg) 
 
BD (Heidelberg 
 
Miltenyi Biotec (Bergisch Gladbach) 
 
BD (Heidelberg) 
 
BD (Heidelberg) 
 
BD (Heidelberg) 
 
BioLegend (Uithoorn, Netherlands) 
 
BD (Heidelberg) 
 
AbD Serotec (Düsseldorf) 
 
BD (Heidelberg) 
 
 
FITC 
 
APC-Cy7 
 
APC 
 
FITC 
 
PE 
 
FITC 
 
FITC 
 
FITC 
 
PE-Cy7 
 
PE 
 
FITC 
 
PE 
 
 
Beta Glucan 
 
CD11b 
 
CD11c 
 
CD3ε 
 
CD4 
 
CD40 
 
CD80 
 
CD86 
 
F480 
 
I-A/I-E class MHCII 
 
IgG2b 
 
CD4 
 
 
101210 
 
M1/70 
 
HL3 
 
66275 
 
5051025059 
 
HM-40-3 
 
16-10A1 
 
GL1 
 
BM8 
 
2G9/M5/114.15.2 
 
101210 
 
5090120098 
 
 
Table 3-17  List of antibodies used for Western blot analysis 
 
Species 
 
 
Source 
 
Antigen  
 
Phosphorylation 
sites 
 
 
Final 
dilution 
 
Rabbit 
 
Rabbit 
 
Rabbit 
 
Rabbit 
 
Rabbit 
 
Rabbit 
 
Rabbit 
 
Rabbit 
 
Rabbit 
 
Rabbit 
 
Rabbit 
 
Mouse 
 
Anti-mouse 
 
Anti-rabbit 
 
 
Cell Signaling Technology (Frankfurt) 
 
Cell Signaling Technology (Frankfurt) 
 
Cell Signaling Technology (Frankfurt) 
 
Cell Signaling Technology (Frankfurt) 
 
Cell Signaling Technology (Frankfurt) 
 
Cell Signaling Technology (Frankfurt) 
 
Cell Signaling Technology (Frankfurt) 
 
Cell Signaling Technology (Frankfurt) 
 
Cell Signaling Technology (Frankfurt) 
 
Cell Signaling Technology (Frankfurt) 
 
Cell Signaling Technology (Frankfurt) 
 
Millipore (Schwalbach) 
 
Cell Signaling Technology (Frankfurt) 
 
Cell Signaling Technology (Frankfurt) 
 
 
β-actin 
 
p42/p44 (ERK) 
 
IκBα 
 
pp42/p44 
 
pIκBα 
 
pJNK/SAPK  
 
pp38 
 
pPyk2 
 
Pyk2 
 
pSyk 
 
pSTAT1 
 
SOCS1 
 
Mouse IgG (HRP coupled) 
 
Rabbit IgG (HRP coupled) 
 
- 
 
- 
 
- 
 
Tyr202/Tyr204 
 
Ser32 
 
Thr183/Tyr185 
 
Thr180/Tyr182 
 
Tyr402 
 
- 
 
Tyr519/Tyr520 
 
Tyr701 
 
- 
 
- 
 
- 
 
1 : 1000 
 
1 : 1000 
 
1 : 1000 
 
1 : 1000 
 
1 : 1000 
 
1 : 1000 
 
1 : 1000 
 
1 : 1000 
 
1 : 1000 
 
1 : 1000 
 
1 : 1000 
 
1 : 500 
 
1 : 4000 
 
1 : 4000 
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Table 3-18  List of antibodies used for in vitro T-cell assays and IL10 blocking experiments 
 
Species 
 
 
Source 
 
 
Antigen 
 
 
Anti-mouse 
 
Anti-mouse 
 
Anti-mouse 
 
Anti-mouse 
 
Anti-mouse 
 
BD (Heidelberg) 
 
BD (Heidelberg) 
 
PeproTech (Düsseldorf) 
 
eBioscience (Frankfurt) 
 
eBioscience (Frankfurt) 
 
CD28 
 
CD3ε 
 
IFNγ 
 
IL10 
 
IL4 
 
 
3.1.12. Stimulating agents and inhibitors 
Stimuli 
Stimuli used in this study are listed in table 3-19. 
Table 3-19  List of stimuli and sources 
 
Stimulus 
 
Source 
 
Stock concentration 
 
 
CpG-ODN 1668-PTO 
(5´-TCCATGACGTTCCTGATGCT-3´) fully 
PTO modified 
 
Depleted Zymosan 
 
Ionomycin from Streptomyces conglobatus 
 
Lipopolysaccharid (LPS) from Salmonella 
minnesota (smooth form) 
 
Pam3Cys-Ser-(Lys)4 [Pam3CSK4] 
 
 
Phorbol-12-myristate-13-acetate (PMA) 
 
Polyinosinic-polycytidylic acid [Poly(I:C)] 
 
R848 (resiquimod) 
 
Recombinant murine IFNγ 
 
Recombinant murine IL10 
 
Recombinant murine IL12 
 
Recombinant murine IL4 
 
Recombinant murine IL6 
 
Recombinant human TGFß 
 
 
MolBiol (Berlin) 
 
 
 
InvivoGen (Toulouse, France) 
 
Merck, Calbiochem (Darmstadt) 
 
Provided by U. Seydel (Borstel) 
 
 
EMC Microcollections GmbH 
(Tübingen) 
 
Merck, Calbiochem (Darmstadt) 
 
Sigma-Aldrich (Taufkirchen) 
 
InvivoGen (Toulouse, France) 
 
PeproTech (Hamburg) 
 
Immunotools (Friesoythe) 
 
PeproTech (Hamburg) 
 
PeproTech (Hamburg) 
 
Peprotech (Hamburg) 
 
Peprotech (Hamburg) 
 
 
250 µM (in Aqua dest.) 
 
 
 
5 mg/ml (in Aqua dest.) 
 
1 mg/ml (in DMSO) 
 
100 µg/ml (in Aqua dest.) 
 
 
1 mg/ml (in Aqua dest.) 
 
 
1 mg/ml (in DMSO) 
 
5 mg/ml (in Aqua dest.) 
 
1 mg/ml (in Aqua dest.) 
 
1 mg/ml (in Aqua dest.) 
 
100 µg/ml (in 0.1% BSA w/v,Aqua dest.) 
 
100 µg/ml (in Aqua dest.) 
 
100 µg/ml (in Aqua dest.) 
 
20 µg/ml (in 0.1% BSA w/v, PBS) 
 
10 µg/ml (in 0.1% BSA w/v, PBS) 
 
Inhibitors 
Inhibitors used in this study are listed in table 3-20. 
Table 3-20 List of inhibitors and sources 
 
Inhibitor 
 
Source 
 
Stock concentration 
 
 
 AG17 (Pyk2 inhibitor) 
 
BAPTA (Calcium chelator) 
 
 
 
Merck, Calbiochem (Darmstadt) 
 
Merck, Calbiochem (Darmstadt) 
 
 
 
10 mM (in DMSO) 
 
10 mM (in DMSO) 
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Bay 11-7082 (NF-κB inhibitor) 
 
Bay 61-3606 (Syk inhibitor IV) 
 
Cycloheximid (inhibitor of protein translation 
 
KN93 (CaMK inhibitor) 
 
PP1 (Src inhibitor) 
 
Merck, Calbiochem (Darmstadt) 
 
Merck, Calbiochem (Darmstadt) 
 
Merck, Calbiochem (Darmstadt) 
 
Merck, Calbiochem (Darmstadt) 
 
Merck, Calbiochem (Darmstadt) 
 
 
10 mM (in DMSO) 
 
10 mM (In DMSO) 
 
- (freshly prepared) 
 
10 mM (in DMSO) 
 
10 mM (in DMSO) 
 
3.1.13. Mouse strains 
C57BL/6 mice were purchased from Charles River Laboratories (Willmington, MA USA) and 
bred under specific pathogen free (SPF) conditions. Breeding and monthly control of 
infections were performed according to the list of GV-SOLAS 1995. Killing and dissection 
were approved and experiments were properly recorded and reported to the regional 
commission Tübingen.  
Knockout mice 
All knockout mice were on C57BL/6 background. IFN-α/β receptor deficient mice (IFNAR1-/-) 
were kindly provided by Rainer Zawatzky (Heidelberg, Germany), MyD88/TRIF double 
deficient mice by U. Kalinke (Düsseldorf, Germany). Dectin1-/- mice were received from G. 
Brown (Aberdeen, UK), IFNγ-/- and SOCS1-/-/IFNγ-/- were obtained from Martin Rottenberg 
(Stockholm, Sweden). Conditional SOCS1 knockout mice were received from T. Kay 
(Melbourne, Australia). 
3.1.14. Eukarytotic cells  
All cells were cultured at 37 °C and 5 % CO2 in a humidified environment. Composition of the 
respcetive cell media is decribed in chapter 3.1.15 and 3.2.1 (“generation and stimulation of 
bone marrow cerived dendritic cells and macrophages”). 
Murine BMDCs and BMMs 
Murine bone marrow derived dendritic cells (BMDCs) and macrophages (BMMs) were 
generated from bone marrow out of tibiae and femur as described in  
Murine T-cells 
Isolation of untouched murine CD4+ Th-cells from spleen was performed as described in 
3.2.1. 
3.1.15. Growth media 
Inactivation of fetal calf serum (FCS) (Biowest, France) 
Heat treatment of FCS inactivates the containing complement proteins. Sterile FCS was heat 
inactivated at 56 °C for 1 h, decanted into aliquots and stored at -20 °C. 
RPMI 1640 
Before use, the medium was complemented with 1 % (v/v) Penicillin / Streptomycin, 50 mM 
2-Mercaptoethanol and with 10 % (v/v) or 2 % (v/v) heat inactivated FCS. During 
differentiation DCs were grown in medium with 10 % FCS but when harvested, the cells 
where starved in medium with 2 % FCS before stimulation. 
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DMEM 
DMEM (Dulbecco’s modified eagle media) was supplemented with 10 % (v/v) heat 
inactivated FCS (or 2 % in case of stimulation assays of BMMs) and 1 % Penicillin G (100 
IU/ml) / Streptomycin (100 IU/ml). 
3.2. Methods 
3.2.1. Cell biology 
Cell culture of mammalian cells 
All eukaryotic cells were grown under 95 % humidity atmosphere at 37 °C and 5% CO2 in an 
incubator. To determine the cell number of a cell suspension, 10 µl of cell suspension was 
mixed with 90 µl of trypan blue solution which stains exclusively dead cells. Cell numbers 
were determined with a Neubauer cell counting chamber. 
Generation and stimulation of primary bone marrow-derived dendritic cells and 
macrophages 
Generation of medium containing GMCSF or MCSF 
LGM cells (as a source for GM-CSF) were grown in supplemented RPMI (see 3.1.4, RPMI) 
and L929 cells (as a source for M-CSF) were grown in supplemented DMEM (see 3.1.4, 
DMEM). Every third day, the cells were split. The old medium was removed and collected as 
a GM-CSF or M-CSF containing differentiation medium, respectively. The cells were 
incubated in 1x trypsin/ EDTA solution (Table 3-5) for 5 min at 37 °C, 5 % Co2. The cells 
were detached from the flasks by gently pipetting up and down and split into new flasks at a 
ratio of 1:3 in fresh medium.  
Generation of murine primary bone marrow-derived dendritic cells and 
macrophages 
GM-CSF-derived dendritic cells (BMDCs) and M-CSF derived macrophages (BMMs) were 
prepared from 4- to 10-week-old mice as described by Inaba (135) with minor modifications. 
Briefly, mice were sacrificed by CO2 asphyxia. Bone marrow was collected from femurs and 
tibiae by flushing with supplemented RPMI (BMDCS) or DMEM (BMMs) using a 27 G 
syringe. Afterwards, the cell suspension was centrifuged at 13.000 rpm for 5 min (Multifuge 3 
SR). The pellet was resuspended in 20 ml of the respective medium (BMDCS in RPMI, 
BMMs in DMEM). Cells were placed in 145 cm2 tissue-culture plates in 20 ml of the 
respective medium (BMDCS: RPMI 1640, 10 % (v/v) FCS, 1 % (v/v) Penicillin G / 
Streptomycin and 50 mM 2-mercaptoethanol; BMMs: DMEM, 10 % (v/v) FCS, 1 % (v/v) 
Penicillin G / Streptomycin). After 24 h non-adherent cells (fibroblasts) were collected, 
washed and counted. Further differentiation was done as follows. 
BMDCs: 
107 of non-adherent cells were seeded into 145 cm2 tissue-culture plates in 20 ml of 
differentiation medium (RPMI 1640, 10 % (v/v) FCS, 1 % (v/v) Penicillin G / Streptomycin, 
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50  mM 2-mercaptoethanol and 4 % of GM-CSF containing supernatant). At day 5 fresh 
differentiation medium (20 ml) was added and at day 9 non-adherent, immature dendritic 
cells (CD11c+, B220-) were harvested by centrifugation (1300 rpm, 5min). Dendritic cells 
were plated for further stimulation assays. GM-CSF was derived from X-63 which are 
cytoplastoma cells secreting G-MCSF (LGM cells). 
BMMs: 
2–2.5 x 107 non-adherent cells were seeded into 145 cm2 petri dishes (to avoid strong 
attachment of the cells) in 20 ml of differentiation medium ( DMEM, 10% (v/v) FCS, 1% (v/v) 
penicillin G / Streptomycin and 30 % of M-CSF containing supernatant). At day 3, 20 ml fresh 
M-CSF containing supernatant (30 %) was added and at day 7, adherent BMMs were 
harvested. For this purpose, BMMs where washed with 1 x PBS and detached by 5 minutes 
incubation with 1xTrypsin/EDTA solution at 37 °C, 5% CO2.Cells were washed with PBS / 2% 
FCS to inactivate trypsin. Cells were centrifuged (133 rpm, 5 min) and replated for 
stimulation.  
Cell stimulation 
Dendritic cells or macrophages were plated at 2x105 in 96-well flat bottom format for ELISA. 
5x105 (BMDCs) or 3x105 (BMMs) were plated in 24-well format for RNA preparation or 3x106 
and 6x106 in 6-well format for protein lysates. Stimuli, inhibitors or blocking antibody (anti- 
IL10) were used as indicated in figure legends. For transwell-experiments, cells were placed 
in the lower and upper wells of a 24-transwell system (pore size: 0.4 µm, Ø 6.5 mm, clear 
inserts) and stimuli were added into the lower wells (BMDCs: 5x105 in lower wells, 2x105 in 
upper wells; BMMs: 3x105 in lower wells, 1x105 in upper wells). Cells in both chambers were 
analyzed by means of gene expression for transcript level as indicated.  
In vitro T-cell stimulation assay 
Isolation of CD4+ T-cells  
Splenic CD4+ T-cells were purified from WT C57BL/6 mice and applying a protocol of the 
manufaturer. First, splenocytes were segregated from spleens by means of Percoll gradient. 
Briefly, organs are ruptured by a syringe punch and a cell strainer (pore size 100 µm) which 
served as a cell homogenizer. The cells were washed with ice-cold 1 x PBS and pelleted by 
centrifugation (1300 rpm, 10 min, 4 °C). Lymphocytes were isolated by means of Percoll (p = 
1.09 g/ml) separating solution. After gradient centrifugation (4000 rpm, 20 min, 4 °C without 
brake), the Interphase between the two gradients contains the naïve T-cells and was taken 
off very gently. Cells were washed two times with ice-cold PBS (w/o) (1300 rpm, 10min, 
4 °C). The pellet was resuspended in ice-cold PBS. Cells were counted and used as a 
source for naïve T-cells.  
Magnetic-associated cell sorting 
The immunomagnetic cell separation is based on magnetic antibody labeling (MACS-
Microbeads). Labelled cells were separated by enrichment in a magnetic field and then 
eluted in a semi-automatic manner from the column via the AutoMACS device. 
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Purification of CD4+ T-cells was performed using the CD4+ T-cell isolation kit II according to 
manufacture’s protocol. The cell pellet was reconstituted in 40 µl MACS buffer per 107 cells. 
10µl/107 cells of a cocktail containing different biotin labeled antibodies against CD8a, 
CD11b, CD11c, CD19, CD45R, CD49b, CD105, anti-MHC class II and Ter 19 were used to 
separate CD4+ T-cells (10 min, 4 °C). Afterwards an Anti-Biotin mix (20 µl/107 cells) was 
applied and the labelled cells were incubated for 15min at 4°C. After the labelling procedure, 
cells were washed with 2 ml/107 cells MACS buffer (1300 rpm, 10 min, 4 °C). Cells were 
resuspended in 500 µl MACS buffer per 108 cells. T-cells were then isolated by depletion of 
magnetically labelled cells via the AutoMACS Separator. CD4+ T-cells were eluted in the 
negative fraction by means of the programm “Deplete”. Thus, the negative fraction 
represents the enriched CD4+ T-cells. 
APC / T-cell co-culture 
WT sorted CD4+ T-cells (1x 105) were cultured together with BMMs or BMDCs (1 x 104) from 
SOCS1-/-/IFN-/- or IFNγ-/- control mice. Alternatively, 1x105 CD4+ T-cells were cultured with 
1x104 BMMs from SOCS1lox/- Cre+ (conditional SOCS1 knockout, described in 3.2.2.3) or 
SOCS1lox/- Cre- mice as control. Co-cultures were carried out in 96 well-format. 2 µg/ml of 
plate-bound anti- CD3ε and 2 µg/ml of soluble anti-CD28 were added in order to activate T-
cells. Therefore, 2 µg/ml anti- CD3ε antibody in 200 µl ice-cold PBS per well was added into 
96-well plates and incubated at 4 °C for 16 h. At the next day, PBS was removed and sorted 
CD4+ T-cells were added together with soluble anti-CD28 in medium. When T-cells were 
cultured in presence of BMMs, DMEM supplemented with 10 % (v/v) FCS and 1 % Penicillin 
G / Streptomycin was used. Co-cultures that consisted of T-cells and BMDCs were placed in 
RPMI, supplemented with 10 % (v/v) FCS, 1 % (v/v) Penicillin G / Streptomycin and 50 mM 
2-mercaptoethanol. BMDCs or BMMs within the co-culture setting were stimulated with either 
100 µg/ml depleted Zymosan, 1 µM CpG 1668 or a combination thereof. Th17 control were 
obtained from CD4+ T-cells from WT C57BL/6 mice co-cultured with APCs from       
SOCS-/-/IFNγ-/- or IFNγ-/- control mice or conditional SOCS1 ko BMMS and the respective 
control. To induce Th17 cells, 10 ng/ml TGFβ, 20 ng/ml IL6 and neutralizing antibodies 
against IFNγ (2 µg/ml) and IL4 (2 µg/ml) were added. Th1 control cells were induced by IL12 
(2 ng/ml) and Th2 control wells by IL4 (10 ng/ml); both of them cultivated together either with 
APCs form SOCS1-/-/IFNγ-/- mice or BMMs derived from conditional knockout mice.  
On day 5, all cells were restimulated for 5 h (for ELISA) or 3 h (for RNA lysates) with PMA 
(50 ng/ml) and Ionomycin (750 ng/ml). Cytokines in the supernatants were analyzed by 
sandwich ELISA or cells were lysed to analyze gene expression by RT-PCR. 
Instead of SOCS1-/-/IFNγ-/- or IFNγ-/- cells macrophages from conditional SOCS1 deficient 
mice, that fail to express SOCS1 only in the myeloid compartment, and their appropriate 
controls were used for some experimental approaches.  
As growth medium, DMEM supplemented with 10 % FCS and 1 % Penicillin G / 
Streptomycin was used. 
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Cell viability assay 
Viability of stimulated cells was determined by MTT assay. MTT substrate is reduced by 
various mitochondrial dehydrogenases resulting in a change of substrate colour. After 
removing cell free supernatants for cytokine detection, MTT solution was prepared according 
to the manufacturer’s recommendations and added to culture medium in a ratio of 1:20 (v/v). 
Cells were incubated for 30 min to 1 h at 37 °C and absorbance at 550 nm with 650 nm 
reference wave length was measured in a photometer. 
Enzyme-linked immunosorbant assay (ELISA) 
To determine the quantities of secreted cytokines or interferons cell free supernatants were 
analyzed by means of sandwich ELISA as indicated in the respective protocols of the 
manufacturers. In case of IL12p40, TNFα, IL10 and IL6 ELISA supernatants were diluted in 
1  x PBS, supplemented with 10 % FCS (v/v) (blocking buffer).The dilution/blocking–buffer 
for IL17 and IL8 (KC) ELISA was composed of 1 x PBS, supplemented with 1 % BSA (w/v). 
Buffers for TGFβ, IFNγ, IL4 and IL23 ELISA were used according to the recommendations of 
eBioscience. Analyses were carried out in duplicates and all experiments were performed 
two to three times as indicated. Cytokines were detected by measuring the absorbance at 
490 nm with 650 nm reference in a photometer (SUNRISE Absorbance reader, Tecan, 
Salzburg, Austria). Cytokine concentrations were calculated using a standard dilution of the 
respective recombinant cytokines. Finally, concentrations were calculated with the Magellan 
V 5.0 software (Tecan, Salzburg, Austria). Standard determination was performed according 
to the 4 parameter fit regression method. 
Detection of NF-κB binding 
All buffers used were provided by the manufacturer. For measurement of transcription factor 
activity, nuclear extracts were prepared 6 h after stimulation of SOCS1-/-/IFNγ-/- or IFNγ-/- 
BMMs (9x106; therefore, 3 wells of 6-well format were combined, each well contained 3x106 
cells). Lysates were prepared using the Nuclear extract kit according to the protocol. In 
principle, media was aspirated and cells were washed with 2.5 ml per well ice-cold PBS 
supplemented with Phosphatase inhibitors. 1.5 ml PBS/Phosphatase inhibitors was added 
and cells were scraped from the dish. Thereupon, cells were centrifuge at 13.000 rpm, 10 
min at 4 °C. Cell pellet from 3 respective wells was combined by resuspension in 750 µl 1x 
ice-cold hypotonic buffer. The cell suspension was transferred in a pre-chilled 
microcentrifuge tube and incubated for 20 min on ice. 37.5 µl detergent was added. 
Afterwards, the cell suspension was centrifuged at 13.000 rpm, 2 min at 4 °C. The nuclear 
pellet was resuspended in 50 µl complete lysis buffer by pipetting up and down and 
incubated for 30min on ice on a rocking platform (150 rpm). After centrifugation at 4 °C for 10 
min, the supernatant containing the nuclear fraction (50 µl) was either stored at -80 °C or 
protein concentration was directly determined by means of BCA (3.2.3). For detection of 
NF-κB activity, the nuclear protein lysates were analyzed analyzed using the TransAM® NF-
κB Transcription Factor Assay Kit. Analyses were performed according to manufacturer’s 
protocol in duplicates and experiments were carried out two to three times as indicated. In a 
first step, 30 µl complete binding buffer was added to each well of a 96 well plate. The plates 
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are pre-coated with DNA oligonucleotides containing the NF-κB consensus sequence. 
Afterwards, 10 µg of nuclear fraction (in 20 µl complete lysis buffer) was added. The plate 
was incubated for 1 h at RT with mild agitation (100 rpm, rocking platform). Plates were 
washed 3 times with 200 µl 1 x wash buffer. Thereupon, 100 µl/well primary antibody diluted 
1:1000 in 1 x antibody binding buffer was added. The provided antibodies recognize an 
epitope on the respective NF-κB subunit (p50, p65, p52, c-Rel, RelB). This epitope is 
accessible when NF-κB is activated. After 1h incubation at RT, the plate was washed 3 times 
with 1x wash buffer. An HRP-conjugated secondary antibody (100 µl/well, diluted 1:1000 in 
1 x antibody binding buffer) detects the first antibody. Absorbance was measured at 490 nm 
with a reference wavelength of 650 nm in a photometer (SUNRISE Absorbance reader, 
Tecan, Salzburg, Austria). 
Flow cytometry 
In order to evaluate the purity of BM derived cells and to analyze the expression of co-
stimulatory molecules on the surface, cells were marked with fluorescence-labeled 
antibodies (Table 3-16). Approximately 3x105 cells were washed with 1 x PBS, supplemented 
with 2 % BSA (v/v). Afterwards, the supernatant was removed and cell suspension was 
adjusted to a volume of 100 µl with 1 x PBS / 2 % BSA and transferred into 5 ml-tubes. Cell 
suspension was incubated with the respective antibodies for 30 min at 4 °C and then washed 
two times with 1 x PBS / 2 % BSA. Afterwards, cells were analyzed in a flow cytometer. A 
first gate was set on viable cells as defined by forward (size) / sideward (granularity) scatter 
characteristics. Unlabeled and isotype stained cells served as negative control. Percentage 
of positive cells as well as mean fluorescence intensity (MFI) of positive cells was recorded 
and monitored using the FACS DIVA V 4.12 software. 
siRNA transfection 
For RNAi-mediated gene-silencing of endogenously expressed genes, cells were seeded in 
different formats. In the following, all denoted volumes correspond to one well. When cells 
were used for the preparation of RNA, 30 pmol siRNA was incubated in a volume of 100 µl of 
OptiMEM with 1.5 µl Lipofectamine2000 RNAiMAX within a 24-well format for 20 min. For 
preparation of protein lysates, 160 pmol siRNA was incubated in 6-well format with 7.5 µl of 
Lipofectamine2000 RNAiMAX. Afterwards, cells were applied directly to the reaction mixture 
(reverse transfection). For 24-well plates, 400 µl medium (DMEM without serum or 
antibiotics) containing 3x105 cells was seeded. For 6-well plates, 2x106 cells in a volume of 
1.5 ml medium were plated. Cells were incubated at 37 °C. After 20 h, cells were stimulated 
as indicated in the respective figure legends. Knockdown efficiency was determined by 
Western blotting and quantitative RT-PCR.  
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3.2.2. Molecular biology 
DNA sequencing 
Sequencing was performed commercially by GATC (Konstanz). 50 ng/µl DNA (PCR product) 
was analyzed with standard primers (3.1.7). Results were validated by aligning with the 
theoretical sequences using the alignment program CLUSTALW2 
(www.ebi.ac.uk/Tools/clustalw2). 
Quantitative RT-PCR 
RNA preparation 
Total RNA from BMMs or BMDCS was isolated using the High Pure RNA Isolation Kit or 
additionally the peqGOLD Total RNA kit according to manufacturers’ protocol. RNA 
preparation included a DNase I digestion to exclude amplification of genomic DNA during 
RT-PCR. RNA was either stored at -80 °C or directly used for cDNA synthesis. 
cDNA synthesis 
Synthesis of cDNA was performed with the High-capacity cDNA transcription kit or with the 
RevertAid™ First Strand cDNA Synthesis Kit. Messenger RNA was amplified using 
Oligo(dT)18 primers. Briefly, 10 µl RNA lysate was added to 10 µl Master Mix containing 
dNTP’s, Reverse transcriptase, RNAse inhibitors and Oligo(dT)18 primer. The mixture was 
transcribed according to manufacturer’s protocol. Finally, the cDNA (20 µl) was diluted in 
Aqua dest at a ration of 1:3. 
Quantitative real-time (RT)-PCR 
For quantification of cDNA, two approaches were used. First, the cyanid fluorescent dye 
SYBR-green that interferes with double-stranded DNA was used to monitor amplicon 
development. Second, a hybridization probe was used which shows increased specificity in 
detection. The probe constituted of a short complimentary oligonucleotide that binds to the 
respective internal target sequence of the amplicon. A fluorophore (5’-FAM) and a quencher 
(3’-TAMRA) were covalently attached to the probe. The emission of the reporter fluorophore 
is repressed via FRET (fluorescence resonance energy transfer) by the quencher. During 
PCR, primers and probe hybridize at their binding site within the target sequence. Upon 
amplification the probe is degraded through the 5’-3’ exonuclease activity of the Taq 
polymerase. Thereupon, FRET is suppressed and the sequence specific signal can be 
detected. 
In principle, 2 µl of template (cDNA) was added to 18 µl of MasterMix (table 3-20), 
respectively. Thereupon, the mix was distributed into 96-well format. The plates were sealed 
and gene expression was performed in the 7900 HT Fast Real-Time PCR System (Applied 
Biosystems, Darmstadt). The program for amplification was carried out as follows: 95 °C 15 
min; 40 x [95 °C, 15 sec; 60 °C, 1 min].  
Typically, gene expression was measured in duplicates for each cDNA sample. Automatic 
detection of baseline and threshold values was used and the determined Ct values were 
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substracted from the Ct values of an endogenous constitutively expressed reference gene 
(β -actin) resulting in a ΔCt for each target gene. Relative expression (rE) was calculated as 
rE = 1/(2ΔCt). PCR reactions had been verified for similar efficiencies. Specificity of reactions 
was controlled by no-template as well as no-RT (no reverse transcriptase) samples. For 
SYBR-green detection, the dissociation curves of each amplicon were analyzed to determine 
the melting point. Respective test settings are listed in table 3-21. 
Table 3-21  Test parameters for quantitative RT-PCR 
 
Template/reaction 
 
Primer (fw and rv)/reaction 
 
Probe/reaction 
 
Reaction mix 
 
 
2 µl 
 
 
2 µl 
 
 
25 pmol 
 
 
12.5 pmol 
 
3.7 pmol 
 
 
- 
 
10 µl of Absolute QPCR ROx Mix (Thermo 
Scientific, Warrington, UK)  
 
10 µl of PowerSYBR®Green PCR Master 
Mix (Applied Biosystems, Darmstadt) 
 
 
Genotyping of mice 
Conditional SOCS1  
Tissue-specific SOCS1-deficient mice were generated using the Cre/LoxP system (136, 
137). Therewith, Socs1lox/lox mice, that carry a Socs1 allele flanked by two LoxP sites (Flox), 
are bred with Cre transgenic mice. The consequence of SOCS1 deficiency in myeloid cells 
(macrophages) was investigated by breeding Socs1lox/lox mice with Socs1+/- mice and mice 
expressing Cre under the promoter of endogenous Lysozyme M (LysM-Cre). We asked to 
obtain progeny that were Socs1lox/- and positive for LysM-Cre. Thus, the macrophages of 
these mice only have one floxed SOCS1 allele that is excised by the cre recombinase. 
Human CD4 (hCD4) containing a F43I mutation and intracellular truncation which abrogates 
its function was utilized as a reporter for effective Cre-mediated recombination. The presence 
of only one copy of Socs1lox ensures the most efficient deletion (136, 137). 
Purification of genomic DNA 
DNA was isolated from tails of the respective knockout or control mice and tissue was 
digested with 18 units (895 units/ml) of Proteinase K at 56 °C over night. Thereupon, 
genomic DNA was isolated using the QIAamp®DNA Blood Mini kit (Qiagen, Hilton) according 
to manufacturer’s protocol. In principle, mice tails were incubated in 180 µl buffer ATL with 20 
µl (18 units) Proteinase K over night. Thereupon, 200 µl buffer AL was added to the sample 
and the components were mixed by vortexing. Afterwards, 200 µl ethanol (100 %) was added 
immediately and the sample was mixed again by vortexing. The mixture was added onto a 
DNeasy Mini spin column and centrifuged at 8000 rpm for 1 min at RT: After washing with 
buffer AW1 and AW2, the DNA was eluted from the column membrane in 100 µl buffer AE. 
DNA was either used directly for PCR reaction or kept at -20 °C for long-term storage. 
Concentration of DNA was measured by means of the NanoDrop® ND-1000 UV / VIS 
Spectrophotometer. Aromatic rings of the DNA absorb UV light at λ=260 nm. The ratio of 
E260  / E280 (E = extinction coefficient) gives information about the purity of the prepared DNA. 
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Contamination with proteins is detected via the absorption at 280 nm. A value below 1.8 
indicates significant protein contaminants. 
Polymerase chain reaction (PCR) 
PCR was used to exponentially amplify DNA that is synthesized de novo during a cyclic 
reaction process. PCR was performed according to general protocols using Accu Taq LA 
DNA polymerase. Annealing temperatures for standard cloning purposes were 5 °C under 
calculated annealing temperatures. Different PCR conditions are depicted in table 3-22. 
Table 3-22  PCR conditions for genotyping of conditional SOCS1 knockout mice 
 
Gene locus 
 
 
Expected band size 
 
Reaction conditions 
 
PCR programm 
 
Cre recombinase 
 
 
 
 
 
 
 
 
 
SOCS1 ko 
 
 
 
 
 
 
 
 
 
Flox 
 
 
 
 
 
 
 
 
 
WT 
 
650 bp 
 
 
 
 
 
 
 
 
 
160 bp 
 
 
 
 
 
 
 
 
 
600 bp  
 
 
 
 
 
 
 
 
 
340 bp 
 
10x buffer: 2 µl 
dNTPs (10 mM each): 0.4 µl 
5’ Primer (50 µM): 0.2 µl 
3’ Primer (50 µM): 0.2 µl 
Taq Polymerase (125 units): 0.4 µl 
DMSO: 0.4 µl 
DNA: 10 – 200 ng 
ad H2Odes to 20 µl 
 
 
10x buffer: 2 µl 
dNTPs (10mM each): 0.4 µl 
5’ Primer (50 µM): 0.2 µl 
3’ Primer (50 µM): 0.2 µl 
Taq Polymerase (125 units): 0.4 µl 
DMSO: 0.4 µl 
DNA: 10 – 200 ng 
ad H2Odes to 20 µl 
 
 
10x buffer: 5 µl 
dNTPs (10 mM each): 1 µl 
5’ Primer (50 µM): 0.5 µl 
3’ Primer (50 µM): 0.5 µl 
Taq Polymerase (125 units): 0.5 µl 
DMSO: 0.5 µl 
DNA: 10 – 200 ng 
ad H2Odes to 50 µl 
 
 
10x buffer: 5 µl 
dNTPs (10 mM each): 1 µl 
5’ Primer (50 µM): 0.5 µl 
3’ Primer (50 µM): 0.5 µl 
Taq Polymerase (125 units): 0.5 µl 
DMSO:  0.5 µl 
DNA: 10 – 200 ng 
Ad H2Odest to 50 µl 
 
 
95 °C, 5min 
95 °C, 1min 
57 °C, 1min         35x 
72 °C, 1min 
72 °C, 2min 
4 °C, ∞ 
 
 
 
 
95 °C, 5min 
95 °C, 1min 
57 °C, 1min         35x 
72 °C, 1min 
72 °C, 2min 
4 °C, ∞ 
 
 
 
 
95 °C, 5min 
95 °C, 1min 
57 °C, 1.30 min      41x 
72 °C, 1,30 min 
72 °C, 10 min 
4 °C, ∞ 
 
 
 
 
95 °C, 5min 
95 °C, 1min 
53 °C, 1.30 min      41x 
72 °C, 1,30 min 
72 °C, 10 min 
4 °C, ∞ 
 
 
Gel electrophoresis 
For DNA visualization standard agarose gel electrophoresis procedure was performed. In 
brief, DNA sample (50 µl or 20 µl, table 3-21) was mixed with 6 x loading dye. A volume of 20 
µl of the DNA/loading dye mixture was loaded to 1 % (SOCS1ko, WT) or 2 % (Cre 
recombinase, Flox) 1 x TAE agarose gel electrophoresis. Gels were run at 100 V for 
30 min – 1h. For UV-based detection, agarose gels were incubated for approximately 20 min 
in ethidiumbromide (1 µg/ml diluted in 1000 ml H2Odest). As a marker, GeneRuler™DNA 
Ladder Mix (100-10000 bp) was used. 
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3.2.3. Biochemistry 
Preparation of Protein-lysates  
According to the respective experiments, cells were seeded in 6-well cell culture plates. 
Following stimulation, the medium was removed and the cells were washed wit 2 ml/well ice-
cold 1 x PBS supplemented with 1 mM NaF and Na3VO4. After centrifugation of the plates 
(800 rpm, 10 min, 4 °C) cells were lysed in 80 – 100 µl of freshly prepared RIPA lysis buffer 
(3.1.5) for 30 min at 4 °C within the wells of the plate. Incubation of the plates at -20 °C for 
16h ensured proper cell-lysis. Thereupon, the cell suspensions were transferred into 1.5 ml 
tubes and cell debris were removed by centrifugation at 13.000 rpm for 20 min at 4 °C. The 
pellet was discarded and protein concentration in the supernatant was determined by means 
of BCA™ Protein Assay Reagent Kit. Lysates (80-100 µl) were stored at -20 °C. 
Determination of protein concentration 
Bicinchoninacid (BCA) assay kit was used to estimate protein concentrations in cell lysates. 
During the reaction process, compounds that consist of at least two peptide bonds form a 
complex with Cu2+. Thereby Cu2+ is reduced to Cu+. BCA and Cu+-ions build a coloured 
complex that is measured at 540 nm (absorption maximum at 562 nm).  
Samples (20 µl diluted 1:5 with H2Odest) were mixed with 180 µl of freshly prepared 
BCA / cupper sulphate solution in a 96-well plate and incubated at 37 °C for 30 min. BSA 
served as a standard at an initial concentration of 2 mg/ml. The colorimetric detection of 
proteins was performed using a photometer and concentrations were calculated with 
Magellan V 5.0 software. Standard determination was performed according to the 4 
parameter fit regression method. 
SDS – PAGE 
SDS-PAGE (sodium dodecyl sulphate poly-acrylamid gel-electrophoresis) was used to 
separate proteins according to their respective molecular weight. SDS eliminates non-
covalent interactions and charges the proteins negatively. Therefore they can be separated 
by gel electrophoresis exclusively through their molecular weight. 
For protein analysis, cell-lysates (3.2.3) were mixed 4:1 with 4 x SDS-sample buffer (3.1.5) 
and denatured at 95 °C for 5 -10 min. The samples (25 µl – 55 µl) that were adjusted to 
similar protein concentration by BCA (3.2.3) were loaded on an 8 % or 12 % polyacrylamid 
gel and run at constant voltage for approximately 3 h. For PAGE a vertical gel chamber was 
used. A prestained protein marker served as a reference. Proteins from the gel were further 
analyzed by Western Blotting.  
Western blot analysis 
Proteins separated by SDS-PAGE were blotted on nitrocellulose membranes (Millipore, 
Billerica, USA) by semidry blotting procedure with 1.57 mA / cm2 for 2 h. To block unspecific 
binding, membranes were incubated in blocking buffer (3.1.5) for 1 h on a horizontal shaker 
with mild agitation (180 rpm) at room temperature (RT). Afterwards, proteins were detected 
using specific primary antibodies diluted in the appropriate buffers (table 3-4, table 3-16). 
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After incubation at 4 °C overnight, membranes were washed three times with 1 x PBS 
supplemented with 0.05 % (v/v) Tween20 (3.1.5, table 3-4) and incubated with horseradish 
peroxidise (HRP) – conjugated secondary antibody diluted 1:1000 in the respective buffers 
(table 3-16) for 2 h at RT. After three further washing steps with 1 x PBS supplemented with 
0.05 % (v/v) Tween20 bound antibodies were detected by chemiluminescence using 
enhanced luminol. Chemiluminescence was either detected with a cooled CCD-camera 
device or by means of High performance chemiluminescence films that were developed in a 
developing machine. Analysis was performed with the Chemi-Capt software. 
Characterization of IFNγ-/-/SOCS1-/- and IFNγ-/- BMMs or BMDCs 
To determine knockout efficiencies of SOCS1 in BMDCs or BMMS isolated from of      
IFNγ -/-/SOCS1-/- and IFNγ-/- mice (3.2.1). Thereupon, cells were harvested and seeded in 6-
well format (3x106 cells per well in DMEM, 10 % (v/v) FCS, 1 % (v/v) Penicillin/Streptomycin) 
as described in 3.2.1.1, cell stimulation. After 16 h, medium was changed to DMEM, 
supplemented with 2 % (v/v) FCS, 1 % (v/v) Penicillin / Streptomycin.The cells were 
stimulated with LPS (100 ng/ml) for 4 h. Afterwards, cells were lysed and treated as 
described in 3.2.3. Expression of SOCS1 was analyzed by Western blot (3.2.3). 
Stripping of nitrocellulose membranes 
To detect further proteins on membranes already exposed to ECL, Restore™ Western Blot 
stripping buffer was used. The membranes were washed three times with 1 x PBS 
supplemented with 0.05 % (v/v) Tween20 (3.1.5, table 3-4) and afterwards incubated with 
15ml Restore™ Western Blot stripping buffer for 15 min at RT on a horizontal shaker (180 
rpm) to remove bound antibodies (stripping). Upon three washing steps membranes were re-
subjected to the respective antibodies as described in 3.2.3 and table 3-17. 
Electrophoretic Mobility Shift Assay (EMSA) 
EMSA constitutes a method for the detection of nuclear transcription factor activity. Within 
this assay, binding of nuclear transcription factors (i.e., egr1) to its respective labeled 
sequence can be analyzed. To detect binding of egr1 to the target sequence within the 
SOCS1 promoter region, Cy3 fluorescent probes were used (3.1.7, table 3-10). The 
migration of the probe which is bound by a transcription factor is retarded in the gel due to 
the higher molecular weight of this complex. Thus, an activated transcription factor is 
detected as a shifted band, whereas unbound probe rapidly migrates through the gel. EMSA 
was performed as described by Andrews and Faller (138) and Bode et. al. (139). In the 
following, the used protocol is explained in brief. 
To detect binding of active egr1 to the SOCS1 promoter, 1,2x107 BMMs from WT C57/BL6 
mice were seeded (4x106 cells per well in 6-well plates, 3 wells combined for lysis) and 
stimulated as indicated. Afterwards, cells were washed with ice-cold PBS supplemented with 
1 mM PMSF and 1 mM Na3VO4. Subsequently, the cells were harvested in 1 ml ice-cold 
PBS / 1 mM PMSF / 1 mM Na3VO4 and 3 wells were combined for centrifugation (1300 rpm, 
10 min, 4 °C). After removing the supernatant completely, nuclear extracts were prepared in 
2 steps. First, cytoplasmatic fraction of stimulated cells was isolated by means of 400 µl 
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buffer A (3.1.5, table 3-7) for 20 min on ice. Nuclei were pelletd by centrifugation (1300 rpm, 
5 min, 4 °C). Incubation of the nuclear pellet in 40 µl complete lysis buffer (buffer C, 3.1.5, 
table 3-7) for 30 min on ice resulted in nuclear extracts that were either stored at -80 °C or 
used directly for EMSA after determination of the protein concentration (3.2.3). 
To achieve binding of transcription factors within the nuclear extract to the probes, binding 
reaction was set up as published (138). Briefly, 3 µl of nuclear extract (about 9 µg protein) 
were mixed with 50 fmol probe in a total reaction volume of 20 µl EMSA binding buffer (3.1.5, 
table 3-7) for 15 min at RT. Afterwards, the DNA-protein complexes were loaded on a native 
gel without the usage of bromphenol blue containing loading buffer. As a control for a proper 
run, one lane of the gel was loaded with loading buffer only. After approximately 3 h at 100 V, 
4 °C, the gel was analyzed. Fluorescence was directly detected within the gels using the 
Typhoon Trio detector. Cy3 was excited at 550 nm and emission was detected at 570 nm.  
3.2.4. Statistical analysis 
All experiments were performed at least two times and the number of experiments is stated 
in the legends. Means + SD are shown. Significant differences were evaluated by analysis of 
variance (ANOVA) to compare three or more groups followed by Dunnett’s test to compare 
selected groups. Data were analyzed by means of GraphPad prism 4.03 program (GraphPad 
Software, San Diego California, USA); p<0.05 (*), p<0.01 (**), p<0.001 (***) were considered 
significant. Quantification of bands from respective immunoblots was performed with the 
QuantiOne software from Bio-Rad. 
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4. Results 
4.1. Dectin-1 engagement induces SOCS1 expression in myeloid cells 
It has been shown that suppressor of cytokine signalling proteins (SOCS) 1 and 3 and 
cytokine-inducible SH2-domain containing protein (CIS) can be induced in innate immune 
cells including dendritic cells and macrophages where they regulate the cells’ 
responsiveness to various cytokines (89, 140, 141). SOCS proteins are not only induced via 
the Jak-STAT pathway but can also be expressed when pattern recognition receptors 
(PRRs), especially TLRs, are engaged. This work addressed the question whether SOCS 
proteins, in particular SOCS1, can also be induced by the non-TLR PRR Dectin-1 in murine 
bone marrow derived dendritic cells (BMDCs) and macrophages (BMMs). Moreover, the 
pathways involved in Dectin-1 induced SOCS1 expression should be analyzed as well as 
possible functions of SOCS1 in Dectin-1 signalling. 
4.1.1. Depleted Zymosan induces SOCS1 in BMMs and BMDCs  
The initial step was to clarify the question whether Dectin-1 is able to trigger SOCS1 
expression. It is known that Dectin-1 signalling partially interacts with signals from TLR2 or 
TLR6 (55, 63). This interaction results in an increase and prolongation of NF-κB activity and 
cytokine production upon receptor engagement as described for dendritic cells (76, 77). 
Therefore we made use of depleted Zymosan that should lack any TLR activating capacity 
(71). Depleted Zymosan is a cell wall preparation of the yeast Saccharomyces cerevisiae 
treated with hot alkali to remove all its TLR binding properties. Thus, depleted Zymosan acts 
as a Dectin-1 agonist but does not bind and activate TLRs. In contrast, untreated Zymosan is 
capable of binding to both, Dectin-1 as well as TLRs, especially TLR2. 
Stimulation of bone marrow derived macrophages (BMMs) and dendritic cells (BMDCs) 
resulted in a robust induction of SOCS1 on transcriptional and protein level. SOCS1 mRNA 
was induced up to 40-fold in BMMs and 20 fold in BMDCs upon stimulation with depleted 
Zymosan and comparable to well-known SOCS1 inducers like LPS or IFNs (Fig. 4-1 [A, B]). 
LPS was always used as a positive control for proper SOCS1 induction. Additional priming of 
BMMs with IFNγ previous to stimulation with depleted Zymosan led to a further significant 
increase by 10-fold in SOCS1 mRNA (Fig. 4-1 [A]). Furthermore, triggering of Dectin-1 
resulted in a dose-and time-dependent expression of SOCS1 as examined by qRT-PCR (Fig. 
4-1 [C]). Whereas induction of SOCS1 mRNA displayed a peak-induction time at 4.5 h in 
BMMs, expression in BMDCs reached a plateau already after 2 h with constant expression 
even 16 h after initial stimulation. Importantly, LPS induced a constant expression of SOCS1 
within the indicated time frame as well; SOCS1 mRNA was induced even up to 100-fold as 
compared to unstimulated control. In contrast, in previous reports LPS was described as a 
fast but short-termed inducer of SOCS mRNA. Protein levels of SOCS1 reflected mRNA 
induction. Depleted Zymosan clearly induced SOCS1 protein expression, even at lower 
concentrations (100 µg/ml). Similarly, LPS stimulation displayed induction of SOCS1 proteins 
at the used concentrations. However, LPS induced higher amounts of SOCS1 protein as 
compared to cells stimulated with depleted Zymosan (Fig. 4-1 [B]). This was expected since 
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LPS is published to be a strong inducer of SOCS1. Besides SOCS1, SOCS3 and CIS are 
well characterized members of the SOCS family. Thus, we analyzed BMDCs and BMMs for 
expression of the latter transcripts. Both cell types displayed an induction of SOCS3 and CIS 
upon engagement of Dectin-1 (Fig. 4-1 [D], [E]). In contrast to SOCS1, SOCS3 and CIS 
transcripts were induced up to 20-fold as compared to unstimulated control. Again, LPS 
served as positive control, leading to a strong expression of the displayed SOCS molecules.  
 
Fig. 4-1  Suppressors of cytokine signalling (SOCS) are induced upon engagement of Dectin 1 
[A],[C], [D] and [E], RT-PCR analysis: BMDCs (5x10
5
) or BMMs (3x10
5
) from WT mice were stimulated with different 
concentrations of dZ ([A], [D] and [E], 100 µg/ml; [C], 10 µg/ml, 100 µg/ml, 500 µg/ml) or LPS (100 ng/ml)). [A, D and E], cells 
were lysed after 4.5 h of stimulation. [C], cells were stimulated for the indicated time-points. For priming experiments (BMMs, [A]), 
cells were pre-incubated with IFNγ (50 ng/ml) for 16 h. Cells were lysed and gene expression of SOCS1 [A, C], SOCS3 and CIS 
[D, E] was measured by quantitative RT-PCR. Depicted are expression levels normalized to the expression of the housekeeping 
gene β-actin. rE, relative expression. [B] BMDCs or BMMs (18x10
6
) were stimulated with increasing concentrations of LPS (10 
ng/ml to 100 ng/ml) or dZ (100 µg/ml to 500 µg/ml) for 6 h and lysates were analyzed by immunoblot with antibodies against 
SOCS1 or β-actin as control. [A], [D] and [E] n=3, mean + SD; [C] n=2, mean + SD, results in [B] are representative for 3 
independent experiments. mock, unstimulated control 
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4.1.2. SOCS1 induction by depleted Zymosan is independent of TLRs 
As mentioned above, Zymosan is capable of engaging also TLRs, but depleted Zymosan 
should only trigger Dectin-1. Therefore we analyzed BMDCs and BMMs isolated from wild 
type (WT) or MyD88/Trif-/- mice to ensure that depleted Zymosan induces SOCS1 
independently of any TLR activity. All known TLRs use MyD88 or Trif (TLR3) as adaptor 
proteins for appropriate signalling. No reduction of SOCS1 mRNA levels could be observed 
when stimulating BMDCs and BMMs from knockout mice with depleted Zymosan as 
compared to cells from the WT control (Fig. 4-2 [A]). In contrast, LPS mediated expression of 
SOCS1 was completely abolished in cells from MyD88/Trif double deficient mice as expected 
from published data since LPS triggered TLR4 is able to signal via both, MyD88 and Trif (32, 
34, 35). Compared to Fig. 4-1 [A] and [C], the SOCS1 expression in WT DCs induced by 
depleted Zymosan was attenuated. This could be due to variability in activation of primary 
cells. We observed in some DC preparations that the cells were pre-stimulated, resulting in a 
decreased induction of SOCS proteins as compared to other preparations. Consistent with 
the above observations that depleted Zymosan induced SOCS1 expression was not altered 
in MyD88/Trif-/- mice compared to WT mice, downstream signalling was unaffected in 
MyD88/Trif knockout BMDCs and BMMs. Phosphorylation of the MAPK ERK was not altered 
upon Dectin-1 triggering in WT compared to knockout cells (Fig.4-2 [B]). As expected, LPS 
induced ERK activation was completely abolished in the knockout cells. Importantly, BMDCs 
generated from MyD88/Trif double deficient mice were not able to develop a murine DC 
phenotype (low CD11c expression). Additionally, these cells showed no induction of ERK 
activation upon stimulation. This could be due to the knockout of MyD88 since this adaptor 
protein is an important myeloid differentiation factor (34). In contrast, BMMs displayed a 
normal phenotype (high CD11b, high F480), comparable to WT murine BMMs.  
Also, cells from TLR2 knockout mice displayed an unmodified expression of SOCS1 
compared to WT cells when stimulated via Dectin-1 (Fig. 4-3 [A]). The TLR2 ligand 
Pam3CSK4 was capable of inducing SOCS1 expression in WT BMDCs and BMMs up to 40-
fold compared to unstimulated cells whereas SOCS1 expression in TLR2 knockout mice was 
abrogated (Fig. 4-3 [A]). Pam3CSK4 served as a control for appropriate knockout. 
Accordingly, TLR2 that is described to be an important co-receptor of Dectin-1 is not involved 
in SOCS1 induction in Dectin-1 triggered cells. In addition, MyD88/Trif dependent pathways 
can be excluded, thus identifying Dectin-1 as a receptor that is able to induce SOCS1 upon 
stimulation with depleted Zymosan. 
These findings were confirmed by stimulating BMMs isolated from Dectin1-/- mice with 
depleted Zymosan. As a result, SOCS1 expression was entirely abolished in the knockout 
BMMs in contrast to wildtype cells when stimulated with depleted Zymosan. LPS stimulation 
led to SOCS1 expression of more than 100-fold in WT BMMs at the same level as compared 
to Dectin1-/- cells (Fig.4-3 [B]). Thus, we could clearly demonstrate that SOCS1 induction 
upon triggering of cells with depleted Zymosan was exclusively mediated by Dectin-1. 
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Fig. 4-2  Zymosan induced SOCS1 is expressed independently of TLR signaling 
[A], BMDCs (5x10
5
) or BMMs (3x10
5
) from WT or MyD88/TRIF
-/-
 mice were stimulated with either 500 µg/ml dZ or 100 ng/ml 
LPS for 4.5 h. Cells were lysed and gene expression of SOCS1 was analyzed by quantitive RT-PCR. Depicted are expression 
levels normalized to the expression of the housekeeping gene β-actin. rE, relative expression. [B], BMMs (3x10
6
) from WT or 
Myd88/TRIF
-/-
 mice were incubated with LPS (100 ng/ml) or dZ (500 µg/ml) as indicated. Lysates were analyzed by 
immunoblot. Blots were probed with antibodies specific for ERK 1/2 phosphorylated on Thr 
202
/Tyr 
204 
or β-actin as control. [A] 
n=2, mean + SD, results in [B] are representative for 2 independent experiments 
Our results show that SOCS1 is induced in both cell types, BMMs as well as BMDCs upon 
ligation of Dectin-1 with depleted Zymosan on transcript and protein level. In comparison to 
the used TLR stimuli (LPS, Pam3CSK4), Dectin-1 triggered SOCS1 expression was 
completely independent of any TLR activity as shown in MyD88/Trif knockout as well as 
TLR2 knockout cells. The next step was to clarify the question if SOCS1 is induced in a 
direct manner upon engagement of Dectin-1 without the need of any intermediate secreted 
or intracellular factors.  
 
Results 
41 
   
Fig. 4-3  SOCS1 induction is strictly dependent on Dectin-1  
[A], [B] and [C], BMDCs (5x10
5
) or BMMs (3x10
5
) from WT [A, B, C], TLR2
-/- 
[A, B] or Dectin-1
-/- 
cells
 
[C] were triggered with dZ 
(100 µg/ml) [A, B] or Pam3CSK4 (P3C) (100 ng/ml) for 4.5 h. Expression of SOCS1 transcripts was measured by quantitative 
RT-PCR. Displayed are relative expression levels normalized to β-actin expression. [A] and [B] n=2, mean + SD.  
 
4.1.3. SOCS1 is a direct target gene of Dectin-1 
To further analyze the mode of induction of SOCS1 it was necessary to establish whether 
intermediate factors, i.e. secreted auto- or paracrine factors like type I IFNs, participate in 
SOCS1 expression. Foremost we made use of a transwell system in which BMDCs and 
BMMs were placed in both wells. Stimulation with depleted Zymosan or LPS was carried out 
in the lower wells only. The pore size of 0.4 µm of the transwell strainer excluded any 
diffusion of depleted Zymosan (average size of particles: 3 µm (142)) into the upper 
chambers which ensured a sole stimulation of cells in the lower wells. Accordingly, 
expression of SOCS1 in cells of the upper compartments would indicate that soluble, 
intermediate factors produced by depleted Zymosan stimulated BMMs or BMDCs in the 
lower wells participate in SOCS1 induction. Upon stimulation with depleted Zymosan 
expression of SOCS1 mRNA could only be observed within cells of the lower compartments 
(Fig. 4-4). Therein, SOCS1 transcripts were induced up to 20-fold as compared to the 
unstimulated control. In cells placed in the upper compartments, SOCS1 expression was not 
observed. In contrast, LPS that is able to enter the upper wells by diffusion was capable of 
inducing SOCS1 expression in BMMs or BMDCs in both chambers of the transwell (Fig. 4-4). 
Hence, LPS induced SOCS1 in both chambers to the same extent; up to 20-fold in BMDCs 
and 100-fold in BMMs as compared to the unstimulated control in the respective wells. These 
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results indicate that SOCS1 is expressed upon triggering of Dectin-1 in myeloid cells without 
the attendance of soluble factors.  
   
Fig. 4-4  Influence of soluble factors on SOCS 1 induction 
BMDCs or BMMs were seeded in a transwell system (BMDCs: 5x10
5
 in lower wells, 2x10
5 
in upper wells; BMMs: 3x10
5
 in lower 
wells, 1x10
5
 in upper wells). Cells in the lower chambers were stimulated with dZ (100 µg/ml or 500 µg/ml) or LPS (100 ng/ml) 
or left unstimulated (mock). After 4.5 h, cell lysates of both wells were analyzed for SOCS1 expression by qRT-PCR; 
normalization was performed against β-actin as control. n=3, mean+SD 
LPS is described to induce type I IFNs (143, 144). Thus, the expression of SOCS1 observed 
upon stimulation of cells within the upper chambers of the transwell could originate 
additionally from factors produced by LPS triggered cells.  
IFNs produced by LPS or other TLR ligands subsequently activate the Jak/STAT pathway 
and therefore may be responsible for inducing SOCS1. In contrast, other publications 
excluded a contribution of TLR induced type I IFNs to induction of SOCS proteins (143). To 
investigate any possible role of secreted type I IFNs on the induction of SOCS1 after 
engagement of Dectin-1, cells from type I IFN receptor deficient (IFNAR1-/-) mice were 
stimulated.  
SOCS1 induction showed no differences in IFNAR1-/- cells compared to wildtype when 
stimulated with either LPS or depleted Zymosan (Fig. 4-5 [A]). These findings strengthen the 
results observed with the transwell approach in which SOCS1 was induced independently of 
secreted intermediate factors when cells were stimulated via Dectin-1. Importantly, cells from 
the knockout mice triggered with LPS displayed no difference in SOCS1 expression when 
compared to the wildtype control as well. Since it has been shown that TLR4 triggering 
induces SOCS in a direct and type I IFN-independent manner, we expected no difference in 
LPS induced SOCS1 mRNA level in IFNAR1-/- cells (Fig. 4-5 [A]). 
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Fig. 4-5  No contribution of Type I IFNs to the expression of Dectin-1 induced SOCS1 
[A] and [B], BMDCs (5x10
5
) or BMMs (3x10
5
) from WT or IFNAR1
-/- 
(IFNAR
-/-
) mice were stimulated as indicated with dZ (100 
µg/ml) or LPS (100 ng/ml). After 4.5 h, cells were lysed and gene expression of SOCS1 [A] or IRF7 [B] as knockout control was 
analyzed by quantitative RT-PCR. Relative expression levels normalized to β-actin. [A] and [B], n=2; mean + SD   
Expression of IRF7 (Interferon regulatory factor 7), which is a type I IFN dependent gene 
served as control. IRF7 is essential for the induction of IFN α/β dependent genes (39, 40, 
145). Whereas IRF7 was induced by LPS up to 50-fold in WT DCs, IFNAR1-/- BMDCs 
expectedly showed loss of IRF7 induction as well as a reduced basal expression (Fig. 4-5 
[B]). BMMS displayed no induction of IRF7 transcripts when triggered via LPS. Regarding 
treatment of myeloid cells with depleted Zymosan, neither BMDCs nor BMMs induced IRF7 
mRNA. Importantly, the basal levels of IRF7 were reduced in IFNAR1-/- cells (Fig. 4-5 [B]). 
These findings suggest that BMDCs as well as BMMs can not produce type I IFNs when 
stimulated via Dectin-1 since IRF7 is a direct target gene of IFNα or IFNβ. However, many 
other type I IFN inducible genes are described beside IRF7. The transcription factor STAT1 
is shown to be activated by phosphorylation upon stimulation with type I IFNs (146, 147). We 
therefore additionally analyzed STAT1 phosphorylation in BMMs and BMDCs upon 
stimulation with depleted Zymosan as well as LPS. Stimulation of BMMs as well as BMDCs 
with LPS led to a strong phosphorylation of STAT1 in a time-dependent manner. (Fig. 4-6 [A, 
B]) However, depleted Zymosan displayed a clear activation of STAT1 exclusively in BMDCs 
that was not detectable until 90 min after stimulation (Fig. 4-6 [B]). In BMMs, depleted 
Zymosan had no effect on STAT1 phosphorylation when compared to the unstimulated 
control (Fig. 4-6 [A]). Thus, these date rule out a contribution of the Jak/STAT pathway 
(indirect IFN signalling) to the induction of SOCS1. 
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Fig. 4-6  STAT1 activation upon ligation of Dectin-1 
[A], BMMs (3x10
6
) or [B] BMDCs (3x10
6
) from WT mice were triggered by dZ (500 µg/ml) or LPS (100 ng/ml) for the indicated 
time periods. Cell lysates were analyzed by immunoblot; blots were probed with antibodies directed against STAT 1 
phosphorylated on Tyr701 and β-actin as loading control. Results show representative data from 2 independent experiments. 
Based on the results obtained with the transwell experiments as well as the IFNAR1-/- cells, 
we concluded that auto- or paracrine, secreted factors, i.e. type I IFNs were not involved in 
expression of SOCS1 in depleted Zymosan stimulated BMMs as well as BMDCs. 
To exclude that any intracellular intermediate protein may participate in SOCS1 expression, 
we next treated the cells with cycloheximid as an inhibitor of de novo protein biosynthesis. 
Therefore, mRNA is still expressed, whereas protein synthesis is inhibited. Thus, it can be 
analyzed if SOCS1 is transcribed directly without the need of any inducible intermediate 
protein. Application of cycloheximid prior to stimulation with depleted Zymosan or LPS had 
no effect on SOCS1 mRNA induction. Importantly, stimulation with depleted Zymosan 
following cycloheximid treatment even slightly increased SOCS1 mRNA induction (Fig. 4-7 
[A, B]). Since cycloheximid is an inhibitor of protein synthesis, it can be hypothesized that 
also the protein expression of inhibitors of transcription factors is abrogated. This could 
explain an increase in mRNA levels of particular genes. To prove successful inhibition of 
protein synthesis, BMMs and BMDCs were stimulated with LPS and analyzed for secretion of 
IL12p40 and TNFα by ELISA. In case of the pre-treated cells, cytokine secretion was entirely 
abolished (Fig. 4-7 [C, D]). Our results suggest that SOCS1 is induced directly without any 
intermediate protein synthesis. 
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Fig. 4-7  SOCS1 induction is independent of intermediate protein biosynthesis 
[A and B], BMDCs (5x10
5
) or BMMs (3x10
5
) pretreated for 1h with 10 or 50 µM Cycloheximid (Ch) were stimulated as indicated 
for 4.5 h. SOCS1 gene expression was measured by quantitative RT-PCR with β-actin as control reference. [C], BMDCs 
(2x10
5
) or [D] BMMs (2x10
5
) were pretreated with Ch as in [A]. Stimulation was performed with 100 ng/ml LPS for 16 h. 
IL12p40 and TNFα secretion in cell supernatants was determined by ELISA. none; without inhibitor; mock, unstimulated 
control. [A] n=3, mean+SD, [B and C] n=2; mean + SD. 
Upon infection with fungi, myeloid cells generally produce high amounts of the anti-
inflammatory cytokine IL10 (61, 120, 148). For this reason, we additionally wanted to exclude 
IL10 as a mediator of SOCS1 transcription in Dectin-1 triggered cells. Therefore, cells were 
incubated with an anti-IL10 antibody to block IL10 signalling prior to stimulation. Afterwards, 
expression of SOCS1 and SOCS3 mRNA were measured. Neither LPS- nor depleted 
Zymosan- induced SOCS1 could be inhibited by anti-IL10 antibody (Fig. 4-8 [A], [B]). These 
data verify our findings above of a direct SOCS1 expression. IL10 itself was not able to 
induce SOCS1 expression confirming published data (Fig. 4-8 [A]). SOCS3 is known to be 
effectively induced by IL10. Thus, we analyzed BMMs and BMDCs for expression of SOCS3 
upon incubation with anti-IL10 antibody followed by stimulation with IL10. SOCS3 mRNA 
expression was effectively abolished in cells treated with the blocking antibody (Fig. 4-8 [B]). 
Hence, SOCS3 induction served as a control for functional antibody blockade. 
These data further confirm that SOCS1 induction upon Dectin-1 ligation by depleted 
Zymosan is mediated in a direct way. Intracellular or soluble intermediates like type I IFNs or 
IL10 could be excluded. 
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Further, we assessed downstream signalling leading to SOCS1 induction in Dectin-1 
triggered cells. Therefore, we analyzed if the transcription factor NF-κB could be responsible 
for SOCS1 induction.  
   
Fig. 4-8  IL10 does not play a role in Dectin-1-triggered SOCS1 induction 
[A and B], BMDCs (5x10
5
) or BMMs (3x10
5
) were pretreated for 30 min with anti-IL10 antibody (α-IL10, 10 µg/ml) and 
stimulated with dZ (100 µg/ml), LPS (100 ng/ml) or IL10 (10 ng/ml) as control for another 4.5 h. Mock, unstimulated cells. Cells 
were lysed and analyzed for gene expression of SOCS1 [A] or SOCS3 [B] by quantitative RT-PCR. Displayed are relative 
expression levels normalized to β-actin. n=2; mean + SD 
 
4.1.4. NF-κB is not involved in Zymosan induced SOCS1 induction in macrophages 
Previously, Goodrige et al. showed that in BMMs, in contrast to BMDCs, NF-κB is not 
activated upon stimulation of Dectin-1 (71). We therefore investigated downstream signalling 
pathways of Dectin-1 in myeloid cells as our findings hint towards an unknown mode of 
transcriptional induction of SOCS1. First, we analyzed MAPK activation as well as activation 
of spleen tyrosine kinase (Syk) in Dectin-1 triggered cells to ensure activation of down-
stream signalling. Stimulation of BMDCs and BMMs led to a distinct phosphorylation and 
thereby activation of the MAPKs p38, JNKII and ERK as well as Syk. The latter is described 
to mediate proximal signalling of Dectin-1 in cells of the immune system, for example 
dendritic cells and macrophages, but also B-cells or T-cells (46, 52, 70). Importantly, Syk 
was not phosphorylated in BMMs stimulated via LPS (Fig. 4-9 [A]). These findings confirm 
that Dectin-1 triggered cells are capable of activating the MAPK p38, ERK and JNKII. 
Next, a possible contribution of NF-κB to SOCS1 induction in Dectin-1 triggered cells was 
investigated. Activation of NF-κB can be demonstrated indirectly by phosphorylation of the 
NF-κB inhibitor IκBα. Phosphorylated IκBα is degraded and functional NF-κB subunits are 
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released. BMMs and BMDCs were stimulated by depleted Zymosan or LPS and analyzed for 
IκBα phosphorylation by immunoblot. LPS as well as depleted Zymosan led to a distinct 
phosphorylation of IκBα in BMDCs, yet, the unstimulated control already displayed slight 
phosphorylation. In contrast, BMMs showed phosphorylation of the NF-κB inhibitor only when 
stimulated by LPS (Fig. 4-9 [B]).  
   
Fig. 4-9  NF-κB is not activated in BMMs upon Dectin-1 engagement 
[A, B], Immunoblots of lysates of BMMs (3x10
6
) or BMDCs (3x10
6
). [A], cells were stimulated with LPS (100 ng/ml) or dZ (500 
µg/ml) for 30 min. [B], cells were stimulated for the indicated time-periods with LPS (100 ng/ml) or dz (500 µg/ml). [A], blots 
were probed with Abs specific for ERK 1/2 phosphorylated on Thr 
202
/Tyr 
204
, JNKII phosphorylated on Thr
183
/Tyr
185
, p38 
phosphorylated on Thr
180
/Tyr
182 
 and Syk phosphorylated on Tyr
402
. [B], blots were probed with Abs against IκBα 
phosphorylated on Ser
32
, [C], BMMs (3x10
5
) or BMDCs (5x10
5
) were pre-incubated for 1 h with 0, 10 or 50 µM of the NF-κB 
inhibitor Bay 11-7082 and stimulated with LPS (100 ng/ml) or dZ (100 µg/ml). Cells were lysed after 4.5 h and gene expression 
(SOCS1) was measured by quantitative RT-PCR. Shown are relative expression levels normalized against β-actin. Figures [A] 
and [C] show representative data for 3 experiments (mean + SD), results in [B] show representative data for 2 experiments. m, 
mock (unstimulated control) 
These data indicate that NF-κB is not activated in BMMs upon stimulation with depleted 
Zymosan which had additionally been described in previous reports (71). To further confirm 
this observation, we made use of a highly specific NF-κB inhibitor (Bay 11-7082). BMMs and 
BMDCs were treated with 10 µM or 50 µM of the inhibitor 1 h prior to stimulation with LPS or 
depleted Zymosan. After 4.5 h of stimulation, cells were lysed and analyzed for SOCS1 
mRNA expression. With respect to BMMs, none of the applied concentrations of the NF-κB 
inhibitor had an effect on SOCS1 induction. The induction was even slightly increased (Fig. 
4-9 [C]). LPS stimulated cells displayed a decrease of SOCS1 transcripts when pre-treated 
with the inhibitor as expected, since TLR ligands are shown to activate NF-κB. Higher 
inhibitor concentrations down-regulated SOCS1 expression by more than 10-fold in LPS 
stimulated cells. In BMDCs, SOCS1 induction was diminished to basal levels upon the 
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application of the inhibitor followed by stimulation with depleted Zymosan as well as LPS 
(Fig. 4-9 [C]). Based on these results we claim that NF-κB plays a role in SOCS1 induction 
exclusively in BMDCs but not in BMMs when triggered via Dectin-1. The observed 
phosphorylation of IκBα upon stimulation with depleted Zymosan in BMDCs confirms a role 
of NF-κB only in these cells (Fig. 4-9 [B]). In contrast, LPS is capable of inducing SOCS1 in 
an NF-κB dependent manner in both cell types. Inhibition of NF-κB in both cells, BMDCs as 
well as BMMs led to a clear-cut inhibition of LPS induced SOCS1 expression. Additionally, 
phosphorylation of IκBα was observed in both cell types upon LPS stimulation. 
As a NF-κB independent SOCS1 induction was never shown before, we carried out most of 
the following experiments in BMMs to reveal a possible new pathway to express SOCS1. 
NFAT (nuclear factor of activated T-cells) is reported to be one of the first transcription 
factors that is activated upon recognition of Zymosan or live C. albicans yeast by Dectin-1 
(61, 149). Since we excluded a contribution of NF-κB to SOCS1 induction in BMMs, we 
examined if NFAT could be a possible candidate. Therefore, we made use of a potent 
inhibitor of NFAT activity. Cyclosporin A (CsA) blocks nuclear translocation of activated 
NFAT and thus inhibits transcription of NFAT dependent genes. Early growth response 
factors (egr) are a family of transcription factors that are directly induced by NFAT. In BMDCs 
and BMMs, it has been shown that heat killed Candida albicans as well as Zymosan induce 
NFAT and egr1 and egr2 transcription. Thus, we first examined if egr1 and egr2 are 
expressed in BMMs that are stimulated via depleted Zymosan. 
          
Fig. 4-10  egr1 and egr2 are induced in Dectin-1 triggered BMMs 
BMMs (3x10
5
) from WT mice were triggered by LPS (100 ng/ml) or dZ (100 µg/ml) for 1h. Cell lysates were analyzed by 
quantitative RT-PCR. Relative expression of [A] egr1, [B andD] egr2 and [C] SOCS1 is displayed normalized to β-actin. [C and 
D], 3x10
5
 BMMs were pre-treated with 10 µM CsA 1 h prior to stimulation. Cells were stimulated with 100 µg/ml depleted 
Zymosan and analyzed for expression after [C] 1 h or [D] 4.5 h. n=2; mean + SD  
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As illustrated in Fig. 4-10, egr1 [A] and egr2 [B] were definitely induced in BMMs by 10-fold 
as compared to unstimulated (mock) control following Detin-1 stimulation. Importantly, LPS 
showed a significant expression of egr1, but was not able to induce egr2 expression (Fig. 4-
10 [A] and [B]). Afterwards, cells were incubated with 10 µM CsA for 1 h prior to stimulation 
with depleted Zymosan. Analysis of mRNA expression of depleted Zymosan induced SOCS1 
revealed that CsA had no inhibitory effects on SOCS1 induction. The expression of SOCS1 
was rather increased up to 10-fold as compared to stimulated cells that were not treated with 
the inhibitor (Fig. 4-10 [C]). In addition, induction of egr2 mRNA was examined to prove 
efficacy of the inhibitor. Cells were treated with 10 µM CsA prior to stimulation with depleted 
Zymosan. Thereupon, cells were analyzed for egr2 expression. Treatment of BMMs with CsA 
reduced the induction of egr2 transcripts by more than 70 % compared to stimulated cells 
(Fig 4-10 [D]). Based on these results, we concluded that NFAT activity is efficiently blocked 
by CsA since this inhibitor diminished egr2 expression. Otherwise, CsA even increased 
depleted Zymosan induced SOCS1 expression but did not at all block synthesis of SOCS1 
mRNA. Thus, NFAT is not involved in SOCS1 induction. It even had anti-inhibitory effects. 
We next attempted to confirm those findings and examined if egr transcription factors show 
binding activity to the SOCS1 promoter by EMSA. The consensus sequence of the egr 
factors has already been published (GCG(G/T)GGGCG) (150). Promoter elements of human 
SOCS1 to which murine egr could bind are described before (150). A probe was generated 
that comprised the sequence of the SOCS1 promoter with a Cy3-fluorophor coupled to the 
5’-end (see 3.1.7 and Fig. 4-11 [B]). The binding sequence of egr1 differs in one base from 
the consensus sequence as depicted in Fig. 4-11 [B]. To test whether depleted Zymosan 
could induce binding of egr to the SOCS1 probe, cells were stimulated with depleted 
Zymosan, LPS or Zymosan and nuclear extracts were prepared after 6 h of stimulation. At 
earlier time-points, extracts from Zymosan stimulated cells did not show any binding 
activities. Binding activity of proteins from the nuclear extracts was assessed by EMSA. 
Detection of the probe was achieved via the coupled fluorophor Cy3. The EMSA results are 
depicted in Fig. 4-11 [A]. In all lanes, one band was detectable which might be assigned to 
an unspecific binding as it appears to be constant within all lanes. However, an additional 
band increased upon stimulation with LPS or Zymosan (Fig. 4-11 [A], indicated by an arrow). 
This band possibly corresponds to egr1. Supershift experiments with an antibody against 
egr1 could clarify these observations. Importantly, even unstimulated cells showed a weak 
binding of egr1 to the SOCS1 probe. Thus, the unstimulated control was already pre-
activated.  
Transcriptional function of egr for SOCS1 expression could not be verified in cells stimulated 
with depleted Zymosan. However, nuclear extracts from LPS as well as Zymosan stimulated 
cells showed an increase in binding activites. Since Zymosan also exhibits TLR binding 
activity, the observed binding of nuclear proteins extracted from Zymosan stimulated cells 
could originate from the TLR binding moiety.  
Our results indicate that SOCS1 is induced in Dectin-1 triggered BMMs and BMDCs in a 
direct way. Additionally, BMDCs are shown to induce expression of SOCS1 in an NF-κB 
dependent manner. In BMMs, expression of SOCS1 by depleted Zymosan is independent of 
NF-κB as well as NFAT or egr. 
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Fig. 4-11  Analysis of binding activities of nuclear extracts to an egr1 binding probe within the SOCS1 promoter 
[A], BMMs (9x10
6
) from WT mice were stimulated with LPS (100 ng/ml), dZ (500 µg/ml), Z (500 µg/ml) or left unstimulated 
(mock). After 6 h, nuclear extracts were prepared and added to the Cy3-labeled SOCS 1.2 probe containing an egr1 binding 
site. Samples were run in 6% acrylamide native gels and Cy3 fluorescence was detected. Asterisk indicates unspecific binding, 
arrow indicates a specific band. [B], Sequence of the probe including the binding site (red letters). Numbers indicate relative 
position from the A in the ATG initiation site in the human SOCS1 gene. Consensus sequence of egr1 is depicted below the 
probe. Results are representative for 2 independent experiments. 
 
4.1.5. Pyk2 and ERK are key signalling molecules in SOCS1 induction in Dectin-1 
triggered BMMs 
On the basis of the above results, we next were interested in downstream molecules that 
could participate in Dectin-1 mediated expression of SOCS1. It has been proposed that the 
MAPK ERK acts downstream of C-type lectins, i.e. Dectin-1. Indeed, we easily observed 
ERK phosphorylation upon ligation with depleted Zymosan (Fig. 4-9 [A]). 
Proline rich tyrosine kinase 2 (Pyk2) was recently identified as a member of cytoplasmatic 
protein tyrosine kinases that can be activated via Src and Syk kinases. Phosphorylated Pyk 2 
itself is shown to activate downstream MAPK ERK (151, 152). To address the question 
whether Dectin-1 mediates Pyk2 / ERK activation in BMMs, cells were stimulated and 
activation of Pyk2 was determined. BMMs were stimulated with depleted Zymosan for 
different time-periods (15 min, 90 min and 240 min) and phosphorylation of Pyk2 was 
examined by means of immunoblot. Pyk2 phosphorylation could be detected in depleted 
Zymosan stimulated cells at any time point that was analyzed. After 240 min, 
phosphorylation of Pyk2 was even increased (Fig. 4-12 [A]). Quantification of the various 
bands is displayed as percentage of the unstimulated (mock) control directly above the 
respective blots. The unstimulated control (mock) was set 100 %. An increase in Pyk2 
phosphorylation up to 325 % could be observed after 240 min of stimulation. After 15 or 90 
min, intensities were increased up to 158 % (90 min) or 128 % (15 min) (Fig. 4-12 [A]). Since 
we observed SOCS1 peak induction after 4.5 h (Fig. 4-1 [C]), this late up-regulation of Pyk2 
activity could be a hint for a possible contribution of Pyk2 to SOCS1 induction. Notably, Pyk2 
displayed a basal activation in unstimulated cells. Utilization of inhibitors directed against Src 
(PP1) and Syk (Syki) kinases led to a strong reduction of Pyk2 phosphorylation almost to the 
levels of the unstimulated control. This places Pyk2 downstream of Src and Syk kinases. 
Again, band intensities are shown directly above the blots (Fig. 4-12 [A]).  
Pyk2 also comprises a calcium binding motif by which it can be activated in a calcium 
dependent manner. Thus we used inhibitory reagents to block calcium signalling pathways. 
BAPTA is described as a chelator of intracellular calcium. Similarly, KN-93 is a potent and 
specific inhibitor of CaMK (calmodulin dependent protein kinase). When bound to Ca2+, 
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calmodulin activates CaMK. AG17 directly inhibits tyrosine phosphorylation of Pyk2. BMMs 
were treated with 10 µM of the respective inhibitors prior to stimulation with depleted 
Zymosan and analyzed for Pyk2 activation. Surprisingly, Pyk2 phosphorylation could still be 
detected in the presence of BAPTA or KN-93 (Fig. 4-12 [B]). In contrast, AG17 abolished 
activation of Pyk2 (Fig. 4-12 [B]) as shown by band intensities above the blot (78 % when 
compared to unstimulated control). 
               
Fig. 4-12  Pyk2 is phosphorylated upon stimulation with dZ and is activated Src and Syk dependently 
[A and B], WT BMMs (3x10
6
) were pretreated for 1 h with 10 µM Syk inhibitor IV (Syki), 10 µM Src inhibitor (PP1) [A] or 10 µM 
BAPTA, AG17 and KN93 [B]. [A] Cells were stimulated for the indicated time periods with dZ (500 µg/ml). [B] Cells were 
stimulated with dZ (500µg/ml) for 30 min. Cells were lysed and probed by means of immunoblot with antibodies specific for 
Pyk2 phosphorylated on Tyr
402 
or β-actin. m, unstimulated control; 0, without inhibitor. AG17, Pyk2 inhibitor; BAPTA, calcium 
chelator; KN93, inhibitor of CaMK. Results are representative for 3 independent experiments. Densitometry data are stated 
directly above the blot (unstimulated control (mock) = 100%) as percentage of mock and are shown as bar graphs in the 
appendix. 
Thus, Pyk2 is supposedly activated in a calcium independent way by Src and Syk kinases. 
Next, we assessed the activation of the MAPK ERK, JNKII and p38 after the application of 
calcium as well as Pyk2 inhibitors. Additionally, the effect of the inhibitors on the expression 
of SOCS1 protein had to be analyzed. BMMs were pre-treated with the respective inhibitors 
as described above. Phosphorylation of ERK, p38 and JNKII was detected by means of 
immunoblot after stimulation with depleted Zymosan. Importantly, ERK phosphorylation was 
completely blocked in cells pre-treated with AG17 and displayed activation at the levels of 
the mock control (as shown by intensities) (Fig. 4-13 [A]). In contrast, BAPTA and KN-93 had 
no effect on ERK phosphorylation; band intensities were similar to that of unstimulated 
probes. Concerning p38 and pJNKII, AG17 had no effect on the phosphorylation status. (Fig. 
4-13 [B], [C]). Activation of p38 was even further increased by 67 % as compared to depleted 
Zymosan alone (Fig. 4-13 [B]) where cells were treated with AG17. 
Accordingly, our data on the one hand show that the applied inhibitors BAPTA, KN-93 and 
AG17 are functional as they inhibited MAPK activation. Otherwise, AG17 was a potent 
inhibitor of Pyk as well as ERK phosphorylation, whereas it had no effect on p38 or JNKII 
activation. BAPTA and KN-93 were effective inhibitors of p38 and JNKII phosphorylation but 
did not affect ERK phosphorylation.  
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Fig. 4-13  Effects of Pyk2 inhibition on MAPK activity and SOCS1 expression 
[A] – [C], WT BMMs (3x10
6
) were pretreated for 1h with 10 µM BAPTA, AG17 or KN93. [A]-[C], cells were stimulated for 30min 
with dZ (500 µg/ml). Cell lysates were analyzed by immunoblot. Blots were probed with antibodies specific for [A] ERK 1/2 
phosphorylated on Thr 
202
/Tyr 
204
, [B], p38 phosphorylated on Thr
180
/Tyr
182
,
 
[C], JNKII phosphorylated on Thr
183
/Tyr
185 
or β-actin. 
[D], WT BMMs (18x10
6
) were pretreated as in [A] – [C]. Afterwards, cells were stimulated for 6 h with dZ (500 µg/ml). Cells 
were lysed and proteins were analyzed by western blot. Blots were probed with antibodies against SOCS1 or β-actin. Data are 
representative of 3 independent experiments. Band intensities are depicted directly above the blots (unstimulated control 
(mock) = 100%) as percentage of mock. Bar graphs of the quantitative data are shown in the appendix. 
Subsequently the impact of the Pyk2/ERK pathway on the expression of SOCS1 had to be 
assessed. Therefore, we checked for SOCS1 induction by western blot after pre-incubation 
with Pyk2 and calcium inhibitors. In case of treatment with AG17, SOCS1 induction was 
completely abrogated whereas calcium inhibitors had no effect (Fig. 4-13 [D]). Thus, SOCS1 
protein expression is probably independent of calcium signalling pathways as also observed 
for the activation of the MAPK ERK. Additionally, ERK as well as SOCS1 are most likely 
situated downstream of the tyrosine kinase Pyk2. We next had to analyze if ERK as well as 
SOCS1 are also placed downstream of Src and Syk kinases as already shown for Pyk2 (Fig. 
4-12 [A]). BMMs were incubated for 1 h with 10 µM of PP1 (Src inhibitor) or Syki (Syk 
inhibitor), respectively. Afterwards, cells were stimulated with depleted Zymosan and 
analyzed for MAPK activation or induction of SOCS1. Application of Src and Syk inhibitors 
largely suppressed ERK activation as compared to stimulated cells. In contrast, pp38 and 
pJNKII were only affected by inhibiting Src (Fig. 4-14 [A, B, C]). Activation of p38 and JNKII 
was diminished to the level of unstimulated cells (mock). Src kinases also signal via the 
serin/threonin kinase Raf1. Raf1 is described to be an important activator of MAPKs. 
Therefore, it is possible that p38 for example is activated via a Src-Raf1 signalling pathway. 
SOCS1 expression induced by depleted Zymosan was entirely abolished by Src and Syk 
inhibitors as displayed by band intensities (Fig. 4-14 [D]). Thus, Syk kinase when activated, 
induces ERK phosphorylation as well as SOCS1 expression. 
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Fig. 4-14  Influence of Src and Syk inhibition on SOCS1 expression and MAPK phosphorylation 
Immunoblots of BMM cell lysates pretreated for 1h with either 10 µM Syki or 10 µM PP1. [A]-[C], Cells (3x10
6
) were stimulated 
with 500 µg/ml dZ for 30 min. Cells were lysed and blots were probed with Abs against  [A] ERK 1/2 phosphorylated on 
Thr  
202
/Tyr 
204
, [B] p38 phosphorylated on Thr
180
/Tyr
182 
[B], [C] JNKII phosphorylated on Thr
183
/Tyr
185
. [D], cells (18x10
6
) were 
lysed and blots were probed with Ab against SOCS1. β-actin served as loading control. Displayed experiments show 
representative data for 3 independent experiments. Band intensities are depicted directly above the blots (unstimulated control 
(mock) = 100%) as percentage of mock. Bar graphs of the quantitative data are shown in the appendix. 
Dectin-1 can also signal independently of Syk. Here, the serin/threonin kinase Raf1 is 
phosphorylated by Ras proteins. Ras proteins are activated by Src (52, 76). To test the 
relevance of Raf1 for the ERK dependent induction of SOCS1, we pre-treated BMMs with an 
inhibitor against Raf1.  
BMMs were pre-incubated with 10 µM of PP1, Syki or Rafi (Raf1 inhibitor), respectively. The 
stimulated cells were analyzed for activation of ERK, p38 as well as for SOCS1 expression. 
As displayed in Fig. 4-15, only the activation of p38 was diminished when Raf1 was inhibited, 
whereas phosphorylation of ERK and expression of SOCS1 were not affected. Thus, 
synthesis of SOCS1 was independent of Raf1 but is rather regulated by the tyrosine kinase 
Syk.  
 
Fig. 4-15  SOCS1 is induced independently of Raf1 in Dectin-1 triggered cells 
[A], BMMs (3x10
6
) were triggered by dZ (500 µg/ml) for 30 min after a 1h incubation time with 10 µM Syki, Rafi or PP1. [B], 
BMMs (18x10
6
) were pre treated with 10 µM Rafi, Syki or PP1 and afterwards stimulated with dZ (500 µg/ml). [A] and [B], cells 
were lysed and immunoblot was performed with Abs specific for ERK 1/2 phosphorylated on Thr 
202
/Tyr 
204
, p38 phosphorylated 
on Thr
180
/Tyr
182
 [A], SOCS1 [B] or β-actin [A] and [B]. Data are representative for 2 independent experiments. Band intensities 
are directly depicted above the respective blots (unstimulated control (mock) =100%) as percentage of mock. Bar graphs of the 
quantification analysis are shown as bar graphs in the appendix. 
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So far, the signalling pathway to induce SOCS1 can be described as follows. Upon 
engagement of Dectin-1, the tyrosine kinase Src gets activated by phosphorylation. 
Therupon, the Spleen tyrosine kinases (Syk) is activated by Src kinase and subsequently 
phosphorylate the tyrosine kinase Pyk2. Via a yet unknown mechanism, Pyk2 activates the 
MAPK ERK. Thereupon, pERK induces expression of SOCS1 via an ERK dependent 
transcription factor. 
To strengthen the observation that Pyk2 is involved in SOCS1 induction, we next analyzed 
Pyk2 as well as SOCS1 expression following knockdown of Pyk2. BMMs were transfected 
either with a siRNA directed against Pyk2 (siPyk2) or a control siRNA (siCon) with a non-
genomic sequence to control sequence-specific RNA interference. After 20 h, cells were 
stimulated with depleted Zymosan or left unstimulated and analyzed for ERK phosphorylation 
and SOCS1 expression. Further, Pyk2 expression was analyzed in unstimulated cells to 
determine the knockdown efficiency.  
     
Fig. 4-16  Pyk2 knockdown reduces Dectin-1 mediated expression of SOCS1 
[A]-[C] BMMs were transfected with 50 nM control or Pyk2-specific siRNA for 20 h. Afterwards, stimulation was performed for 
[B] 4.5 h, [D] 6 h or [C] 30 min. [A] Cells (2x10
6
) were lysed and western blot was performed with Ab against Pyk2 to validate 
knockdown. [B] Cells (3x10
5
) were lysed and analyzed for gene expression and knockdown by quantitative RT-PCR. 
Transcription was compared with control siRNA. [C], [D] Cells (2x10
6
 [C] or 18x10
6
 [D]) were stimulated with dZ (500 µg/ml) 
and immunoblot was performed with Abs against ERK 1/2 phosphorylated on Thr 
202
/Tyr 
204
 [C] or SOCS1 [D]. siCon; control 
siRNA. Results show representative data of two independent experiments (mean + SD). Band intensities are directly depicted 
above the respective blots (unstimulated control (mock) =100%) as percentage of mock. Bar graphs of the quantification 
analysis are shown as bar graphs in the appendix. 
As depicted in Fig. 4-16 [A] and [B], siRNA directed against Pyk2 decreased Pyk2 
expression by 50 % as compared to cells transfected with control siRNA. On protein level, 
densitometry analysis was carried out to determine the knockdown efficiencies. Stimulated 
cells were analyzed for SOCS1 expression on mRNA as well as protein level. SOCS1 
transcripts were decreased by 50 % in stimulated cells transfected with the Pyk2 siRNA as 
compared to stimulated cells transfected with the control siRNA (Fig. 4-16 [B]). SOCS1 
protein expression was almost completely abolished as analyzed by means of densitometry 
measurements. In BMMs transfected with the control siRNA, depleted Zymosan induced 
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SOCS1 expression up to 228 % compared to mock control (100 %) (Fig. 4-16 [D]). In 
contrast, in siPyk2 transfected cells, stimulation with depleted Zymosan did not increase 
SOCS1 expression over the level of the unstimulated control (Fig. 4-16 [D]). Similarly, ERK 
activity was blocked by Pyk2 siRNA. Stimulation of siPyk2-transfected cells with depleted 
Zymosan decreased ERK activation by 50 % as compared to stimulated cells that were 
transfected with the control siRNA (Fig. 4-16 [C]). ERK was phosphorylated by more than 
500 % in siCon treated cells. Similarly, SOCS1 was induced by 120 %. The values are 
comparable to those observed in previous experiments with WT BMMs, i.e. in Fig. 4-13 [A] 
and [D] or Fig. 4-14 [D]. Thus, the expression of the respective genes seems to be 
unaffected by the control siRNA.  
The data confirmed that SOCS1 induction in Dectin-1 triggered BMMs is mediated by Pyk2 
and the downstream situated MAPK ERK. Accordingly, siRNA based downregulation of Pyk2 
inhibited ERK activation and SOCS1 expression as shown for inhibition of Pyk2 via AG17.  
Application of UO126 that specifically inhibits ERK phosphorylation verified these findings. 
Pre-incubation of BMMs with UO126 diminished SOCS1 expression by 40 % as compared to 
the control cells stimulated with depleted Zymosan (Fig. 4-17). However, we still could detect 
residual induction of SOCS1. ERK phosphorylation was completely abrogated upon 
incubation with UO126. UO126 is described as a potent inhibitor of MEK1 and MEK2, both of 
them activate ERK MAPK. In contrast, inhibitors directed against JNKII (JNKIIi) or p38 
(SB203580) displayed no effect on SOCS1 expression (Fig. 4-17). Taken together, ERK is 
activated by Pyk2. ERK thereupon is responsible for SOCS1 induction as shown by inhibitor 
studies (inhibition of Syk, Src and Pyk2 kinases inhibited ERK activation and SOCS1 
induction). Knockdown of Pyk2 inhibited phosphorylation of ERK and synthesis of SOCS1. 
      
Fig. 4-17  The ERK inhibitor UO126 diminished Dectin-1 induced SOCS1 expression 
Cells (18x10
6
 BMMs) were treated with 10 µM of JNKIIi, SB203580 or UO126 prior to stimulation with 500 µg/ml dZ. Cells were 
stimulated for another 6h and proteins were measured in the lysates by immunoblot. Blots were probed with Abs specific for 
SOCS1 or β-actin. Results show representative data of 2 independent experiments. Band intensities are depicted directly 
above the blots (unstimulated control (mock) = 100%) as percentage of mock. Bar graphs of the quantitative data are shown in 
the appendix. JNKIIi, inhibitor of JNKII; SB203580, p38 inhibitor; UO126, ERK inhibitor  
 
4.1.6. The signalling pathway leading to the induction of SOCS1 in BMDCs differ 
from that in BMMs 
In BMDCs IκBα was clearly activated as shown by phosphorylation following engagement of 
Dectin-1. Upon inhibition of NF-κB, SOCS1 induction was decreased; thus it has to be 
concluded that NF-κB is involved in SOCS1 induction only in BMDCs but not in BMMs 
(Fig. 4-9). Consequently, phosphorylation status of IκBα was analyzed in cells treated with 
Pyk2 and calcium inhibitors (4.1.4) prior to stimulation with depleted Zymosan.  
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BAPTA and KN-93 led to diminished phosphorylation of IκBα by more than 50 % as 
compared to stimulated control. AG17 as a direct inhibitor of Pyk2 activity completely 
abolished it (Fig. 4-18 [A]). Hence, we checked for activation of Pyk2 in BMDCs with or 
without the application of the aforementioned inhibitors (Fig. 4-18 [B]). In contrast to BMMs, 
BMDCs showed a marked decrease of Pyk2 phosphorylation upon pre-incubation with 
BAPTA as well as KN-93 (about 60 %). In BMMs, Pyk2 phosphorylation was not affected by 
the calcium inhibitors. AG17 had similar effects in both cell types, BMMs as well as BMDCs. 
Pyk2 phosphorylation was abolished in BMDCs (Fig. 4-18 [B]) and BMMs (Fig. 4-12 [B]).To 
determine whether the Pyk2 as well as calcium inhibitors had the same effect on MAPK 
activation as observed in BMMs (Fig. 4-13), we analyzed MAPK phosphorylation. ERK 
phosphorylation was only diminished when Pyk2 was directly inhibited via AG17, whereas 
none of the inhibitors affected p38 phosphorylation. Otherwise, JNKII phosphorylation was 
completely blocked by BAPTA, KN-93 and AG17. Phosphorylation was even less as 
compared to mock control (Fig. 4-18 [A]). This led us to the assumption that pJNKII seems to 
play a role in the phosphorylation of IκBα. JNKII in turn is activated by pPyk2 (Fig. 4-18 [A]). 
Importantly, this pathway seems to be calcium dependent.  
 
Fig. 4-18  SOCS1 protein expression is diminished in BMDCs upon treatment with Pyk2 and calcium inhibitors 
[A] and [B], BMDCs (3x10
6
) were pre-incubated for 1 h with 10 µM of the delineated inhibitors (BAPTA, AG17, KN93) and 
stimulated afterwards with dZ (500 µg/ml) for 90 min. Activation of MAPKs, Pyk2 and pIκBα was not observed until 90 min of 
stimulation. Cell lysates were analyzed by immunoblot with antibodies specific for ERK 1/2 phosphorylated on Thr
202
/Tyr
204
, p38 
phosphorylated on Thr
180
/Tyr
182
, JNKII phosphorylated on Thr
183
/Tyr
185
, IκBα phosphorylated on Ser
32 
or β-actin. [C], BMDCs 
(18x10
6
) were treated with inhibitors as described for [A] and [B] and stimulated for 6 h with dZ (500 µg/ml). Western blot of 
lysed cells was carried out with antibodies directed against SOCS1 or β-actin. Results show representative data for 2 
independent experiments. 
Regarding SOCS1 induction, Pyk2 and calcium inhibitors decreased SOCS1 protein 
expression levels by more than 50 %, respectively (Fig. 4-18 [C]). Notably, SOCS1 protein 
could be detected at the highest level after 6 h of stimulation as also observed for BMMs 
(Fig. 4-1 [B]). In conjunction with the fact that utilization of a NF-κB inhibitor down-regulated 
SOCS1 induction (Fig. 4-9 [B]), we speculate that in BMDCs, SOCS1 is induced in a calcium 
and NF-κB dependent way. The pathway leading to SOCS1 induction in BMDCs can 
probably be described as follows. Most likely, Src and Syk kinases are activated upon 
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binding of depleted Zymosan by Dectin-1. Syk kinase may activate Pyk2 kinase. IκBα is 
phoshorylated and thereupon, NF-κB induces transcription of SOCS1.  
Whether NFAT plays a role in SOCS1 induction in BMDCs has to be further analyzed. 
Nevertheless, it is shown that calcium dependent, NFAT independent pathways are indicted 
to be responsible for downstream signalling of Dectin-1 (66).  
As a NF-κB independent SOCS1 induction was never shown before, we carried out most of 
the following experiments in BMMs to reveal a possible new pathway to express SOCS1. 
4.1.7. Summary of part 4.1 
It could clearly be shown that the engagement of Dectin-1 by depleted Zymosan induced 
SOCS molecules, namely SOCS1, SOCS3 and CIS in murine BMDCs and BMMs. SOCS1 
was induced without the attendance of any TLR as shown by the application of cells from 
MyD88/Trif double deficient mice. Further, SOCS1 was directly induced upon stimulation of 
BMDCs and BMMs with depleted Zymosan since no intermediate or secreted factor was 
needed. SOCS1 was still induced in the presence of cycloheximid or when cells from 
IFNAR1-/- mice were employed. Moreover, NF-κB as a possible transcription factor could be 
ruled out in BMMs. In BMMs, in contrast to BMDCs, the NF-κB inhibitor IκBα was not 
phosphorylated after Dectin-1 stimulation. Also, a NF-κB inhibitor only reduced Dectin-1 
induced SOCS1 expression in BMDCs but not in BMMs. The transcription factors NFAT and 
egr1 as possible candidates to induce SOCS1 could be excluded. We further show evidence 
for a signalling pathway that involves the kinases Src and Syk as direct targets after Dectin-1 
ligation. Importantly, Pyk2 is phosphorylated upon triggering of Dectin-1 by depleted 
Zymosan. Pyk2 is described to be activated in a Src dependent way.  
In this study it is for the first time shown that Pyk2 is linked to SOCS1 induction. In BMMs, 
the following pathway can be proposed. Upon ligation of Dectin-1 by depleted Zymosan, Src 
and Syk kinaseas are activated by phosphorylation at the activated receptor. Thereupon, 
Pyk2 is phosphorylated and activates ERK. Activated ERK mediates the expression of 
SOCS1 via and ERK dependent transcription factor. NF-κB as well as NFAT are not involved 
in SOCS1 induction in BMMs. In contrast, we show that SOCS1 in BMDCs is induced via 
NF-κB. We next assessed possible properties of SOCS1 idnuced upon Dectin-1 
engagement. 
4.2. Influence of SOCS1 on Dectin-1 and TLR signalling pawthays 
SOCS proteins have been initially identified as negative feedback inhibitors of type I and II 
IFNs. Since the Jak/STAT pathway is used by different cytokines, the properties of SOCS 
proteins are not only restricted to its inducing pathway (feedback), but also inhibit other 
Jak/STAT dependent cytokine signalling pathways (crosstalk). However, recent findings 
indicate that SOCS1 possibly also influences Jak/STAT independent signalling modules. 
Accordingly, a direct effect of SOCS1 on the TLR/NF-κB pathway has been proposed (109, 
110). Therefore, it had to be studied whether SOCS1 might contribute to fine-tuning of 
Dectin-1 or TLR signalling. 
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4.2.1. No effect of SOCS1 on Dectin-1 signalling  
First, we investigated the impact of SOCS1 as a feedback inhibitor of Dectin-1. For this 
purpose, BMMs from SOCS1-/- mice on IFNγ knockout background were used. Normally, 
SOCS1-/- develop a multi-inflammatory syndrome and die within 3 weeks after birth.  
The neonatal defect is mainly based on hypersensitivity towards IFNγ. SOCS1/IFNγ double 
deficient mice display a diminished pathology and survive the neonatal period. Thus, we 
used SOCS1-/-/IFNγ-/- cells to analyze phosphorylation of the kinases involved in SOCS1 
expression in WT BMMs. As BMMs do not produce IFNγ, the IFNγ-/- background should have 
no impact when analyzing isolated cells. SOCS1-/-/IFNγ-/- and the respective IFNγ-/- control 
cells were stimulated with depleted Zymosan for 15 min, 90 min or 240 min. Thereupon, 
phosphorylation of Syk, Pyk2 as well as the MAPK ERK was determined by means of 
immunoblot. In cells from the knockout as well as the control mice, phosphorylation of Syk 
and Pyk2 was observed after 90 min and was still detectable after 240 min of stimulation 
(Fig. 4-19 [A], [B]). These results were comparable to the phosphorylation status of WT 
BMMs stimulated by depleted Zymosan (Fig. 4-12, 4-13). ERK phosphorylation was induced 
in SOCS1-/-/IFNγ-/- as well as IFNγ-/- BMMs already after 15 min and even could be measured 
after 240 min of stimulation. Interestingly, none of the kinases showed a difference in 
activation profile in cells from SOCS1-/-/IFNγ-/- mice as compared to IFNγ-/- control cells (Fig. 
4-19 [A], [B]). 
As mentioned above, egr2 is one of the first genes directly activated by triggering of Dectin-1. 
Therefore, we next tested for a possible regulation of this transcription factor. Cells from 
double knockout and control mice were stimulated with depleted Zymosan and analyzed by 
RT-PCR for transcript levels of egr2. BMMs from the knockout as well as the control mice 
displayed a 10-fold induction, comparable to that of the WT cells (Fig. 4-10). No difference in 
egr2 expression could be observed (Fig. 4-19 [C]). NFAT and egr transcription factors are 
important for IL10 production. We additionally examined the secretion of this cytokine in 
SOCS1-/-/IFNγ-/- and IFNγ-/- BMMs via an ELISA-based determination of the amount of IL10 in 
the supernatant of stimulated cells. However, IL10 secretion was not altered in      
SOCS1-/-/ IFNγ-/- cells (Fig. 4-19 [B]). 
These data indicate that SOCS1 is not a feedback inhibitor of the Dectin-1 pathway. No 
differences of the key kinases involved in Dectin-1 mediated SOCS1 induction, Syk, Pyk2 
and ERK could be detected. Also, egr2 and IL10 as important molecules induced by Dectin-1 
were not affected. Therefore, we next analyzed a possible impact of Dectin-1 induced 
SOCS1 on TLR signalling pathway.  
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Fig. 4-19  SOCS1 is not a feedback inhibitor of Dectin-1 signalling 
[A], [B] BMMs (3x10
6
) from SOCS1
-/-
/IFNγ
-/- 
or IFNγ
-/- 
mice were stimulated for the indicated time periods with dZ (500 µg/ml) or 
left unstimulated (mock). Cells were lysed and immunoblot was performed with Abs specific for [A], Pyk2 phosphorylated on 
Tyr
402
, Syk phosphorylated on Tyr
519
/Tyr
520
 and [B], ERK1/2 phosphorylated on Thr 
202
/Tyr 
204
. [C], [D] BMMS from        
SOCS1
-/-
/IFNγ
-/- 
or IFNγ
-/- 
control mice were stimulated with dZ (100 µg/ml). [C] 3x10
5 
cells were lysed after 4.5h and analyzed for 
egr2 expression by quantitative RT-PCR. [D] Supernatants of 2x10
5
 cells were analyzed for the secretion of IL10 after 24h by 
ELISA.  Results in [A and B] show representative data of 3 independent experiments. [C and D] n=3 (mean + SD).  
 
4.2.2. TLR activation is modulated by Zymosan induced SOCS1 
Besides its interaction with TLR2, Dectin-1 is able to modulate the responses of different 
TLRs, including TLR2/1, TLR2/6, and TLR4 (55, 63). In these cases, the production of IL12 
was down-regulated by the addition of β-glucan what activates Dectin-1. As SOCS1 is 
induced through Dectin-1 but has no impact on this pathway, we assumed that it could act as 
a crosstalk inhibitor for TLR signalling. First of all, we analyzed whether WT BMMs triggered 
with depleted Zymosan could influence TLR signalling. Therefore, we stimulated cells with 
depleted Zymosan to trigger Dectin-1 solely or used it in a co-stimulatory approach with 
CpG-DNA or other pure TLR ligands (LPS, Pam3CSK4, Poly(IC) (PIC), R848). BMMs were 
pre-stimulated with the respective TLR ligand for 4h followed by stimulation with depleted 
Zymosan. Notably, pre-stimulation with depleted Zymosan prior to the application of the 
respective TLR ligands had the same effects on cytokine secretion.  
Thereupon, secretion of IL12p40, TNFα and IL8 in supernatants of stimulated cells was 
determined. IL12p40 secretion was markedly reduced in BMMs and BMDCs upon co-
activation of Dectin-1 and different TLRs when compared to stimulation with the sole TLR 
ligand, respectively (Fig. 4-20 [A]). Cells co-stimulated with CpG-DNA and depleted Zymosan 
showed a reduction of IL12p40 of about 50 %. Depleted Zymosan together with Pam3CSK4 
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even decreased IL12p40 cytokine production by almost 90 %. Interestingly, LPS was much 
less simulative than the other tested TLR ligands (CpG-DNA, Pam3CSK4, R848, PIC). Also, 
depleted Zymosan had almost no effect on LPS induced IL12p40 secretion. The amount of 
IL12p40 was only decreased by about 10 %. Notably, R848 production was unaltered in the 
co-stimulatory setting. In contrast, TNFα and IL8 cytokine secretion was up-regulated when 
cells were triggered via TLRs and Dectin-1 (Fig. 4-20 [B], [C]). Regarding TNFα, CpG-DNA 
and R848 turned out to be the most potent ligands in combination with depleted Zymosan. 
Cytokine secretion was increased by 90 %, whereas the production upon stimulation with 
LPS as well as Pam3CSK4 or PIC was only slightly up-regulated. Similarly, IL8 secretion was 
increased by co-stimulation. Cells stimulated by depleted Zymosan in combination with CpG-
DNA, R848 or Pam3CSK4 displayed an increase in cytokine secretion of about 80-90 % when 
compared to TLR ligands alone (Fig. 4-20 [C]).  
    
Fig. 4-20  Dectin-1 co-stimulation modulates TLR-induced cytokine profile 
[A-C], WT cells (2x10
5 
BMMs) were stimulated with dZ (100 µg/ml), CpG DNA (1 µM), LPS (100 ng/ml), P3C (100 ng/ml), PIC 
(25 µg/ml) or R848 (500 ng/ml) for 16 h. In case of co-stimulation, cells were pre-stimulated with the respective TLR ligands for 
4h following incubation with dZ (12 h). Secretion of [A] IL12p40, [B] TNFα or [C], IL8 was detected by ELISA. n=2 (mean + SD); 
n.s., not significant 
Less is known about an influence of β-glucans like Zymosan on TLR9 signalling. 
Nonetheless, it was shown that the C-type lectin receptor DC-SIGNR1 is able to induce 
SOCS1 after an infection with mycobacteria which comprise a high CG-DNA content, thus 
triggering TLR9. Also, Dectin-1 was shown to be triggered by M. tuberculosis and 
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Mycobacterium abscessus (46, 153, 154). Due to these facts, we decided to analyze if 
SOCS1 could influence the crosstalk between TLR9 and Dectin-1. First, we examined BMMs 
from SOCS1-/-/IFNγ-/-and IFNγ-/- mice for the production of cytokines when both Dectin-1 and 
TLR9 were triggered. As in wildtype cells, depleted Zymosan reduced the production of 
IL12p40 by CpG-DNA in IFNγ-/- cells significantly by 40 %. Notably, the induction of IL12p40 
by CpG DNA was much higher in SOCS1-/-/IFNγ-/-and IFNγ-/- (Fig. 4-21 [A]) as compared to 
WT BMMs (Fig. 4-20 [A]). This could be attributed to the IFNγ-/- background. It is reported that 
IFNγ-/- mice are more sensitive to pathogenic stimuli (155-157).  
 
 
Fig. 4-21  SOCS1 expressed by depleted Zymosan differentially regulates TLR triggered cytokine production 
[A]-[D] 2x10
5
 BMMs from SOCS1
-/-
/IFNγ
-/- 
or IFNγ
-/- 
mice were stimulated with dZ, CpG-DNA (CpG), LPS or a combination 
thereof. [A] and [B], Cells (2x10
5
) were stimulated with dZ (100 µg/ml), CpG (1 µM) or LPS (100 ng/ml) for 16 h. [C], 2x10
5
 cells 
were stimulated as depicted for [A] and [B]. [D], BMMs (2x10
5
) were stimulated with dZ (100 µg/ml) or CpG (1µM) for 20 h. For 
costimulation settings, cells were pre-stimulated for 4 h with CpG ([A]-[D]) or LPS ([A], [B]) following incubation with dZ (12 h [A-
C]; 20 h [D]). Supernatants were analyzed for secretion of IL12p40, TNFα, IL8 or IL10 by ELISA.n=3 (mean + SD) 
In comparison to IFNγ-/- cells, BMMs from SOCS1-/-/IFNγ-/- displayed no decrease in IL12p40 
secretion anymore when costimulated with CpG-DNA and depleted Zymosan. Cytokine 
secretion was even significantly enhanced up to nearly two fold as compared to IFNγ-/- cells 
(Fig. 4-21 [A]). This indicates that SOCS1 which is expressed upon engagement of Dectin-1 
inhibits CpG-DNA induced IL12p40 production. When we focused on TNFα or IL8 secretion, 
we could not detect any difference in cytokine expression since TNFα and IL8 were up-
regulated to the same extent upon co-stimulation in BMMs from knockout and control 
animals (Fig. 4-21 [B], [C]). Regarding IL10, cytokine secretion was markedly enhanced to 
more than two-fold in SOCS1-/-/IFNγ-/- in comparison to the respective control (Fig. 4-21 [C]). 
LPS only slightly induced expression of IL12p40, TNFα or IL8. 
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Importantly, co-stimulation of SOCS1 knockout cells only had an influence on IL12p40 and 
IL10 secretion, but not on TNFα or IL8. Thus, Dectin-1 shapes the TLR9 cytokine profile, and 
this is partly dependent on SOCS1. 
4.2.3. Increased activity of NF-κB subunits in SOCS1 knockout cells  
It has been reported before that SOCS1 contributes to ubiquitination of NF-κB subunits 
resulting in subsequent degradation. Therefore, we wanted to examine whether the 
activation of NF-κB transcription factors is altered after co-stimulation with CpG-DNA and 
depleted Zymosan. We first verified if the level of SOCS1 protein differs in cells that were 
stimulated via TLR9 and Dectin-1. Therefore, we stimulated BMMs from WT mice with CpG-
DNA or depleted Zymosan or a combination thereof and analyzed SOCS1 expression on 
protein level. As depicted in Fig. 4-22 [A], expression of SOCS1 could clearly be amplified 
after concomitant application of CpG-DNA and depleted Zymosan in comparison to cells 
stimulated with the individual ligands, respectively. Worth mentioning is the fact that depleted 
Zymosan alone had a higher potential to induce SOCS1 than CpG-DNA. The higher 
expression level of SOCS1 could explain the decrease of IL12p40 when TLR9 and Dectin-1 
are triggered the same time.  
To further address this issue, we tested for IκBα degradation and phosphorylation by 
immunoblot. BMMs from SOCS1-/-/IFNγ-/- and IFNγ-/- control mice were stimulated with 
depleted Zymosan, CpG-DNA or a combination of both ligands for different time periods (15 
min, 90 min and 240 min). BMMs from the control mice showed no phosphorylation as well 
as degradation of IκBα when stimulated by depleted Zymosan. In contrast, CpG-DNA treated 
cells from the knockout as well as the control mice displayed a fast phosphorylation and 
subsequent degradation of IκBα that already vanished after 90 min of stimulation. 
A prolonged and increased degradation as well as phosphorylation of IκBα was achieved via 
application of depleted Zymosan and CpG-DNA at the same time in cells from       
SOCS1-/-/IFNγ-/- mice as compared to IFNγ-/- cells. After 90 min of stimulation, pIκBα could be 
detected and after 240 min, degradation of IκBα was measurable. The individual ligands 
alone also induced activation of IκBα in the knockout cells but with different kinetics. Whereas 
CpG-DNA induced IκBα degradation already after 15 min, the degradation of IκBα caused by 
depleted Zymosan developed after 90 min and 4 h; that would be in line with the clear 
increase in phosphorylation at the later time-points in a co-stimulatory setting (Fig. 4-22 [B]). 
Overall, the results suggest regulation of IκBα activation kinetics by SOCS1.  
Accordingly, SOCS1 seems to influence the kinetics of IκBα phosphorylation and degradation 
and thus possibly also NF-κB activity. Reduced NF-κB activation could explain reduction of 
IL12p40 by Zymosan in IFNγ-/- , which disappeared in cells from SOCS1-/-/IFNγ-/- mice. 
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Fig. 4-22  Different kinetics of IκBα phosphorylation and degradation in cells from SOCS1
-/-
/IFNγ
-/- 
 and IFNγ
-/- 
mice
 
 
[A], WT cells (BMMs, 18x10
6
) were incubated with dZ (500 µg/ml), CpG-DNA (1 µM) or dZ+CpG-DNA for 6h. Lysates were 
analyzed by immunoblot with Abs specific for SOCS1. [B], cells from IFNγ
-/- 
or SOCS1
-/-
/IFNγ
-/-
 (3x10
6
) were stimulated with dZ 
(500 µg/ml), CpG-DNA (1µM) or dZ+CpG for the indicated time periods, cells were lysed and immunoblot with Abs against IκBα 
or IκBα phosphorylated on Ser
32
 was performed. β-actin was used as loading control. Reults in [A] are representative for 2 
independent experiments; data presented in [B] are representative for 3 independent experiments.  
Next, we investigated transcriptional activity of NF-κB using an ELISA based system. Herein, 
the binding of different NF-κB subunits to their respective DNA elements was measured by 
an ELISA-based system (Trans-AM®). BMMs from SOCS1-/-/IFNγ-/- and IFNγ-/- mice were 
stimulated by depleted Zymosan, CpG-DNA or depleted Zymosan in combination with CpG-
DNA. After 1 h and 6 h, cells were lysed and nuclear extracts were performed (3.2.1.5). 
Nuclear extracts were applied to 96 well plates pre-coated with a consensus binding site 
oligonucleotide of the transcription factor of interest (p50, p52). Similar to the method of 
ELISA, the transcription factors present in the nucleus upon activation are detected via a 
primary and a secondary, HRP-coupled antibody. 
It is published that the NF-κB subunit p50 either as homodimer (p50/p50) or heterodimer 
(p50/p52) is responsible for the expression of IL12p40 and IL10 in BMMs (158, 159). 
Additionally, Dectin-1 is the only known CLR to induce the non-canonical NF-κB pathway, 
resulting in functional p52 subunits. Since we observed a significant up-regulation of IL12p40 
and IL10 in SOCS1-/-/IFNγ-/- when compared to IFNγ-/- cells, we decided to analyze p50 as 
well as p52 activation in these cells. 
We observed a significant, time-dependent increase of NF-κB activity in BMMs from  
SOCS1-/-/IFNγ-/- mice as compared to IFNγ-/- BMMs after co-ligation of Dectin-1 and TLR9 
(Fig. 4-23). After 1h, only a slight increase in NF-κB activity was observed in SOCS1-/-/IFNγ-/- 
BMMs (Fig. 4.23 [A]). In contrast, at the later time-point (6 h), the activity of both subunits 
was much higher (Fig. 4-23 [B]). As compared to CpG-DNA or depleted Zymosan, we 
detected an increase of about 50% in SOCS1-/-/IFNγ-/- cells that were co-stimulated. Even 
depleted Zymosan alone caused an increase in p50 and p52 activity in the double-knockout 
cells.  
Our data indicate that SOCS1 induced by depleted Zymosan decreases NF-κB activation in 
CpG-DNA triggered cells and thereby modulates the latter activity. With regard to cytokine 
secretion, SOCS1 seems to influence IL12p40 and IL10, but not TNFα or IL8. Whereas 
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IL12p40 and IL10 are increased in the absence of SOCS1, TNFα and IL8 production was 
unmodified. IL12 as well as IL10 are delayed-type genes that showed late and prolonged 
NF -κB recruitment to the respective promoter (139).  
  
Fig. 4-23  Changes in NF-κB activity in SOCS1 deleted BMMs 
BMMs (9x10
6
) from SOCS1
-/-
/IFNγ
-/- 
or IFNγ
-/-
 mice were incubated with dZ (100 µg/ml), CpG-DNA (1 µM) or dZ+CpG-DNA for 
[A] 1 h or [B] 6 h. Cells were lysed and nuclear extracts were analyzed for DNA binding activity of NF-κB subunits (p50 and 
p52) by TransAM
®
 NF-κB Transcription Factor Assay Kit. n = 3 (mean + SD)  
 
4.2.4. Summary of part 4.2 
In the second part of the study it could be shown that SOCS1 induced via depleted Zymosan 
is not a feedback inhibitor of Dectin-1 signalling pathway. We observed no differences in the 
phosphorylation status of Syk, Pyk2 as well as ERK; kinases involved in SOCS1 induction 
(part 4.1). Thus, SOCS1 has no influence on its induction pathway. However, SOCS1 acts as 
a crosstalk inhibitor on TLR signalling. In BMMs from SOCS1-/-/IFNγ-/- mice the secretion of 
IL12p40 was enhanced upon co-stimulation with CpG-DNA and depleted Zymosan, whereas 
IFNγ-/- cells produced less IL12p40 when co-stimulated. Similarly, IL10 secretion was 
significantly up-regulated more than two-fold in SOCS1-/-/IFNγ-/- BMMs as compared to cells 
from IFNγ-/- mice. This indicates an inhibitory role of SOCS1 in TLR/IL12p40 or IL10 
regulation. The levels of TNFα, as well as IL8, were unaltered in knockout cells as compared 
to the control cells.  
Co-stimulation of WT BMMs with depleted Zymosan and CpG-DNA resulted in an increase in 
SOCS1 expression what could explain the decrease in IL12p40 secretion in WT and IFNγ-/- 
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BMMs. Thus, IκBα was analyzed for phosphorylation and subsequent degradation. Indeed, 
we detected an increased and extended phosphorylation and subsequent degradation of 
IκBα in BMMs from double knockout mice when co-stimulated via Dectin-1 and TLR9. 
Additionally, we analyzed NF-κB activity in SOCS1-/-/IFNγ-/- and IFNγ-/- control BMMs. As it 
was shown that p50 and p52 are the NF- κB subunits responsible for IL12 and IL10 induction 
in BMMs, we determined the activation of these subunits. Indeed, we detected a significant 
increase in p50 and p52 activity in nuclear extracts from SOCS1-/-/IFNγ-/- BMMs as compared 
to IFNγ-/- cells after co-stimulation with depleted Zymosan and CpG-DNA. Thus, SOCS1 
induced by depleted Zymosan supposedly inhibits the activity of p50 and p52. This inhibition 
may be responsible for the decrease in IL12p40 production observed in WT as well as IFNγ-/- 
BMMs. 
4.3. Dectin-1 induced SOCS1 influences T-cell priming 
The recently discovered Th-cell subset Th17 plays an important role in protection against 
invading fungal pathogens. It has been shown in vitro and in vivo that activation of the 
Dectin-1 pathway leads to the generation of Th17 cells (125-127). Moreover, it has been 
published that SOCS1 may be involved in T-cell functions, i.e. regulatory T-cells (160). As 
stimulation of BMMs led to a decrease in IL12p40 secretion upon co-engagement of TLR9 
and Dectin-1 and since IL12 is one of the major cytokines that is responsible for Th1 
polarization we wished to link our findings to adaptive immune responses. 
4.3.1. Production of key cytokines required for Th17 specification 
IL6 and TGFβ are reported to be the most important cytokines required for lineage 
commitment of Th17-cells whereas IL23 is a critical factor for sustaining these cells and for 
obtaining their pathogenic function in vivo (119, 161, 162).  
Therefore, we first examined the secretion of these cytokines in BMMs from SOCS1-/-/IFNγ-/- 
and the respective control (IFNγ-/-) that were stimulated by depleted Zymosan together with 
CpG-DNA or the respective ligands alone. BMMs from IFNγ-/- mice displayed an elevated 
production of IL23, IL6 and TGFβ when co-stimulated by CpG-DNA and depleted Zymosan 
(Fig. 4-24 [A]-[C]). These cytokines were regulated the opposite way as compared to 
IL12p40. Whereas IL12p40 was decreased in IFNγ-/- BMMs, IL23, IL6 and TGFβ production 
was increased in the IFNγ-/- control cells as compared to the SOCS1-/-/IFNγ-/- BMMs. 
Regarding TGFβ, depleted Zymosan alone led to an increase. Though, in SOCS1-/-/IFNγ-/- 
BMMs secretion of these cytokines was neither up-regulated after stimulation via the sole 
ligand depleted Zymosan nor when TLR9 and Dectin-1 were triggered in parallel (Fig. 4-24 
[A-C]). These data indicate that SOCS1 induced by Dectin-1 engagement influences the 
TLR9 cytokine profile. Therefore we conclude that SOCS1 might be responsible for the 
observed up-regulation of the cytokines required for Th17 induction, namely IL6, IL23 and 
TGFβ. 
Thus, we further tested whether SOCS1 produced in BMMs by depleted Zymosan could shift 
T-cell response to IL17 producing cells. 
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Fig. 4-24  Influence of SOCS1 on the secretion of cytokines required for induction of Th17-cells 
[A]-[C], BMMs (2x10
5
) from SOCS1
-/-
/IFNγ
-/- 
or IFNγ
-/- 
mice were incubated with dZ (100 µg/ml), and CpG-DNA (1 µM) as 
indicated for 16 h [A] or 20 h [B]-[C]. In case of dZ+CpG, cells were pre-stimulated with CpG (4 h) following incubation with dZ 
(12 h [A]; 20 h [B], [C]). Secretion of IL6, TGFβ and IL23 in supernatants was measured by ELISA and experiments were 
carried out in duplicates. [A]-[C], n=2 (mean + SD) 
 
4.3.2. SOCS1 produced via Dectin-1 increases CpG-DNA induced IL17 production 
from T-cells 
Interplay between BMMs lacking endogenous SOCS1 and wildtype T-cells was studied by 
means of BMM/T-cell co-cultures. Co-culture experiments were set up in SOCS1-/-/IFNγ-/- 
BMMs (and BMDCs) or the respective control cells (IFNγ-/-) and results were also compared 
to BMMs from conditional SOCS1 knockout mice. The latter mice are deficient in SOCS1 
exclusively in cells from the myeloid lineage, especially macrophages (3.2.2). In the 
following, BMMs from knockout animals and the appropriated control were cultured together 
with isolated CD4+ Th-cells from spleens from WT C57BL/6 mice as described in 3.2.1. After 
cultivation for 5 days, cytokine secretion was measured. First, we focused on SOCS1 
knockout BMMs as well as BMDCs on an IFNγ-/- background. Therefore, BMMs or BMDCs 
from either SOCS1-/-/IFNγ-/- or IFNγ-/- were stimulated with CpG-DNA, depleted Zymosan or a 
combination thereof. Thereupon, WT CD4+ Th-cells were isolated and co-cultured with the 
respective cells as described in 3.2.1. 
The key cytokine that is produced by Th17 cells is IL17 (124). After re-stimulation with PMA 
and ionomycin (3.2.1), we measured the secretion of IL17 within the co-cultures after 5 days 
of cultivation. Controls were set up as described in Fig. 4-25. Concerning Th17 positive 
control, cytokines to induce IL17-producing Th-cells were added extra. Thus, secretion of 
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IL17 should not differ between cultures with SOCS1-/-/IFNγ-/- or IFNγ-/- cells. The same holds 
true for the respective Th1 and Th2 negative controls.  
Secretion of IL17 in the Th17 positive-controls was markedly increased in cultures of WT Th-
cells and IFNγ-/- as well as SOCS1-/-/IFNγ-/- cells as compared to the respective unstimulated 
control (mock) (Fig. 4-25 [A], [B]). In contrast, co-cultures stimulated with Th1 or Th2 
inducing cytokines (IL12 or IL4, respectively) showed no increase in IL17 secretion when 
compared to the unstimulated control. From these results we concluded that the isolated WT 
CD4+ Th-cells are able to become IL17 producers. Therefore, we next analyzed T-cells co-
cultured with BMMs from SOCS1-/-/IFNγ-/- and IFNγ-/- that were stimulated via Dectin-1 and/or 
TLR9 for the production of IL17. 
A clear-cut, significant increase in IL17 expression could be demonstrated when BMMs from 
IFNγ-/- animals were co-ligated via Dectin-1 and TLR9 compared to CpG-DNA or depleted 
Zymosan. In contrast, the concomitant administration of both stimuli to SOCS1-/-/IFNγ-/- 
BMMs did not change cytokine production when compared to CpG-DNA alone (Fig. 4-25 
[A]). Depleted Zymosan alone led to an approximately 2-fold enhancement of IL17 secretion 
in WT T-cell/ SOCS1-/-/IFNγ-/- BMM co-culture. CpG-DNA stimulated BMMs, SOCS1-/-/IFNγ-/- 
as well as IFNγ-/-, displayed a significant increase in IL17 within the co-cultures. However, in 
co-cultures with CpG-DNA stimulated SOCS1-/-/IFNγ-/- BMMs, IL17 production was even 
increased as compared to those with CpG-DNA stimulated IFNγ-/- BMMs. 
Similar results could be observed when BMDCs from SOCS1-/-/IFNγ-/- or IFNγ-/- control mice 
were co-cultured with WT CD4+ Th-cells (Fig. 4-25 [B]). However, CpG-DNA alone had no 
effect on IL17 production, whereas depleted Zymosan increased cytokine secretion in 
cultures of IFNγ-/- BMDCs with WT Th-cells. Co-stimulation significantly increased IL17 
production as compared to CpG-DNA or depleted Zymosan stimulated cultures. In contrast, 
co-cultures with SOCS1-/-/IFNγ-/- BMDCs displayed no increase in IL17 when BMDCs were 
stimulated by depleted Zymosan, CpG-DNA or both stimuli together as compared to the 
unstimulated control. Only the Th17 control displayed an increase in IL17 production. Th-
cells cultured together with IFNγ-/- BMDCs even decreased IL17 secretion upon stimulation 
as compared to unstimulated control (mock) (Fig. 4-25 [B]) 
From the above results we conclude the following: SOCS1-/-/IFNγ-/- BMMs or BMDCs that are 
co-stimulated via depleted Zymosan and CpG-DNA are not able to further increase IL17 
production in WT T-cells when compared to CpG-DNA or depleted Zymosan stimulated 
APCs. On the other hand, in the presence of SOCS1 (IFNγ-/- cells), BMDCs and BMMs 
induced a significant increase in IL17 secretion as compared to CpG-DNA or depleted 
Zymosan stimulated BMMs or BMDCs. Thus, SOCS1 that is induced via Dectin-1 in cells of 
the immune system (BMMs, BMDCs) leads to an increase in IL17 production in cells of the 
adaptive immune system (Th-cells). This could probably be mediated via cytokines that are 
responsible for the induction of the Th17 lineage, namely IL6, IL23 and TGFβ. These 
cytokines are markedly increased in BMMs from IFNγ-/- mice upon co-ligation of Dectin-1 and 
TLR9 when compared to BMMs from SOCS1-/-/IFNγ-/- mice (Fig. 4-24). Therefore, IL6, IL23 
and TGFβ are up-regulated in the presence of SOCS1 and supposably shift T-cell response 
towards a Th17 cell phenotype. 
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Fig. 4-25  SOCS1 expressed in BMMs and 
BMDCs via Dectin-1 leads to an increase in 
IL17 secretion in Tcells 
CD4
+ 
T-cells (1x10
5
) from C57BL/6 WT mice 
were co-cultured for 5 days with  [A] BMMs 
(1x10
4
) or [B] BMDCs (1x10
4
) from    
SOCS1
-/-
/IFNγ
-/- 
or IFNγ
-/- 
mice and anti-CD3ε 
and anti-CD28 in the presence or absence of 
depleted Zymosan (100 µg/ml), CpG-DNA 
(CpG) (1 µM) or a combination thereof. 
Positive controls (Th17) were treated with 10 
ng/ml TGFβ, 20 ng/ml IL6 and anti-IL4 (2 
µg/ml) and anti-IFNγ (2 µg/ml). Th1 and Th2 
T-cells were induced via IL12 (2 ng/ml) and 
IL4 (10 ng/ml), respectively.  
On day 5, cells were restimulated with PMA 
and Ionomycin for 4 h. IL17 in the supernatant 
was measured by ELISA. Mo; BMMs without 
any stimuli or T-cells, DC; BMDCs without any 
stimuli or Th-cells, mock; CD4
+ 
Th-cells + 
BMMs [A] or BMDCs [B], unstimulated. A], 
n=4 (mean + SD) [B], n=3 (mean + SD).  
Since RORγT is one of the main transcription factors through which Th17 cells can be 
identified (163, 164), we next examined the expression levels of RORγT transcripts in T-cells 
from co-cultures. Experiments were set up as described for Fig. 4-25. After re-stimulation on 
day 5 for 4 h, cells were lysed and analyzed by means of quantitative RT-PCR for the 
expression of RORγT mRNA. Only in Th-cells cultured with BMMs from control mice (IFNγ-/-), 
RORγT mRNA was markedly up-regulated by 10-fold upon engagement of Dectin-1 whereas 
depleted Zymosan had no effect on mRNA expression in the SOCS1-/-/IFNγ-/- BMMs/ WT Th -
cell cultures (Fig. 4-26). Surprisingly, co-stimulation only slightly increased the expression of 
the transcription factor by two-fold as compared with depleted Zymosan stimulated cells (Fig. 
4-26).  
Overall, the expression of RORγT is only increased in co-cultures with WT Th-cells cultured 
together with IFNγ-/- but not in cultures with SOCS1-/-/IFNγ-/- BMMs. These results strengthen 
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the above findings that SOCS1 induced by Dectin-1 in BMMs is involved in the induction of 
Th17 cells. 
               
Fig. 4-26  Expression of RORγT transcription factor in BMM/Th-cell co-cultures 
CD4
+ 
Th-cells (1x10
5
) from C57BL/6 WT mice were co-cultured for 5 days with BMMs (1x10
4
) from SOCS1
-/-
/IFNγ
-/- 
or IFNγ
-/- 
mice and anti-CD3ε and anti-CD28 in the presence or absence of depleted Zymosan (100 µg/ml), CpG-DNA (CpG) (1 µM) or a 
combination thereof. Positive controls (Th17) were treated with 10 ng/ml TGFβ, 20 ng/ml IL6 and neutralizing antibody against 
IL4 (2 µg/ml) and IFNγ (2 µg/ml), respectively. Th1 and Th2 T-cells were induced via IL12 (2 ng/ml) and IL4 (10 ng/ml), 
respectively. On day 5, cells were restimulated with PMA and Ionomycin for 4 h. Cells were lysed and gene expression was 
determined by quantitative RT-PCR. Relative expression is depicted, normalized to β-actin. n=3 (mean + SD) 
Next, we wanted to compare the above illustrated results with an approach where BMMs 
from conditional SOCS1 knockout animals were used.  
First of all, cells were controlled by the appropriate genotype. LysM-Cre has previously been 
reported to mediate efficient loxP recombination in myeloid cells, i.e. BMMs. For an efficient 
deletion of SOCS1 in BMMs, mice with the genotype SOCS1lox/- were required. One copy of 
SOCS1 is flanked by two loxP sites (floxed) whereas the other SOCS1 allele is completely 
deleted. Additionally, cells have to be positive for the Cre recombinase gene- under the 
promoter of Lysozyme M (LysM)- to ensure an entire knockout (136, 137) (Fig. 4-27 [A]). The 
tyrosine recombinase Cre is known to catalyze site-specific recombination events. It 
recognizes loxP sites that flank a specific DNA sequence or gene. Upon recognition of the 
loxP sites, the Cre recombinase excises the DNA in between. Thus, mice with the genotype 
SOCS1lox/- that express the Cre recombinase are able to delete both alleles of SOCS1. The 
Lysozyme M is shown to be expressed especially in macrophages upon stimulation. The 
SOCS1lox allele is placed under the natural SOCS1 promoter and carries a truncated version 
of human CD4. When Cre mediated deletion of SOCS1 was effective, the human CD4 
reporter is switched active. Thus, we measured hCD4 expression in BMMs via FACS 
analyzes. First, BMMs with the genotype SOCS1lox/-/ Cre+ (#124, Fig. 4-27 [A]) as well as the 
respective control cells (SOCS1lox/+/Cre-) (#123, Fig. 4-27 [B]) were stimulated by IFNγ and 
LPS to induce SOCS1 expression. Thereupon, cells were harvested and analyzed by means 
of FACS (3.2.1, “Flow cytometry”). Successful knockout is indicated in case of up-regulation 
of hCD4 (PE-coupled antibody against human CD4 was used). Cells in P2 are gated on P1 
in the forward /sideward scatter diagram and show cells stained positive for hCD4. BMMs 
with the genotype SOCS1lox/+, Cre- do not express the Cre recombinase. These cells have 
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one allele of WT SOCS1 and one allele is floxed. Thus, these mice do not have a SOCS1 
knockout allele and behave like WT mice (136, 137). Accordingly, we did not observe any 
up-regulation of hCD4 in stimulated control BMMs. In contrast, SOCS1lox/-, Cre+ BMMs were 
highly hCD4 positive (76,8 %) after stimulation (Fig. 4-27 [B],lower panel), yet a small 
population was hCD4 negative. This could be due to inefficient staining with anti-hCD4 or 
incomplete knockout. 
 
 
Fig. 4-27  Tissue specific SOCS1 deficiency 
[A], Results of genotype PCR. Genomic DNA was isolated from the respective knockout or control mice as described in 
Materials and Methods “Purification of genomic DNA” in 3.2.2. PCR reaction conditions for the different PCRs are described in 
“Polymerase chain reaction” in 3.2.2. 10-200 ng DNA was loaded on a 1.5% (SOCS1 ko and Cre PCR) or 2% (FLOX and WT 
PCR) agarose gel and analyzed. 123, control (Fig. 4-28) that is negative for LysMCre (Cre
-
). 124, SOCS1
flox/- 
LysMCre
+ 
(Cre
+
). 
M, marker; n.C., negative control; *, specific bands: WT (340 bps), FLOX (600 bps), Cre (650 bps), SOCS1 ko (160 bps). [B], 
FACS analysis of hCD4 surface expression in SOCS1
flox/- 
LysMCre
+
 BMMs (SOCS1ko) and SOCS1
flox/+ 
LysMCre
-
Cells (appr. 
4x10
5
) were stimulated for 16h with 50 ng/ml IFNγ and 100 ng/ml LPS (lower panels) or left unstimulated for 16h (upper 
panels). Afterwards, cells were stained with PE labelled anti-hCD4 antibody and analyzed via FACS.  
Consequently, those cells were used to investigate T-cell responses in a co-culture of 
SOCS1 knockout BMMs together with wildtype CD4+ Th-cells. Cells were incubated as 
described for SOCS1-/-/IFNγ-/-. After 5 days, supernatants were analyzed for cytokine 
secretion after re-stimulation for 4 h with PMA and ionomycin. Concerning Th17 markers, 
namely IL17 and RORγT, we measured a similar pattern as analyzed in case of      
SOCS1-/-/IFNγ-/- and IFNγ-/- cells. IL17 secretion was significantly increased by 50 % when 
control (SOCS1lox/- Cre-) BMMs within the co-culture setting were co-stimulated with depleted 
Zymosan and CpG-DNA as compared to ligation of Dectin-1 or TLR9, respectively      
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(Fig. 4-28 [A]). Within the Th17 control, IL17 secretion was markedly increased as compared 
to Th1 or Th2 controls.  
These results could be reflected by RORγT expression (Fig. 4-28 [B]). Within the control 
BMMs/ WT Th-cell co-culture, stimulation of the control cells with depleted Zymosan, CpG-
DNA or a combination of both stimuli induced an increase in mRNA expression up to 10-fold 
over mock. However, co-stimulation of the control BMMs via TLR9 and Dectin-1 within the 
co-culture did not further increase RORγT expression as compared to CpG-DNA or depleted 
Zymosan stimulated cells. In co-cultures of SOCS1 knockout BMMs and WT Th-cells, only 
the stimulation with CpG-DNA induced a slight but significant increase in RORγT mRNA 
expression in WT Th-cells. In contrast, neither the stimulation with depleted Zymosan nor the 
concomitant application of CpG-DNA and depleted Zymosan induced RORγT expression 
over the unstimulated control.   
Consequently, we confirmed the results displayed for SOCS1-/-/IFNγ-/- or IFNγ-/- cells. The 
advantage of the conditional knockout system is that the knockout of SOCS1 is inducible in 
particular cell types. When the cre recombinase is expressed under the promoter of 
Lysozyme M, a knockout is only achieved within cells of the myeloid lineage, i.e. 
macrophages. 
 
Fig. 4-28  IL17 secretion and expression 
of RORγT in T-cells cultured with 
conditional SOCS1 ko BMMs 
CD4+ T-cells (1x105) from C57BL/6 WT mice 
were co-cultured for 5 days with BMMs 
(1x104) from SOCS1flox/- LysMCre+ mice or 
control mice (SOCS1flox/+ LysMCre-). Anti-
CD3ε and anti-CD28 in the presence or 
absence of depleted Zymosan (100 µg/ml), 
CpG-DNA (1 µM) or a combination thereof 
was added. Positive controls (Th17) were 
treated with 10 ng/ml TGFβ, 20 ng/ml IL6 and 
neutralizing antibody against IL4 (2 µg/ml) and 
IFNγ (2 µg/ml), respectively. Th1 and Th2 T-
cells were induced via IL12 (2 ng/ml) and IL4 
(10 ng/ml), respectively. On day 5, cells were 
restimulated with PMA and Ionomycin for 4 h. 
Cells were lysed and gene expression was 
determined by quantitative RT-PCR. Relative 
expression is depicted, normalized to β-actin. 
Experiments were carried out in duplicate 
wells. 
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4.3.3. Summary of part 4.3 
In the last part it could be demonstrated that SOCS1 induced by depleted Zymosan affects 
T-cell priming. SOCS1 influences the shift of CD4+ Th-cells towards IL17 producing T-cells to 
some extent. The key cytokines that are claimed to be responsible for inducing Th17 cells, 
namely IL6, TGFβ and IL23 were markedly increased in IFNγ-/- BMMs upon co-stimulation 
with CpG-DNA and depleted Zymosan. In the absence of SOCS1 (SOCS1-/-/IFNγ-/- BMMs), 
only triggering of TLR9 led to an up-regulation of these cytokines. Consequently, secretion of 
IL17 from WT Th-cells that were cultured with IFNγ-/- BMMs or BMDCs was significantly 
increased upon co-stimulation with depleted Zymosan and CpG-DNA of the innate immune 
cells. The same holds true for the hallmark transcription factor of Th17 T-cells, RORγT.  
This contribution of SOCS1 expressed in BMMs to the induction of IL-17 producing Th-cells 
represents an important link between innate and adaptive immune responses. 
Discussion 
73 
5. Discussion 
5.1. Direct induction of SOCS1 in myeloid cells upon ligation of Dectin-1 
It had not been shown before that engagement of the PRR Dectin-1 could lead to the 
induction of SOCS proteins. Though, the here presented results show that SOCS1 mRNA 
and protein is expressed in BMDCs and BMMS when Dectin-1 is stimulated by depleted 
Zymosan.  
In terms of SOCS1 mRNA expression, a time- and dose-dependent induction was achieved 
within BMDCs as well as BMMs when stimulated via depleted Zymosan. LPS led to a 
maximum SOCS1 induction already after 2 h of stimulation. With both stimuli, a steady-state 
SOCS1 induction was achieved that even remained constant 16 h after addition of LPS or 
higher concentrations of depleted Zymosan. In BMMs a slight decrease was observed after 
16 h. However, previous reports described a fast but shortened SOCS1 expression that 
declined already 4 h after stimulation as shown for IL6 dependent induction of SOCS1 (104, 
165). In general, the genes encoding for SOCS proteins are small and comprise only less 
introns (SOCS1 and SOCS3: one intron, SOCS2 and CIS: two introns).Thus, these genes 
display characteristics of immediate early genes (95, 141, 166, 167) and transcription can 
occur much faster than the expression of mRNA transcribed from poly cistronic genes. This 
could explain the rapid induction of SOCS1 mRNA upon stimulation of BMMs or BMDCs with 
LPS or depleted Zymosan. Otherwise, mRNA was stable even 16 h after stimulation. Gene 
expression can be regulated at different levels. On the one hand, mRNA translation can be 
inhibited by microRNAs. The double stranded miRNA is incorporated into a protein complex 
(RISC). The double strand is uraveled and the formed single-strand binds to its 
complementary target sequence within the respective mRNA. Thereupon, the 
microRNA/mRNA structure is either degraded by an endoribonuclease within the RISC 
complex or the complex is stable, thus leading to repression of translation (168). 
MicroRNA 155 (miRNA 155) is described to bind to SOCS1 mRNA; thereby SOCS1 mRNA 
is degraded (169, 170). Due to the durable stability of depleted Zymosan or LPS induced 
SOCS1 mRNA, SOCS1 in this case may be regulated differentially.  
On the other hand, protein stability is regulated. It could be demonstrated that the SOCS1 
protein has a short half-life time, and thus is degraded rapidly after its synthesis by the 
proteasom. Additionally, SOCS1 has been shown to be regulated via translational repression 
(171, 172). This regulatory mechanism is mediated by an additional start codon within the 5’ 
non-translated region and possibly leads to the decreased SOCS1 expression that is 
observed in resting cells. 
Further, priming of BMMs with IFNγ prior to stimulation had synergistic effects on SOCS1 
expression. Macrophages respond to a range of different cytokines and chemokines during 
innate and adaptive immune responses. Among these, IFNγ (originally called macrophage-
activating factor) is described to be the most important one. IFNγ orchestrates leukocyte 
attraction, growth and maturation of many cell types as well as enhancement of natural killer 
(NK) cell activity (173). It has been reported that treatment of macrophages with IFNγ 
followed by LPS stimulation alters intracellular signalling pathways in different ways. On the 
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one hand, pre-incubation of macrophages with IFNγ augmented DNA binding of NF-κB in 
response to LPS (174, 175); similar results were obtained when DCs were treated with 
Dectin-1 agonists in combination with TLR2 stimuli (53). Otherwise, LPS affected the IFNγ 
signalling pathway by increasing the activation of STAT1 binding to DNA. Finally, it could be 
demonstrated that interaction between LPS and IFNγ not only occurs at the level of signal 
transduction, but also may involve the induction of factors that act in an autocrine manner 
(174, 176, 177). One could claim that within BMMs that were stimulated via Dectin-1 
following priming with IFNγ similar effects could lead to the observed up-regulation of SOCS1 
transcripts. Either depleted Zymosan influences JAK/STAT activation or IFNγ affects activity 
of transcription factors responsible for SOCS1 induction in Zymosan triggered cells. 
Additionally, IFNγ itself is able to induce SOCS proteins (87, 88, 165). This could also explain 
the increased expression of SOCS1 observed by co-stimulation of BMMs with depleted 
Zymosan and IFNγ. Similarly, co-stimulation of TLR9 and Dectin-1 increased SOCS1 
expression. Hence, co-stimulation of TLR9 and Dectin-1 synergistically influenced SOCS1 
expression. 
5.1.1. Dectin-1 induced SOCS1 is expressed TLR independently 
Engagement of Dectin-1 by depleted Zymosan led to an induction of SOCS1 in a MyD88/Trif 
independent manner. This observation rules out any contribution of TLRs to SOCS 
expression.  
MyD88 is utilized by all TLRs with the exception of TLR3 that activates downstream 
signalling through Trif (178). Importantly, LPS is capable of employing both, MyD88 and Trif. 
Depleted Zymosan was able to induce SOCS1 expression in both, WT and MyD88/Trif 
double deficient mice to the same extent. Also, downstream signalling as depicted for ERK 
activation was completely unaltered when cells were triggered via Dectin-1. In contrast, 
expression of SOCS1 mRNA as well as ERK phosphorylation were completely abrogated 
when knockout cells were triggered via TLR4, thus confirming the importance of MyD88 as 
well as Trif adaptor molecules for TLR4 signalling but not for Dectin-1 mediated downstream 
signalling. Therefore, a participation of MyD88 and/or Trif adaptor proteins in the Dectin-1 
signalling pathway can be excluded as well as any TLR ligands that could be present as 
contaminants within depleted Zymosan. Zymosan is extracted from the cell wall of the yeast 
Saccharomyces cerevisiae that is shown to bind also to TLR2 and TLR9, yet the real TLR 
ligand within Zymosan is not identified (44, 46, 55, 63). Depleted Zymosan is generated out 
of Zymosan by treatment with hot alkali to remove any TLR binding moiety (61, 62). Thus, we 
corroborated that SOCS1 expression induced by depleted Zymosan is exclusively mediated 
by Dectin-1. This could be confirmed by stimulation of cells from Dectin1-/- mice where 
SOCS1 induction vanished completely.  
5.1.2. Intermediate factors are not involved in Dectin-1 mediated SOCS1 induction 
Next, we had to clarify the question whether the induction of SOCS1 occurs in a direct or 
indirect pathway dependent on para- or autocrine factors as described by different groups 
(103, 140, 143). Crespo et al. claimed that LPS is capable of inducing SOCS1 via type I IFNs 
(IFNα/β) as auto/paracrine acting factors. LPS-induced SOCS1 production was diminished in 
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an assay where neutralizing antibodies against IFNα/β were used. In contrast, Baetz et al. 
could clearly show that SOCS1 is induced directly upon stimulation with LPS, without the 
contribution of type I IFNs. Dendritic cells isolated from IFNAR1-/- mice were stimulated with 
different TLR ligands, i.e. LPS or LTA. SOCS1, SOCS3 and CIS mRNA induction showed no 
difference in the knockout cells as compared to WT control cells. 
Here, Dectin-1 dependent SOCS1 induction was independent of any intermediate or 
secreted factors as examined by different methods. First, a transwell system was used to 
exclude any secreted factor that could be responsible for Dectin-1 mediated SOCS1 
induction. BMMs as well as BMDCs were seeded in the two compartments of a transwell. 
Cells within the lower wells were stimulated and cells of both chambers were analyzed for 
SOCS1 mRNA expression. Depleted Zymosan particles have a size of about 3 µm (142) and 
thus are not able to enter the upper wells. We observed SOCS1 induction only in cells of the 
lower compartments upon stimulation with depleted Zymosan. Similar results could be 
obtained by the group of Crespo et al. Macrophages generated from LPS-responsive 
C3H/HeN-mice and LPS-none responsive C3H/HeJ mice were placed in a transwell system. 
Upon stimulation with LPS, no induction of the SOCS1-gene could be observed within 
macrophages generated from C3H/HeJ mice (140). Thus, an influence of an auto-or 
paracrine factor on the expression of SOCS1 could be excluded.  
Therefore, we propose a direct induction of SOCS1 by depleted Zymosan, independent of 
secreted factors. These results could be verified with BMMs generated from IFNAR1 
deficient mice. In these cells, SOCS1 could still be expressed upon engagement of Dectin-1 
with depleted Zymosan. Interestingly, also LPS was still able to induce SOCS1 mRNA within 
the knockout cells. This could also be observed by Baetz et. al. TLR ligands like LPS, LTA or 
CpG-DNA induced SOCS1 molecules in a direct way, independent of IFNs (143).  
It is described that TLR ligands induce type I IFNs, i.e. IFNβ and thereupon STAT1 activation 
(105, 147, 173, 179). TLR3 and TLR4 signalling pathways use Trif/TICAM-1 as adaptor 
molecules. Thereupon, Type I IFNs (i.e., IFNβ) are secreted and activate the expression of 
STAT1/2 dependent genes via the JAK/STAT pathway (146, 179). Thus, we analyzed 
BMDCs and BMMs for STAT1 phosphorylation and detected STAT1 phosphorylation in 
BMMs and BMDCs following LPS stimulation. Though, depleted Zymosan only led to STAT1 
activation when applied to BMDCs but not BMMs. However, a contribution of IFN signalling 
to SOCS1 induction could be ruled out as examined by transwell as well as IFNAR1 
knockout experiments.  
Additionally, we analyzed SOCS1 expression after treatment of cells with a blocking antibody 
directed against IL10. IL10 is one of the first cytokines that is produced upon an infection with 
pathogenic fungi (66-68). Inhibition of IL10 receptor prior to stimulation with depleted 
Zymosan had no effect on SOCS1 induction in BMMs and BMDCs. The same effect could be 
observed when LPS was used as a trigger for SOCS1. On the other hand, SOCS3 
expression was diminished in cells pre-treated with anti-IL10 following stimulation with IL10. 
Since IL10 was described as an inducer for SOCS3 but not for SOCS1, we therefore 
expected an influence of anti-IL10 only on SOCS3 expression (180, 181). 
To foreclose a participation of intracellular intermediates, we used cycloheximid to block 
intermediate protein biosynthesis. Subsequently, SOCS1 mRNA was analyzed by 
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quantitative RT-PCR. SOCS1 transcripts could still be detected after stimulation with 
depleted Zymosan. Surprisingly, we observed a slight increase in SOCS1 transcripts. This 
may point towards other classes of signalling inhibitors. These inhibitors may have the ability 
to inhibit signalling cascades and thereby also SOCS1 expression (103, 109). Thus, the 
blockade of protein biosynthesis by cycloheximid possibly also abrogates the synthesis of 
these inhibitors, thereby increasing SOCS1 expression. Again, also LPS induced SOCS1 
mRNA independently of any intermediates. Similar results were obtained by the group of 
Stoiber et al. It could be shown that LPS induced SOCS3 on mRNA level. The expression 
was resistant to cycloheximid treatment, yet it was even increased (102). Additionally, 
Nakagava et al. claimed that the induction of SOCS1 was independent of any intermediate 
protein (109). Raw264.7 macrophages were pre-treated with cycloheximid followed by 
stimulation with LPS for different time-periods. Afterwards, an induction of SOCS1 mRNA 
was already detected after 1 h of stimulation (109). Also, SOCS3 was described to be 
induced in a direct manner. Bode et al. could show that LPS as well as TNFα are capable of 
inducing SOCS3 mRNA directly, without the contribution of an intermediate factor (100). In 
this context, the induction of SOCS proteins was linked to MAPK activation. It could be 
shown that the MAPK p38 is involved in the induction of SOCS3 mRNA expression, 
especially upon stimulation with TNFα (100).Beside TNFα, IL1β was able to induce SOCS3 in 
a direct way as shown in liver cells (182). In addition, the direct activation of the MAPK 
pathway by PMA (phorbol myristate actetate) led to an induction of SOCS3 protein (183).  
5.2. NF-κB does not serve as a transcription factor for SOCS1 induction in 
BMMs stimulated via Dectin-1 
One important difference between BMDCs and BMMs triggered via Dectin-1 is the activation 
of the transcription factor NF-κB. In previous reports, it was demonstrated that zymosan-
stimulated DCs activated NF-κB in a CARD9/Bcl10/MALT1 dependent manner (75). Indeed, 
we could confirm these findings with regard to IκBα. This inhibitor of NF-κB is phosphorylated 
and degraded by the proteasom upon stimulation of PRRs (184, 185). Ligation of Dectin-1 
and TLR4 induced phosphorylation of IκBα in BMDCs. In contrast, IκBα was not activated in 
BMMs after stimulation of Dectin-1. 
Previous studies have indicated that in macrophages, Dectin-1 signals collaborate with TLR2 
signals to enhance TLR2-mediated NF-κB activation and proinflammatory cytokine 
production. In contrast, Dectin-1 signals alone appear to be insufficient for activation of the 
transcription factor and cytokine induction (71). It was rather discussed that CARD9 in 
macrophages is recruited to phagosomes where it activates p38 MAPK signalling without the 
attendance of NF-κB. However, in correlation with the data mentioned above, priming of 
BMMs with IFNγ or GM-CSF contributed to Dectin1-CARD9-induced TNFα production (71). 
These data again point to a cross-talk between different receptor signalling cascades, 
thereby modifying the outcome of a stimulated cell. Importantly, the contribution of Dectin-1 
signals to pro-and anti-inflammatory cytokine induction seems to be variable in different 
macrophage or dendritic cell populations since Dectin-1 engagement directly triggers TNFα 
production by resident peritoneal cells and alveolar macrophages but not in Flt3L-derived 
DCs (71). We could confirm the above results through the application of an NF-κB inhibitor. 
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In BMDCs, the inhibition of NF-κB decreased SOCS1 expression levels when cells were 
stimulated by LPS or depleted Zymosan, whereas SOCS1 induction in BMMs was only 
abrogated when cells were triggered by LPS following incubation with the inhibitor. Thus, we 
excluded that SOCS1 induction occurs through NF-κB signalling in BMMs. However, in 
BMDCs, NF-κB seems to be involved in SOCS1 expression upon stimulation with depleted 
Zymosan.  
Nuclear factor of activated T-cells (NFAT) is a transcription factor that is rapidly activated 
upon ligation of Dectin-1 (61, 67, 149). Thus, we speculated that NFAT might play a role in 
induction of SOCS1 in BMMs. NFAT is situated in the cytoplasm and is activated in a Ca2+ 
dependent manner (186). Calmodulin triggers dephosphorylation of NFAT via calcineurin, 
thereby promoting transport of the transcription factor into the nucleus. Within the nucleus, 
NFAT can cooperate with multiple transcriptional partners, including AP1 (186, 187). On the 
other hand, calcium pathways activate CaM (calmodulin) dependent kinase (CaMK) that 
contributes to MAPK activation (149). It is described that NFAT, when activated via Dectin-1 
is responsible for the fast induction of early growth response factors (61), another family of 
transcription factors that in turn can bind to the IL10 promoter (188-190). Moreover, egr1 
transcription factor has been found to bind to the SOCS1 promoter (150). However, we were 
not able to ascertain any contribution of NFAT to the expression of SOCS1, since CsA, a 
very specific NFAT inhibitor, was ineffective in inhibiting SOCS1 expression. Furthermore, 
we were not able to detect any binding activity of egr1 to the respective binding site within 
the SOCS1 promoter upon ligation with depleted Zymosan, although egr transcription factors 
(egr1 and egr2) were induced at the transcript level. Binding of egr to the SOCS1 promoter 
was analyzed by means of electromobility shift assay (EMSA) with a labelled probe that 
comprised the binding sequence of egr1 within the SOCS1 promoter. Importantly, only the 
stimulation with LPS or Zymosan induced binding of egr1 to the promoter. In contrast to its 
depleted form (depleted Zymosan), Zymosan also exhibits TLR2 and TLR6 binding activity 
(44, 55, 63). Thus, the slight increase in egr1 binding to the respective SOCS1 promoter 
sequence could be caused by stimulation of TLRs via Zymosan. As shown by other groups, 
egr1 induced by LPS regulates SOCS1 expression. Via ChIP analysis, it could be 
demonstrated that the SOCS1 promoter is bound to egr1 in vivo (150). Since IFNγ was 
shown to be a potent inducer of SOCS1 mRNA in a STAT dependent manner, the promoters 
of SOCS family members were analyzed for STAT binding. Indeed, the promoter region of 
SOCS3, CIS and SOCS1 displayed STAT binding elements. A deletion of the STAT1/STAT3 
binding element within the SOCS3 promoter resulted in a defect of SOCS3 induction via LIF 
(leukemia inhibitory factor) (191). In addition, it was described that IRF1 (interferon regulatory 
factor1) is upregulated in a STAT1 dependent manner and binds to the AANNGAAA repeat 
sequence within the SOCS1 promoter (150, 192). Also, transcriptional repressors, GFI-1B 
and Krüppel-like factor 4, were able to regulate the SOCS1 promoter (192).  
Interestingly, depleted Zymosan induced egr1 and egr2 expression in BMMs, whereas LPS 
only induced expression of egr1. As activation by dephosphorylation and translocation of 
NFAT into the nucleus is strictly calcium dependent and since we did not observe any 
contribution of CaMK on SOCS1 expression, this strongly supports our findings of a calcium 
independent induction of SOCS1.  
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5.3. Downstream signalling molecules involved in Dectin-1 mediated SOCS1 
induction 
5.3.1. Pyk2 (proline-rich kinase 2) plays a key role in Dectin-1 mediated SOCS1 
induction 
Besides the differences in contribution of NF-κB to SOCS1 expression, the upstream 
signalling pathways also displayed some differences in BMMs as compared to BMDCs. First, 
we focused on Dectin-1 signalling within murine BMMs. It has been shown that the non-
receptor tyrosine kinase Pyk2 (proline-rich kinase 2) is activated upon triggering of Dectin-1 
(66). Pyk-2 was responsible for the production of IL10 in human macrophages, but this was 
shown to be Ca2+ dependent as delineated above (66). So far, only little is known about the 
role of Pyk2 kinase in inflammation. Thus, different activation patterns of Pyk2, calcium 
dependent (66) as well as calcium independent are possible. Under homeostatic conditions, 
Pyk2 is important for cell morphology, motility and adhesion in a variety of cells including 
macrophages (151, 193). Additionally, Pyk2 has been shown to be activated in response to a 
broad range of stimuli, including extracellular signals that elevate intracellular calcium 
concentrations, agonists of G protein-coupled receptors and engagement of Ag receptors on 
T cells, B cells and mast cells (151, 193, 194). 
In addition, it emerged that Syk (spleen tyrosine kinase) and Src kinases were situated 
upstream of Pyk. Src and Syk have been reported to be directly recruited to phosphorylated 
Dectin-1 receptor (44, 46, 195). Interestingly, also LPS was shown to induce IL8 expression 
via activation of Pyk2 as described for endothelial cells (196). As we clearly identified 
induction of SOCS1 in a Pyk2 dependent way upon ligation of Dectin-1, it would be crucial to 
analyze TLR stimulated cells of the immune system for a possible phosphorylation of Pyk2. 
Further, some data point towards a Pyk2 activation triggered by IFNγ (197). The group of 
Takaoka et al. could show that Pyk2 was phosphorylated by stimulation of murine embryonic 
fibroblasts with IFNγ. Furthermore, it could be observed that Pyk2 contributed to STAT1 
activation within these cells. Thus, Pyk2 is described as a downstream molecule for different 
receptors beside Dectin-1 that are prone to induce SOCS1 as well, i.e. IFNγ/STAT1. 
Interestingly, we observed baseline phosphorylation of Pyk2 in unstimulated BMMs, as also 
reported for human macrophages (198). This could be due to inhibitory phosphorylation of 
Src kinases as already observed in macrophages (199). Src gets phosphorylated at its 
negative regulatory phosphorylation site (Y507), possibly via autophosphorylation. This 
inhibitory phosphorylation seems to be important as macrophages that were deficient in the 
two phosphatases CD45 and CD148, which are described to remove inhibitory phosphate 
residues from Src kinases upon ligation of Dectin-1, were defective in Syk activation. This 
seemed to be specific for Dectin-1 ligands (200). Accordingly, Pyk2 could be regulated in a 
similar manner that inhibitory phospho-tyrosines have to be removed. On the other hand, the 
applied antibody is described to be directed against Pyk2 only when phosphorylated at 
Tyr402 that is required for activation of Pyk2. This may be contrary to the possible detection 
of an inhibitory phospho-tyrosine as displayed by immunoblot.  
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5.3.2. The MAPK ERK is responsible for SOCS1 induction in BMMs but not in BMDCs 
In this study it could be shown that Pyk2 is activated upon Dectin-1 signalling, yet Pyk2-
mediated induction of SOCS1 occurred through ERK in a manner that was independent of 
calcium signalling pathways. Hence, we analyzed activation of MAPKs activated by 
stimulated Dectin-1, namely ERK (p42/p44), p38 and JNKII. All three kinases could be 
activated by phosphorylation as a result of engagement of Dectin-1 by depleted Zymosan. As 
observed for Pyk2 activation, only the application of AG17, an inhibitor specifically directed 
against Phospho-Pyk2, led to an inhibition of Pyk2 and ERK activation, whereas a calcium 
chelator (BAPTA) or an inhibitor of CaMK had no effect on Pyk2 and ERK phosphorylation. 
The missing activation of ERK upon Pyk2 inhibition by AG17 locates ERK downstream of 
Pyk2 (Fig. 5-1). Consequently, SOCS1 induction was lost as also observed by direct 
inhibition of ERK.  
Regarding JNKII and p38 activation, AG17 displayed no effect, yet even slightly increased 
phosphorylation. Otherwise, inhibition of Ca2+ signalling pathways blocked phosphorylation of 
these MAPKs. Confirming these observations, MAPKs have been shown to trigger SOCS 
transcription (100, 143, 201, 202), although ERK specifically had not been analyzed in detail 
so far. The MAPK p38 was linked to SOCS1 induction, i.e. after infection of macrophages 
with Toxoplasma gondii. In this infection model it was proposed that SOCS1 gets activated 
via p38 (202). Otherwise, p38 was directly activated via TNF and thereby led to the induction 
of SOCS3 expression (183). Our data implicate that ERK is responsible for SOCS1 
transcription and is situated downstream of Pyk2 (Fig. 5-1). Pyk2 itself is located downstream 
of Src and Syk kinases since inhibition of Src and Syk abolished Pyk2 as well as ERK 
activity. While the application of a Syk inhibitor specifically abolished ERK but not p38 of 
JNKII phosphorylation, the Src inhibitor PP1 also inhibited phosphorylation of p38 and JNKII. 
The downstream signalling of Dectin-1 additionally comprises the MAPKKK Raf1 (46, 52, 76) 
that is activated via the Src kinase as well. Raf1 activation does not require pSyk, but the 
Raf1 signalling still involves the ITAM-like motif of the Dectin-1 receptor (44, 203). 
Administration of an inhibitor directed against Raf1 largely suppressed phosphorylation of 
p38 and JNKII but not ERK, thus ruling out a contribution of Raf1 in ERK activation. 
Additionally, SOCS1 protein expression was only affected by inhibition of Syk or Src kinases, 
but not when Raf-1 activation was blocked. The exact mechanism by which Pyk2 regulates 
ERK and subsequent SOCS1 expression remains still unclear, but previous work has shown 
that in other cell types Syk and Pyk2 can activate ERK via the MAPKKK Tpl2 (151, 152, 
204). Also, phosphorylated Pyk2 is described to activate ERK via different stimuli, i.e. IL2, 
PMA or MCSF (151, 193, 194) in different cell types (mast cells, monocytes, PBMCs). 
The key role for the tyrosine kinase Pyk2 in ERK activation could be confirmed by means of 
siRNA mediated gene silencing of Pyk2. Knockdown of Pyk2 resulted in an inhibition of ERK 
phosphorylation and SOCS1 expression. Due to a relatively weak knockdown efficiency of 
about 50% it was difficult to attain a complete inhibition of SOCS1 or pERK.  
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Fig. 5-1  Proposed SOCS1 induction pathway in macrophages upon stimulation of Dectin-1 
Ligation of Dectin-1 by depleted Zymosan induces phosphorylation of the intracellular ITAM like motif. The tyrosine kinases of 
the Src family are recruited to the phosphorylated dimerized receptor. Thereupon, spleen tyrosine kinase (Syk) binds to active 
Src kinases and in turn gets phosphorylated. Proline-rich tyrosine kinase 2 (Pyk2) binds to Syk. Thereupon, Syk gets 
phosphorylated and induces ERK activation. Phosphorylated ERK induces SOCS1 expression. Src additionally activates Raf1 
by phosphorylation (44, 46). Raf1 is activated by pSrc and induces phosphorylation of the MAPKs p38 and JNKII.  
Our findings suggest the following SOCS1 induction pathway upon Dectin-1 stimulation 
(Fig. 5-1): Engagement of Dectin-1 via depleted Zymosan probably leads to dimerization of 
Dectin-1 monomers (as also depicted in Fig. 2-2) and subsequent cross-phosphorylation of 
intracellular ITAM-like motifs (195). Src kinases are recruited and activated and thereupon 
phosphorylate spleen tyrosine kinase (Syk). This is followed by phosphorylation and 
activation of Pyk2. MAPK ERK is stimulated and subsequently induces SOCS1 expression. 
ERK is described to activate various transcription factors upon stimulation, i.e. ATF1 or Fos, 
both of which are strongly induced by high levels of ERK activation (148, 205). As described 
in the following, the signalling pathway involved in SOCS1 induction in BMDCs emerged to 
differ from the situation in BMMs. 
5.3.3. JNKII is involved in Dectin-1 mediated SOCS1 induction in BMDCs 
As mentioned, BMDCs induced SOCS1 most likely through the transcription factor NF-κB. 
Thus, we analyzed possible candidates involved in SOCS1 expression in BMDCs. First, it 
was remarkable that these cells displayed less basal phosphorylation of Pyk2 as compared 
to BMMs; the phosphorylation status of Pyk2 might be cell type dependent and possibly also 
the downstream signalling cascades. Additionally, Pyk2 can be activated by stimuli that 
increase intracellular calcium levels. It is also activated in response to stress signals (such as 
TNFα or hyperosmotic shock), thereby inducing Jun N-terminal kinase (JNK) activation (151). 
Indeed, we observed calcium dependent activation of Pyk2 in BMDCs, since the application 
of inhibitors of the calcium signalling pathways abolished Pyk2 phosphorylation. In contrast, 
treatment with calcium inhibitors prior to stimulation with depleted Zymosan had no effect on 
Pyk2 activation in BMMs. The inhibition of CaMK and the chelation of Ca2+ as well as 
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blocking Pyk2 phosphorylation inhibited SOCS1 expression in BMDCs. Further, the 
observations within this study concerning downstream signalling in BMDCs represent 
another hint that NF-κB participates in SOCS1 induction. All utilized inhibitors (AG17, BAPTA 
and KN93) abrogated the phosphorylation of IκBα; thus NF-κB is suggested to be the main 
transcription factor for SOCS1 in these cells. As shown by different groups, Dectin-1 signals 
activated NF-κB directly in a CARD9/Bcl10 dependent manner (71, 75). Gross et al. 
demonstrated that CARD9-deficient BMDCs failed to produce TNFα upon stimulation with β-
glucans (75). Further, Goodridge et al. could clearly show that depleted Zymosan stimulated 
BMDCs displayed a strong NF-κB binding activity in nuclear extracts as displayed by EMSA 
(71). 
Regarding MAPK activation, JNKII phosphorylation was abrogated by all inhibitors, whereas 
none of the latter had an effect on pp38. Therefore, we suppose that SOCS1 induction in 
BMDCs is initiated by Pyk2, mediated via the MAPK JNKII and the transcription factor NF-
κB. Worth mentioning is the observation that ERK activation was also abrogated by AG17 in 
BMDCs. Thus, ERK may somehow be involved in downstream signalling of Pyk2. 
Additionally, some groups could show that NF-κB can be activated in a MAPK dependent 
manner in dendritic cells (148), as depicted for pERK. JNKII MAPK is described to activate 
various different transcription factors, i.e. ATF family members or AP-1 (206). However, 
JNKII has not been associated with NF-κB activation till now. 
5.4. Influence of Dectin-1 induced SOCS1 on the TLR9 pathway 
Concerning the role of SOCS1 in the Dectin-1 pathway, we were not able to find evidence for 
an inhibitory role of SOCS1 as feedback inhibitor. Such a mode of action was proposed for 
SOCS1 regulation upon ligation of the CLR DC-SIGNR I (207). Innate immune cells (murine 
DCs and human PBMCs) were infected by Mycobacterium tuberculosis, a pathogenic ligand 
for both, Dectin-1 and DC-SIGNR1. Upon knockdown of SOCS1 via siRNA a significant 
reduction in M. tuberculosis CFU in both mouse DCs and human PBMCs was observed 
(207). In addition, DC-SIGNR1 bound to SOCS1 as shown by immunoprecipitation. 
To circumvent lethality of SOCS1-/- mice, we used BMMs from SOCS1-/-/IFNγ-/- mice to 
analyze a possible inhibitory potential of SOCS1 for Zymosan/Dectin-1 signalling. Since the 
severe phenotype and lethality of SOCS1 deficient mice mostly originates from an increased 
sensitivity to IFNγ, SOCS1 deficiency on an IFNγ-/- background counteracts the early onset of 
a multi-inflammatory syndrome. These mice survived the neonatal phase and displayed a 
reduced pathology (108, 111). First, we checked for activation of the kinases involved in 
SOCS1 induction in BMMs, namely Syk, Pyk2 and ERK. In cells from SOCS1-/-/IFNγ-/- as well 
as IFNγ-/- mice, phosphorylation of the respective kinases could be observed. No differences 
in the phosphorylation profile of Syk, Pyk2 and ERK could be detected in SOCS1-/-/IFNγ-/- 
cells as compared to IFNγ-/- control cells.  Also, direct target genes of Dectin-1 like egr2 and 
IL10 were not differentially expressed in SOCS1-/-/IFNγ-/- BMMs as compared to IFNγ-/- control 
cells. Therefore, SOCS1 induced by Dectin-1 does not serve as an inhibitor on Dectin-1 
signalling. Indeed, less is described about a possible inhibitory role of SOCS1 on JAK/STAT 
independent pathways. The main function of SOCS1 is described as an inhibitor of 
JAK/STAT signalling pathways.  
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Thus, a possible inhibitory potential of SOCS1 on other PRR signalling pathways, namely 
TLRs was analyzed. During an infection, fungi probably will stimulate TLRs (TLR2, TLR6, 
TLR9) in combination with C-type lectins (44, 51, 53, 55, 63). Therefore we speculated that 
SOCS1 might be important for cross-regulation of different receptors. Indeed, it has already 
been described that co-activation of Dectin-1 and TLRs changes the cells’ cytokine profiles 
(55, 63). Co-ligation of Dectin-1 with β-glucans and TLR2 enhanced IL6 and IL23 production 
but downregulated IL12 expression. To address the question if also other TLR ligands differ 
in their cytokine secretion when they are administered together, we first used WT BMMs and 
co-stimulated them with different TLR ligands (Pam3CSK4, CpG-DNA, LPS, Poly(IC) and 
R848) and depleted Zymosan. We observed an inhibition of IL12 secretion, but an up-
regulation in case of TNFα, IL10 or IL8 when Dectin-1 was stimulated parallel to TLR 
activation. Less is known about an influence of β-glucan on TLR9 signalling. It had been 
described that co-stimulation of human PBMCs or murine BMDCs by CpG-DNA and β-glucan 
induced collaborative TNF responses. TNF secretion was significantly increased upon co-
stimulation as compared to CpG-DNA alone (55, 208). Additionally, Dectin-1 was described 
to bind to mycobacteria. Mycobacteria comprise a high CG-DNA content thereby being able 
to stimulate TLR9 (153, 154). Thus, we decided to focus on the possible properties of 
SOCS1 induced by depleted Zymosan on TLR9 signalling.  
The inhibitory effect of depleted Zymosan on CpG-DNA induced IL12p40 was similar in 
BMMs from IFNγ-/- mice as compared to WT cells. However, in SOCS1-/-/ IFNγ-/- cells, this 
inhibition was abrogated; secretion of IL12 was even enhanced by concomitant Dectin-1 
stimulation as compared to CpG-DNA alone. In cells of WT mice, SOCS1 induction could 
clearly be enhanced when cells were co-treated with depleted Zymosan and CpG-DNA. 
From these results, we conclude that the inhibition of CpG-DNA induced IL12 by depleted 
Zymosan was dependent on SOCS1. In contrast, secretion of other cytokines like TNFα or 
IL8 was not modified in SOCS1-/-/ IFNγ-/- cells. Similarly, ligation of Dectin-1 and TLR9 
resulted in an up-regulation of IL10 production, as previously described for co-stimulation of 
BMDCs with Pam3CSK4 and β-glucans (63). The group of Dennehy et al. could show that co-
stimulation of murine BMDCs with Pam3CSK4 markedly increased the secretion of IL10 in 
comparison to Pam3CSK4 stimulated cells (63).  
Knockout of SOCS1 significantly increased the secretion of IL10 as compared to control 
cells. Thus, SOCS1 shapes the overall reaction pattern in situations where multiple, different 
PRRs, like TLRs and CLRs, are triggered in parallel (Fig. 5-2). Accordingly, the reciprocal 
regulation of distinct cytokines, i.e. IL12 and IL10 or IL6 in WT and IFNγ-/- control cells may 
explain how fungi regulate the production of these cytokines. The collaborative effects of 
Dectin-1 and TLR may provide a new approach for adjuvant development, as combinations 
of specific TLR ligands have been described as promising candidates for novel vaccines. It 
has been described that certain TLR-ligands can synergize with each other to enhance T-cell 
response through synergistic activation of DCs (209-211). It was shown by Zhu et al. that 
immunization with an HIV peptide vaccine in combination with the TLR-ligands MALP2, 
Poly(IC) and CpG induced a substantially higher response to viral load as compared to HIV 
peptide in combination with one TLR ligand alone (209). Additionally, a combination of 
TLR7/8 or TLR3 ligands resulted in a strong increase in secretion of pro-inflammatory 
Discussion 
83 
cytokines, i.e. IL12, and a more efficient CD8+ Th-cell priming. Poly(IC) is already approved 
for clinical testing in humans, and can be used to mature DCs ex vivo prior to an 
administration in vivo. On the other hand, an inhibition of T-cell priming and cytokine 
production was observed when LPS and Poly(IC) or Zymosan and Poly(IC) were combined 
(210, 211). 
The opposing regulation of TNF and IL12 or IL10 might be due to the discriminative 
characteristics of the binding of NF-κB subunits to their respective promoter regions. 
Delayed-type genes, i.e. IL12 and IL10 need a prolonged recruitment of NF-κB subunits to 
the promoter. These genes need a sustained binding of the transcription factor to their 
respective promoters and stimulus-dependent chromatin-modifications are required (139). In 
contrast to DCs, it is described that in macrophages, the transcription of IL12p40 and IL10 
can be promoted by p50/p50 homodimers upon stimulation (158, 159). Analysis of 
interactions of NF-κB subunits (p65, p50, c-Rel and RelB) at the IL12p40 promoter in vitro 
revealed that p50/p50 homodimers and with an even higher affinity also p50/c-Rel 
heterodimers bind to the IL12p40 Rel site (159). In addition, it could be shown in 
macrophages that p50 is the onliest Rel family member to drive IL10 transcription upon 
stimulation with LPS (158).  
Thus, in case of induction of the anti-inflammatory cytokine IL10, p50/p50 homodimers might 
play the major role, whereas IL12p40 is mainly transcribed by p50/cRel heterodimers (158, 
159). This indicates a different regulation of pro-and anti-inflammatory cytokines by means of 
different NF-κB subunits. Importantly, Dectin-1 is the only known CLR to induce the non-
canonical NF-κB pathway. In canonical NF-κB signalling, p105 is constitutively processed by 
the proteasom into active p50 but is maintained cytoplasmatically as a hetero- but also 
homo-dimer (with p65 or p50) by its interaction with inhibitory IκB proteins, such as IκBα 
(184, 185). In contrast, in the non-canonical NF-κB signaling pathway, p100 is processed to 
active p52 only when the pathway is activated (212, 213).  
Therefore, we analyzed BMMs from SOCS1-/-/IFNγ-/- as well as from the respective control 
(IFNγ-/- mice) for activation of NF-κB subunits. Indeed, activation of p50 and p52 was 
significantly up-regulated in SOCS1-/-/IFNγ-/- cells co-stimulated with depleted Zymosan and 
CpG-DNA. It can be speculated that SOCS1 blocks activation of NF-κB p50 and p52 
subunits when triggered via TLR9 and Dectin-1. It is published that SOCS1 induces 
degradation of bound p65 within the nucleus (112-115), most likely via its function as an E3 
ubiquitin ligase (93, 94). Ryo et al. showed that SOCS1 associated with p65 and regulated its 
ubuquitin-mediated proteolysis (113). Mouse primary splenocytes were treated with LPS. 
After immunoprecipitation, p65 was shown to bind endogenous SOCS1. Further, it could be 
shown that SOCS1 was transported rapidly into the nucleus following stimulation. 
Thereupon, SOCS1 but not SOCS3 or CIS bound to p65 within the nuclear compartment. 
SOCS1 bound p65 is ubiquinated in a SOCS-box dependent manner (112). 
Thus, we suggest that also other subunits, i.e. p50 and p52, could be possible targets of 
SOCS1 induced ubiquitination and degradation.  
As mentioned, NF-κB dimers are maintained within the cytoplasm by their interaction with 
inhibitory IκB proteins. In TLR9/Dectin-1 co-stimulated SOCS1-/-/IFNγ-/- cells an increase in 
IκBα phosphorylation as well as degradation was observed. The decomposition of IκBα 
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occurred at later time-points, compared to its phorphorylation. This could be explained by the 
fact that phosphorylation of IκB proteins targets the latter for degradation, thus, this event 
has to take place first (184, 185, 214). It has been described that SOCS1 is located within 
the nucleus as well as within the cytoplasm, as shown for SOCS1 transfected HEK cells 
(112). It might also interact with IκBα directly or with the bound NF-κB subunits as described 
for p65 (112, 114). Depleted Zymosan alone led to a subtle phosphorylation of IκBα when 
macrophages on IFNγ knockout background were used as opposed to WT macrophages. 
This might reflect subtle changes in the differentiation status of the cells and indeed missing 
NF-κB activation in macrophages by Zymosan has been discussed controversially (71, 215). 
On the one hand, it is described that Dectin-1 ligation was not able to trigger NF-κB 
dependent TNFα production in murine BMMs as well as thioglycollate-elicited peritoneal 
macrophages (71). Otherwise, Zymosan was capable of inducing NF-κB translocation into 
the nucleus and transcriptional activity within macrophages (215). This might indicate that 
only certain macrophage populations or cells at a particular differentiation status activate NF-
κB transcription factors upon stimulation of Dectin-1. 
We identified SOCS1 induced by depleted Zymosan to be a regulator of TLR9 signalling 
pathway, since it influenced TLR induced cytokine secretion (Fig. 5-2). IL12 secretion was 
decreased in IFNγ-/- BMMs in comparison to SOCS1-/-/ IFNγ-/- BMMs. As IL12 is described to 
be the main cytokine responsible for the polarization of Th1-cells (124, 216), a decrease in 
IL12 may shift Th-cell response, i.e. towards Th17 cells (Fig. 5-2). Thus, SOCS1 expressed 
by Dectin-1 stimulation may secondary modulate Th-cell priming. Therefore, we analyzed Th-
17 cell induction by SOCS1-/-/ IFNγ-/- and IFNγ-/- BMMs upon co-stimulation of Dectin-1 and 
TLR9. 
5.5. SOCS1 expressed in BMMs by Dectin-1 stimulation increases IL17 
production of Th-cells 
It has been shown that Dectin-1 when activated on dendritic cells is able to prime Th17 
responses (44, 120, 125, 126). Upon interaction of activated DCs, i.e. by TLR ligands, with 
CD4+ Th-cells, the latter cells can differentiate into a variety of effector and regulatory 
subsets, including classical Th1- and Th2-cells, follicular helper Tcells, Tregs (regulatory 
Tcells) and Th17-cells (121, 122). The nature of the cytokines produced by APCs in 
response to various ligands defines the type of Th cell differentiation. For example, the 
production of IL23 along with IL6 and TGFβ leads to the generation of Th17-cells, while 
TGFβ in combination with IL2 induces regulatory T-cells (119-121, 217, 218). Dectin-1 
signalling via Syk kinases primarily induces Th17 response (126). It was demonstrated that 
within WT DCs / WT CD4+ Th-cells, the stimulation of DCs with CpG-DNA induced a T-cell 
differentiation mainly towards the generation of IFNγ-producing Th1-cells, whereas the 
presence of curdlan as a Dectin-1 ligand led to the accumulation of IL17-producing Th17-
cells (125). Additionally, stimulation of murine DCs via Dectin-1 led to the production of IL17 
by CD4+CD25+ regulatory T-cells (219). Isolated regulatory WT T-cells were cultured in 
presence of WT DCs that were stimulated via Dectin-1. Thereupon, an increase in IL17 
producing cells could be observed (219). However, the effect of a combination of CpG-DNA 
and curdlan or another Dectin-1 ligand on T-cell differentiation has not been described. 
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Additionally, SOCS1 was linked to T-cell responses. T-cells from Mycobacterium tuberculosis 
infected mice displayed an increased association with the CD3 and CD28 T-cell receptors. 
Further, an increased association of SOCS1 with the IL12-receptor was observed in infected 
T-cells (207). The group of Takahashi et al. also described that SOCS1-/- Treg cells were 
easily converted into IFNγ producing Th1-like cells (160). Thus, SOCS1 plays an important 
role in T-cell differentiation.  
Since it is shown in this study, that the overall reaction pattern in TLR9/Dectin-1 co-
stimulated innate immune cells is regulated by SOCS1 we speculated that SOCS1 might 
also affect subsequent T cell priming. Therefore, we first of all analyzed SOCS1-/-/IFNγ-/- 
BMMs as well as IFNγ-/- control cells for the secretion of IL6, IL23 and TGFβ. Interestingly all 
of these cytokines were markedly increased upon co-stimulation of TLR9 and Dectin-1 in 
IFNγ-/- cells, whereas in BMMs from SOCS1-/-/IFNγ-/- mice the expression of IL6, IL23 and 
TGFβ was inhibited. In contrast to IL12p40, these cytokines were up-regulated in the control 
cells as compared to the SOCS1 knockout BMMs. Similarly, it has been demonstrated that 
IL12 suppressed IL23 and IL17 production in WT DC / WT Th-cells and, vice versa, IL23 and 
IL17 inhibited IL12 production by Th1-cells (126). This indicates a cross-regulation between 
the Th17 / IL23 and Th1 / IL12 pathway. 
Thus, particular cytokines seem to be regulated differentially by SOCS1 in APCs. This in turn 
supposedly influences T-cell lineage commitment. We further show that BMMs or BMDCs 
triggered with depleted Zymosan and CpG-DNA in a co-culture setting induced IL17-
producing Th-cells only in the presence of SOCS1. Additionally, we examined WT T-cells 
cultured together with BMMs derived from conditional SOCS1 knockout mice. These mice 
were deficient in SOCS1 only in cells from the myeloid lineage, especially macrophages. 
Only co-cultures with control BMMs and WT Tcells showed an elevated production of IL17 
when APCs were stimulated with CpG-DNA and depleted Zymosan. RORγT (RAR related 
orphan receptor gamma) is the key transcription factor of Th17 cells. It renders T-cells 
susceptible for IL23 since it controls expression of the IL23 receptor and it amplifies and 
sustains the Th17 cell differentiation process (163, 164, 220). Thus, we also analyzed 
expression of this transcription factor in co-cultures of CD4+ WT T-cells that were either 
cultured together with BMMs from SOCS1 knockout mice on IFNγ knockout background or 
with BMMs from conditional SOCS1 knockout mice and the respective control. The results 
correlated with the findings observed for IL17; only T-cells cultured with control BMMs 
displayed increased induction of RORγ when BMMs were stimulated with CpG and depleted 
Zymosan or depleted Zymosan alone. Worth mentioning is the fact that within the co-
stimulatory setting, no increase in RORγT expression as compared to stimulation with 
depleted Zymosan or CpG could be induced. This could be explained by the observation that 
also other transcription factors are responsible for the Th17 functions, i.e. STAT3 and 
RORalpha. It is shown that IL17 production is diminished but not abrogated in mice deficient 
of RORγT. A recent study reported that RORα could fulfil a similar function as RORγT (123, 
164). In addition, STAT3 directly binds to IL17 promoter, indicating that STAT3 and RORγT 
cooperate (123, 221). Therefore, STAT3 or RORα transcription factors should be analyzed in 
T-cells co-cultured with myeloid cells that were triggered via TLR9 in combination with 
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Dectin-1. This would reveal if other transcription factors beside RORγT within the IL17 
producing Th-cells are also regulated via SOCS1 produced upon co-stimulation of APCs. 
We conclude that SOCS1 expressed upon Dectin-1 stimulation in myeloid cells plays an 
essential role in shifting T-cell responses towards IL17-producing Th-cells. 
          
Fig. 5-2  Overview of the proposed Cytokine regulation in co-stimulated macrophages 
Cytokines are regulated differentially upon co-stimulation of myeloid cells by TLR lignads, i.e. CpG-DNA and CLR ligands, i.e. 
depleted Zymosan. IL12 secretion is decreased upon co-stimulation, whereas TNF, IL8, IL6, IL23 and TGFβ production is 
increased. The regulation of IL12, IL6, IL23 and TGFβ is mediated by SOCS1 expressed upon ligation of CLR. Therefore, 
SOCS1 is supposedly involved in Th17-differentiation processes. On the other hand, SOCS1 does not participate in the 
increased IL8 and TNFα production.  
Accordingly, the influence of SOCS1 expressed through Dectin-1 on the TLR 9 induced 
cytokine profile and subsequent T-cell response can be summarized as follows: 
Upon an infection with microbial pathogens, not only one single PRR is engaged. Different 
PRRs are rather stimulated the same time to coordinate an immune response specific for the 
respective pathogens. Within this study, it could be shown that Dectin-1 and TLR9 
differentially regulate T-cell response when co-stimulated on APCs. On the one hand, 
cytokine profile is shifted in co-stimulated cells when compared to CpG or depleted Zymosan 
triggered cells. IL12 secretion was decreased, whereas the production of IL6, IL23 and TGFβ 
was increased in the presence of SOCS1. On the other hand, CD4+ Th-cell response was 
influnced by SOCS1 in co-stimulated APCs. IL17 production of CD4+ Th-cells was increased 
when APCs isolated from IFNγ-/- were co-stimulated by depleted Zymosan and CpG-DNA as 
compared APCs stimulated with the single ligands. In contrast, IFNγ-/-/SOCS1-/- APCs were 
not able to increase IL17 production in a co-stimulatory setting. Therefore, SOCS1 produced 
within dendritic cells or macrophages is an essential regulator of T-cell responses when 
multiple PRRs are engaged the same time, i.e. during fungal infection. 
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5.6. Outlook 
This study demonstrates that SOCS1 is induced in BMMs and also BMDCs upon Dectin-1 
stimulation in a direct manner without the contribution of auto- or paracrine factors or any 
intracellular intermediates. Pyk2 and ERK were mandatory for SOCS1 expression in BMMs, 
whereas JNKII and NF-κB were involved in SOCS1 transcriptional control in BMDCs. SOCS1 
did not act as a direct feedback inhibitor, but cross-regulated TLR signalling by inhibiting IL12 
expression. As a consequence SOCS1 regulated the activation profile of innate immune cells 
including subsequent stimulation of adaptive immunity. The contribution of SOCS1 
expressed in BMMs and BMDCs to the induction of IL17 producing Th-cells represents an 
important link between innate and adaptive immune responses. 
However, important questions remain to be solved. On the one hand, the transcription factor 
leading to the induction of SOCS1 in BMMs has not been identified. Thus, one should 
analyze possible candidates, i.e. AP1 that is shown to be activated via pERK. Further, the 
upstream pathway leading to activation of Pyk2 and thereupon ERK remains unclear. Syk is 
activated and responsible for SOCS1 induction. In addition, CARD9 is one important 
mediator of Syk downstream pathways. Thus, BMMs and BMDCs from CARD9 knockout 
mice could be examined to figure out if this adaptor protein is involved in the signalling 
pathway presented here. Importantly, a comparison of the Dectin-1 ligand depleted Zymosan 
and a live organism, i.e. Candida albicans, has to be carried out in order to examine an 
organism that binds to different PRRs beside Dectin-1. 
Additionally, another important step would be to analyze IL17 producing T-cells in a co-
culture setting with BMMs or BMDCs isolated form SOCS1 knockout or control mice and 
incubated with fungi like Candida albicans. In this context, the possible role of Th1 or Th2 
cells has to be further analyzed. To evaluate the contribution of SOCS1 to the IL17 pathway 
in vivo, it is necessary to set up an infection model were conditional SOCS1 knockout mice 
are infected with different pathogenic strains of Candida albicans. These mice should then be 
assessed for survival, fungal growth and parameters of inflammatory and adaptive Th1/Th17 
immunity to analyze if SOCS1 is relevant in Th-cell response in vivo. Additionally, the IL17 
producing Th17 cells should be examined further in detail by means of intracellular FACS 
analysis.  
Concerning the downstream signalling leading to the induction of SOCS1 in myeloid cells, 
BMDCs have to be further analyzed to find out if it is possible that Raf1 in this case could 
play a more prominent role in SOCS1 induction.  
Thus, different cell types activate transcription of SOCS1 via different kinases.  
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7. Appendix 
Quantitative Analysis of western blots from Figure 4-12 to Figure 4-18. Data were quantified 
by densitometry and are depicted as percentage of unstimulated (mock) control. Mock was 
set 100%. Fig. 4-12: A, B; Fig. 4-13: C, D; Fig. 4-14: E, F; Fig. 4-15: G, H; Fig. 4-16: I, J, K; 
Fig. 4-17: L; Fig. 4-18: M, N, O.  
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